News & Resources

The COVID-19 International Drug Pregnancy Registry (COVID-PR): Protocol Considerations, Wyszynski, D.F., Papageorghiou, A.T., Renz, C. et al. Drug Saf 47, 195–204 (2024)

mRNA COVID-19 Vaccination Early in Pregnancy and the Risk of Spontaneous Abortion in an International Pregnancy Registry. Mansour O, Hernandez-Diaz S, Wyszynski DF. Pharmacoepidemiol Drug Saf. 2023 Feb 7.

The COVID-19 Vaccines International Pregnancy Exposure Registry (C-VIPER): Protocol and Methodological Considerations. Wyszynski DF, Bhattacharya M, Martínez-Pérez O, Scialli AR, Tassinari M, Bar-Zeev N, Renz C, Hernández-Díaz S.Drug Saf. 2023 Jan 22:1-12.

Social determinants of health associated with COVID-19 severity during pregnancy: a multinational cohort study (in the International Registry of Coronavirus Exposure in Pregnancy). Mack JA, Voss EA, Rusu R, Hernandez MC, Hernandez-Diaz S, Wyszynski DF, Sylvester S, DiSantostefano RL. BMC Public Health. 2022 Dec 3;22(1):2256.

Association between SARS-CoV-2 infection during pregnancy and postpartum depressive and anxiety symptoms: finding from the International Registry of Coronavirus Exposure in Pregnancy (IRCEP) study. Kim S, Hernández-Díaz S, Zhu Y, Wyszynski D, Huybrechts KF. Arch  Womens Ment Health. 2022 Dec;25(6):1105-1118.

Timing and severity of COVID-19 during pregnancy and risk of preterm birth in the International Registry of Coronavirus Exposure in Pregnancy. Smith LH, Dollinger CY, VanderWeele TJ, Wyszynski DF, Hernández-Díaz S. BMC Pregnancy Childbirth. 2022 Oct 18;22(1):775.

First trimester COVID-19 and the risk of major congenital malformations-International Registry of Coronavirus Exposure in Pregnancy. Hernández-Díaz S, Smith LH, Wyszynski DF, Rasmussen SA. Birth Defects Res. 2022 Sep 1;114(15):906-914.

COVID-19 pharmacotherapy utilization patterns during pregnancy: International Registry of Coronavirus Exposure in Pregnancy. Westhoff WJ, Smith LH, Wyszynski DF, Hernandez-Diaz S. Pharmacoepidemiol Drug Saf. 2022 Jul;31(7):804-809.

International Registry of Coronavirus Exposure in Pregnancy (IRCEP): Cohort Description and Methodological Considerations. Hernández-Díaz S, Smith LH, Dollinger C, Rasmussen SA, Schisterman EF, Bellocco R, Wyszynski DF. Am J Epidemiol. 2022 May 20;191(6):967-979.

COVID-19 perceived impacts on sleep, fitness, and diet and associations with mental health during pregnancy: A cross-national study. Choi KW, Kim HH, Basu A, Kwong ASF, Hernandez-Diaz S, Wyszynski DF, Koenen KC. J Affect Disord Rep. 2022 Jan;7:100288.

Stress levels among an international sample of pregnant and postpartum women during the COVID-19 pandemic. Wyszynski DF, Hernandez-Diaz S, Gordon-Dseagu V, Ramiro N, Koenen KC. J Matern Fetal Neonatal Med. 2022 Dec;35(25):7043-7051.

Parisa Emami-Naeini, MD, MPH, Vincent Garmo, MHS, Nick Boucher, BSc, Rusirini Fernando, BSc, Alicia Menezes, MD. “Maintenance of Vision Needed to Drive after Intravitreal Anti-VEGF Therapy in Patients with Neovascular AMD and Diabetic Macular Edema”. American Academy of Ophthalmology (AAO), October 2023. Research Article

Damla Oncel, BS, and Samuel Minaker, MD, MSc. “Smoking Increases Proliferative Vitreoretinopathy Risk in Retinal Detachment”. Ophthalmology Advisor, Presented at American Society of Retina Specialists (ASRS) 41st Annual Meeting; July 28-August 1, 2023; Seattle. Poster

Ella H. Leung, MD, Henry A. Leder, MD, Shriji Patel, MD, MBA, Rahul Reddy, MD, Nick Boucher, BSc, Chakshu Sharma, MEng, Jill Blim, MS, Carl Awh, MD, FASRS, and Paul Hahn, MD, PhD, FASRS. “Opportunity Cost of Retinal Detachment Surgery vs Office-Based Patient Care“. American Society of Retina Specialists (ASRS), July 2022. Journal

Matthew R. Starr, MD, David Xu, MD, Nicholas Boucher, Namrata Saroj, OD, Luv G. Patel, MD, Michael Ammar, MD, Ravi R. Pandit, MD, Thomas L. Jenkins, MD, and Allen C. Ho, MD. “Characterizing Progression to Neovascular AMD in Fellow Eyes of Patients Treated With Intravitreal Anti-VEGF Injections”. Ophthalmic Surgery, Lasers and Imaging Retina, March 2021;52(3):123–128. Journal

Tatiana R. Rosenblatt, Daniel Vail, Namrata Saroj, OD, Nick Boucher, Darius M. Moshfeghi, MD, and Andrew A. Moshfeghi, MD, MBA. “Increasing Incidence and Prevalence of Common Retinal Diseases in Retina Practices Across the United States.” Ophthalmic Surgery, Ophthalmic Surgery, Lasers and Imaging Retina, January 2021;52(1):29–36. Journal

John S. Pollack, MD, David D. Williams, MD, MBA, Tom Brogan, BA, Nick Boucher, BSc, Nitika Aggarwal, BSc. “Tracking the Impact of COVID-19 on the Retina Community – Part 2”. Retina Times, Published by the American Society of Retina Specialists (ASRS), October 2020. Article

John D. Pitcher, III, MD, Andrew A. Moshfeghi, MD, MBA, Genevieve Lucas, B Comm, Nick Boucher, BS, Hadi Moini, PhD and Namrata Saroj, OD. “Evaluation of Patients Receiving Intravitreal Antivascular Endothelial Growth Factor for Diabetic Macular Edema in Clinical Practice in the United States“. VitreoRetinal Journal, September 2020, Journal

Tatiana Rosenblatt, Daniel Vail, Namrata Saroj, Nick Boucher, Darius Moshfeghi, Andrew A Moshfeghi. “Epidemiology of common retinal diseases in retina practices in the United States“. Investigative Ophthalmology & Visual Science, Vol.61, June 2020. Abstract

Tatiana Rosenblatt, Daniel Vail, Namrata Saroj, Nick Boucher, Darius Moshfeghi, Andrew A Moshfeghi. “AMD, DED most common retinal conditions in the United States“. Modern Retina, from Ophthalmology Times, August 2020. Article

Luo, “The progression of retinal disease in eyes of patients lost to follow-up for at least 6 months”. Retina Society, July, 2020, Presentation

Thomas A. Ciulla, MD, John S. Pollack, MD, David D. Williams, MD. “Mean 1-Year Visual Acuity Change in Retinal Vein Occlusion Related Macular Edema Correlates with Anti-VEGF Treatment Intensity: An Analysis of 12,214 Eyes”. American Academy of Ophthalmology (AAO), March 2020. Paper

Thomas A. Ciulla, MD, MBA, John S. Pollack, MD, David D. Williams, MD, MBA. “Visual Acuity Outcomes and Anti-Vascular Endothelial Growth Factor Therapy Intensity in Macular Edema Due to Retinal Vein Occlusion: An Analysis of 12,214 Eyes“. Retina Society, March 2020. Paper

John S. Pollack, MD, David D. Williams, MD, MBA, Tom Brogan, BA, Nick Boucher, BSc, Nitika Aggarwal, BSc. “Tracking the Impact of COVID-19 on the Retina Community – Part 1”. Retina Times, Published by the American Society of Retina Specialists (ASRS), March 2020. Article

Michael Singer, MD, Dilsher Dhoot, MD. “Review of Intravitreal Injections and Endophthalmitis“. Retinal Physician, February 2020. Newsletter

Thomas A. Ciulla, MD, MBA, Rehan M. Hussain, MD, John S. Pollack, MD, David D. Williams, MD, MBA. “Visual Acuity Outcomes and Anti-Vascular Endothelial Growth Factor Therapy Intensity in Neovascular Age-Related Macular Degeneration Patients: A Real-World Analysis of 49, 485 Eyes”. Ophthalmology Retina Volume 4, Number 1, January 2020. Journal

Andrew P. Schachat, MD. “Ophthalmology Retina Enters Year 4: Some comments on Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema”. Ophthalmology Retina Volume 4, Number 1, January 2020. Editorial.

Karen Appold.“NEW PRODUCT APPLICATIONS: Data Analytics Give Retinal Physicians an Edge”. Retinal Physician, Volume: 16, Issue: November/December 2019, page(s): 50, 51. Article

Susan Worley. “Big Data, Analytics, and AI in Retina Practice”. Retinal Physician, Volume: 16, Issue: November/December 2019, page(s): E1-E8. Article

Arshad M. Khanani, MD, MA, Adrian Skelly, MSc, MBA, Vladimir Bezlyak, PhD, Ray Griner, MPH, Laura Rodriguez Torres, MSc, Alexandros Sagkriotis, MSc. “SIERRA-AMD: A Retrospective, Real-World Evidence Study of Patients with Neovascular Age-Related Macular Degeneration in the United States”. Ophthalmology Retina, September 2019. Paper

Andrew P. Schachat, MD. “Real-World Papers, Prophylaxis for Intravitreal Injections, Fluorescein Angiography and Neovascular Age-Related Macular Degeneration, and Anti-Vascular Endothelial Growth Factor Safety”. Ophthalmology Retina, July 2018. Editorial

Kevin Kunzmann. “Real-World Analysis Supports More Frequent Anti-VEGF Dosing for First-Year nAMD”. HCP Live, July 2018. Presentation

Thomas A. Ciulla, MD, MBA, Peter Bracha, MD, John Pollack, MD, David F. Williams, MD, MBA. “Real-world Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema in the United States”. Ophthalmology Retina, April 2018. Editorial

Thomas A. Ciulla, MD, MBA, Forbes Huang, Keith Westby, MBA, David F. Williams, MD, MBA, Sandi Zaveri, RPh, Samir C. Patel, MD. “Real-world Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration in the United States”. American Academy of Ophthalmology (AAO), February 2018. Article

Powell, V., Barkin, J., Delk, T., “Symptoms, burden, and unmet needs of patients living with exocrine pancreatic insufficiency: a narrative review of the patient experience.” BMC Gastroenterology, Volume 24, article number 101. 14 March 2024. Article.

Barkin, J. MD, Hernandez-Barco, Y. MD, Al-Kaade, S. MD, Pannala, R. MD, Pack, J MSN, ACNP-BC, Powell, V MS, Whitcomb, D MD, PhD. “Characterizing Abdominal Pain and Alternative Treatment Approaches for Pain in an Online Patient Community for Chronic Pancreatitis.” American Pancreatic Association (APA). 03-06 November 2022, Orlando, FL. Poster presentation.

Barkin, J. MD, Hernandez-Barco, Y. MD, Al-Kaade, S. MD, Pannala, R. MD, Pack, J MSN, ACNP-BC, Powell, V MS, Whitcomb, D MD, PhD. “Patient Experience Analysis of an Online Community of Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis Using a Patient-Centered Observational Approach.” American College of Gastroenterology (ACG) Annual Scientific Meeting and Postgraduate Course. 24 Oct 2022. Poster presentation. American Pancreatic Association (APA). 03-06 November 2022, Orlando, FL. Encore poster presentation.

Barkin, J. MD, Hernandez-Barco, Y. MD, Al-Kaade, S. MD, Pannala, R. MD, Pack, J MSN, ACNP-BC, Powell, V MS, Whitcomb, D MD, PhD. “Patient Experience Living With Exocrine Pancreatic Insufficiency: A Targeted Literature Review.” American Pancreatic Association (APA). 03-06 November 2022, Orlando, FL. Poster presentation.

Barkin, J. MD, Hernandez-Barco, Y. MD, Al-Kaade, S. MD, Pannala, R. MD, Pack, J MSN, ACNP-BC, Powell, V MS, Whitcomb, D MD, PhD. “The Voice of the Patient With Exocrine Pancreatic Insufficiency Secondary to Chronic Pancreatitis: Preliminary Findings From a Patient-Driven Registry.” American Pancreatic Association (APA). 03-06 November 2022, Orlando, FL. Encore poster presentation.

Barkin, J. MD, Hernandez-Barco, Y. MD, Al-Kaade, S. MD, Pannala, R. MD, Twal, J, PharmD, Powell, V MS, Whitcomb, D MD, PhD. “The Voice of the Patient With Exocrine Pancreatic Insufficiency Secondary to Chronic Pancreatitis: Preliminary Findings From a Patient-Driven Registry.” American College of Gastroenterology (ACG) Annual Scientific Meeting and Postgraduate Course. 24 Oct 2022. Poster presentation.

Elmer, M., Vichnin, M., Karantza, V., Aktan, G., Powell, V. “Leveraging Patient Engagement to Optimize a Phase 3 Clinical Trial Design, Study Participation and Recruitment for Women Diagnosed with Triple-negative Breast Cancer (TNBC).” 2022 ASCO Annual Meeting, 6 June 2022, Chicago, IL. Poster presentation.

Franchetti, K., RN and Powell, V. “Immersing Your Commercial Team in the Patient Experience.” Patient Summit, 03 Nov 2017, Philadelphia, PA. Conference presentation.

Franchetti, K., RN and Powell, V. “Partnering with Patients for Clinical Trial Success.” Orphan Drugs and Rare Diseases, Americas, 12 Sep 2017, San Francisco, CA. Pre-conference workshop.

Murray, M., Powell, V., et. al. “The Changing Role of Employers In Healthcare.” DIA Annual Meeting, 25 June 2019. San Diego, CA. Conference presentation.

Powell, V., Steel, A, and Howard, T. “COVID-19 Interruption of Care Survey Highlights Need for Optimized Healthcare Utilization: Individuals with Chronic Conditions Impacted by Diminished Resources and Restrictions.” DIA Global, 71 June 2020 – 1 July 2020 (virtual). Poster presentation.

Powell, V. “Developing a Patient-Centric Online Registry.” Patients as Partners, 16 Mar 2018, Philadelphia, PA. Conference presentation.

Powell, V and Church, S. “Engaging in Online Communities is Associated with Improvements in Patient Activation.” DIA Global,20 June 2021, Chicago, IL. Poster presentation.

Powell, V., Hernandez-Barco, Y. MD, Barkin, J MD, Alkaade, S MD, Pannala, R MD, Decktor, D PhD MBA, Twal, J PharmD, Pack, J MSN, ACNP-BC, Frommer, C, Whitcomb, D MD PhD. “Innovative Real-World Experience (RWE) Generation: Supplementing Registry Data with Patient Community Input for In-Depth Patient Understanding.” ISPOR 2022, 17 May 2022, Washington, DC. Poster presentation. PancreasFest 2022: Pancreas 306∞ (PF22). 21-22 July 2022, Pittsburgh, PA. Encore poster presentation.

Powell, V. and Thatch. L., RN. “Insight of the Week.” Mapi Group website. Feb 2017 – May 2017. https://mapigroup.com/patient-insights-and-engagement-blog/.

Powell, V. “Medical Communications: Integrating the Patient Voice.” DIA Annual Meeting, 20 Jun 2017, Chicago, IL. Conference presentation.

Powell, V. “Obtaining Patient Insights in Uncertain Times.” HealthiVibe website. 5 Mar 2020. https://blog.healthivibe.com/wp-content/uploads/2020/03/Obtaining-Patien…

Powell, V. “One Size Does Not Fit All: Retention Methods Custom-Designed for Your Specific Patient Population.” DIA Annual Meeting, 20 Jun 2017, Chicago IL. Conference presentation.

Powell, V. “Rare Disease Clinical Trial Design: Incorporating the Patient Perspective.” The Rare Disease Collaboration Summit, 12 July 2016, Philadelphia PA. Conference presentation.

Powell, V. “Selecting the Right Patient for your Next Patient Voice Project.” Summit for Clinical Ops Executives, 21 Feb 2020, Orlando FL. Conference presentation.

Powell, V., GeDay, M., Kallsen, K., Myles, J., and Julian, S. “Simulating Trial Activities with Patients: Our Experiences” DIA Global, 21 June 2022, Chicago, IL. Conference panel discussion.

Powell, V. “The Impact of Patient Insights: Applications from Clinical Development to Commercialization.” Patients As Partners, 14 March 2106, Philadelphia, PA. Conference presentation.

Powell, V., Thompon, S., Wonderlich, G. and GeDay, M., and Howard, T. “The Patient Experience with Digital Technology.” DIA Digital Technology in Clinical Trials, 27 October 2020 (virtual). Conference panel discussion.

Singleton M, Pugach O, Eliot M, McLean RR, Sima A, Litman HJ. Performance of entropy balancing and covariate balancing propensity score methods for controlling confounding under challenging real-world conditions in observational studies: simulation study in the CorEvitas Psoriasis Registry. ISPE Annual Meeting, Berlin, Germany, August 24-28, 2024.

Silverberg J, Balu S, Choi J, Li A, Pugach O, Schneider S, Simpson E. Real-world effectiveness of tralokinumab on clinician and patient-reported outcomes in patients with moderate-to-severe atopic dermatitis in the CorEvitas Atopic Dermatitis Registry. GDPA Dermatology PEARLS Conference, Atlanta, GA, September 5-7, 2024.

Simpson E, Balu S, Choi J, Li A, Pugach O, Schneide S, Silverberg J. Real-world baseline characteristics and persistence in adult patients initiating tralokinumab in the CorEvitas Atopic Dermatitis Registry. GDPA Dermatology PEARLS Conference, Atlanta, GA, September 5-7, 2024.

Silverberg J, Balu S, Choi J, Li A, Pugach O, Schneider S, Simpson E. Real-world effectiveness of tralokinumab on clinician and patient-reported outcomes in patients with moderate-to-severe atopic dermatitis in the CorEvitas Atopic Dermatitis Registry. Maui Derm NP+PA Fall, Nashville, TN, September 15-18, 2024.

Simpson E, Balu S, Choi J, Li A, Pugach O, Schneide S, Silverberg J. Real-world baseline characteristics and persistence in adult patients initiating tralokinumab in the CorEvitas Atopic Dermatitis Registry. Maui Derm NP+PA Fall, Nashville, TN, September 15-18, 2024.

Silverberg J, Balu S, Choi J, Li A, Pugach O, Schneider S, Simpson E. Real-world effectiveness of tralokinumab on clinician and patient-reported outcomes in patients with moderate-to-severe atopic dermatitis in the CorEvitas Atopic Dermatitis Registry. Las Vegas Dermatology Seminar, Las Vegas, NV, September 19-21, 2024.

Simpson E, Balu S, Choi J, Li A, Pugach O, Schneide S, Silverberg J. Real-world baseline characteristics and persistence in adult patients initiating tralokinumab in the CorEvitas Atopic Dermatitis Registry. Las Vegas Dermatology Seminar, Las Vegas, NV, September 19-21, 2024.

Armstrong AW, Ferris LK, Callis Duffin K, Sima AP, Eckmann T, Beeghly A, Patel M, St John G, Garg V, Strober BE. Long-term real-world achievement of skin clearance treatment targets with persistent 24-month risankizumab use in patients with moderate-severe psoriasis, with and without prior biologic experience, from the CorEvitas Registry. EADV Congress 2024, Amsterdam, The Netherlands, September 25-28, 2024.

Lebwohl M, Armstrong AW, Sima A, Gooderham M, Papp KA, Merola JF, Gottlieb AB, Napoli A, Zhuo J, Varga S, Strober B. The Registry of Psoriasis Health Outcomes (RePhlect): Characteristics of early adopters of deucravacitinib in the North American region. EADV Congress 2024, Amsterdam, The Netherlands, September 25-28, 2024.

Armstrong AW, Lebwohl M, Merola J, Gottlieb AB, Papp KA, Gooderham M, Varga S, Zhuo J, Napoli A, Fergestrom N, Sima A, McLean RR, Strober B. Real-world effectiveness of deucravacitinib in patients with plaque psoriasis: 6-month analysis of skin clearance from the RePhlect Registry. EADV Congress 2024, Amsterdam, The Netherlands, September 25-28, 2024.

Lebwohl M, Armstrong AW, Sima A, Gooderham M, Papp KA, Merola JF, Gottlieb AB, Napoli A, Zhuo J, Varga S, Strober B. The Registry of Psoriasis Health Outcomes (RePhlect): Characteristics of early adopters of deucravacitinib in the North American region. EADV Congress 2024, Amsterdam, The Netherlands, September 25-28, 2024.

Armstrong AW, Lebwohl M, Merola J, Gottlieb AB, Papp KA, Gooderham M, Varga S, Zhuo J, Napoli A, Fergestrom N, Sima A, McLean RR, Strober B. Real-world effectiveness of deucravacitinib in patients with plaque psoriasis: 6-month analysis of skin clearance from the RePhlect Registry. EADV Congress 2024, Amsterdam, The Netherlands, September 25-28, 2024.

Strober B, Armstrong AW, Merola JF, Gottlieb AB, Papp KA, Gooderham M, Varga S, Zhuo J, Napoli A, Fergestrom N, Sima A, McLean RR, Lebwohl M. Real-world effectiveness of deucravacitinib in patients with plaque psoriasis: 6-month analysis of symptom and quality of life improvements from the RePhlect Registry. EADV Congress 2024, Amsterdam, The Netherlands, September 25-28, 2024.

Blauvelt A, McLean RR, Beaty SW, Sima AP, Low R, Strong JL, McClung L, Bagel J. Impact of disease burden of patients with psoriasis on biologic therapy switching: real-world evidence from the CorEvitas Psoriasis Registry. Dermatol Ther (Heidelb). 2024, in press.

Harrold LR, O’Brien J, Moore P, Sima A, Yu M, Roberts-Toler C, Bingham C, Pope J, Masri K, Gegear K. Effectiveness of tofacitinib versus tumor necrosis factor inhibitors and in those receiving tofacitinib as different lines of therapy in patients with rheumatoid arthritis: results from the United States CorEvitas Rheumatoid Arthritis Registry. J Rheumatol. 2024, in press.

Tanaka Y, Kishimoto M, Sonomoto K, Amano K, Harigai M, Onofrei A, O’Brien J, Margolin Z, Barr C, Mizuno Y, Agarwal E, Sugiyama N, Yamanaka H. Safety and effectiveness of tofacitinib, biologic disease-modifying antirheumatic drugs, and methotrexate among patients in Japan with rheumatoid arthritis: an observational study within the CorEvitas Registry. Rheumatol Ther. 2024, in press.

Silverberg JI, Stein Gold L, Desai S, Golant A, DiRuggiero D, Fenske C, Li A, Dawson Z, Munoz Maldonado Y, Ho K, Callahan K, Simpson EL. Disease burden and patient characteristics associated with systemic therapy utilization among adults with atopic dermatitis: data from the CorEvitas Atopic Dermatitis Registry. J Dermatological Treatment. 2024, in press.

Mease PJ, Blauvelt A, Jones E, Sima AP, Beaty SW, Low R, Gomez B, Gurrola M, Lebwohl MG. Impact of disease factors of patients with psoriasis and psoriatic arthritis on biologic therapy switching: real-world evidence from the CorEvitas Psoriasis Registry. Dermatol Ther (Heidelb). 2024, in press.

Strober BE, Janak JC, Fitzgerald T, Marchese M, Teneralli RE, Rowland K, Choi O, Chan D, Lesser E, Cameron M, Lebwohl M. Two-year treatment persistence of guselkumab vs. other biologics in plaque psoriasis patients. J Drugs Dermatol. 2024, in press.

Strober B, Patel M, Photowala H, Kaldas MI, Garg V, Sima AP, Eckmann T, Beeghly A, Armstrong A. Real-world achievement of skin clearance targets and improved quality of life with risankizumab in patients with moderate psoriasis: 1-year results from the CorEvitas Psoriasis Registry. Maui Derm Hawaii 2024, Maui, HI, January 22-26, 2024.

Armstrong AW, Ferris LK, Callis Duffin K, Janak JC, Sima AP, Eckmann T, Photowala H, Patel M, Garg V, Strober BE. Long-term real-world achievement of skin clearance treatment targets and maintenance of response with risankizumab in patients with moderate to severe psoriasis: 2-year results from the CorEvitas Psoriasis Registry. AAD, San Diego, CA, March 8-12, 2024.

Simpson E, Fenske C, Dawson Z, Munoz Maldonado Y, Ho K, Li A, Callahan K. Evaluation of disease burden, patient characteristics, and associated treatment utilization among adults with atopic dermatitis, the CorEvitas Atopic Dermatitis Registry. AAD, San Diego, CA, March 8-12, 2024.

Saal RC, Borda LJ, Li A, Choi J, Eckmann T, Encarnacion INM, Ormaza Vera A, Enos CW, Van Voorhees AS. Patterns of systemic treatment in psoriasis patients with a history of malignancy. SID Annual Meeting, Dallas, TX, May 15-18, 2024.

Li A, Dawson Z, Munoz Maldonado Y, Ho K, Callahan K, Stein Gold L, Desai S, Golant A, DiRuggiero D, Silverberg JI. Characteristics of adult patients with atopic dermatitis initiating biologics and JAK inhibitors in the CorEvitas AD Registry. Spring RAD, Chicago, IL, June 8-10, 2024

Silverberg J, Balu S, Choi J, Li A, Pugach O, Schneider S, Simpson E. Real-world effectiveness of tralokinumab on clinician and patient-reported outcomes in patients with moderate-to-severe atopic dermatitis in the CorEvitas Atopic Dermatitis Registry. Spring RAD, Chicago, IL, June 8-10, 2024.

Simpson E, Balu S, Choi J, Li A, Pugach O, Schneide S, Silverberg J. Real-world baseline characteristics and persistence in adult patients initiating tralokinumab in the CorEvitas Atopic Dermatitis Registry. Spring RAD, Chicago, IL, June 8-10, 2024.

Simpson E, Lio P, Pierce E, Cronin A, McLean R, Eckmann T, Atwater A, Dawson Z, Silverberg J. Impact of atopic dermatitis lesion locations and extent on patient burden: A real-world study. April 26, 2024.

Ogdie A, Middaugh N, Choi J, Zema C, Kelleman M, Dahan S, Dodge R, Nowak M, Varga S, Mease PJ. Drug survival of first-line TNFi and apremilast and description of second-line therapy among psoriatic arthritis (PsA) patients in the CorEvitas PsA/Spondyloarthritis (SpA) Registry. EULAR Congress, Vienna, Austria, June 12-15, 2024

Mease PJ, Saffore CD, Ye X, Nakasato P, Kelleman M, Middaugh N, Ho K, Ogdie A. Real-world disease burden by articular involvement among patients with psoriatic arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. EULAR Congress, Vienna, Austria, June 12-15, 2024.

Mease PJ, Ye X, Saffore CD, Parikh B, Ciecinski S, Blachley T, Eliot M, Middaugh N, Ogdie A. Real-world burden of uncontrolled disease despite treatment with tumor necrosis factor inhibitors among psoriatic arthritis patients in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. EULAR Congress, Vienna, Austria, June 12-15, 2024.

Ogdie A, Ye X, Saffore CD, Parikh, Iyile T, Blachley T, Eliot M, Middaugh N, Mease PJ. Real-world burden of uncontrolled disease despite treatment with tumor necrosis factor inhibitors among axial spondyloarthritis patients in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. EULAR Congress, Vienna, Austria, June 12-15, 2024.

Shiff NJ, Mease PJ, Ogdie A, Tesser J, Lin I, Chakravarty SD, Kelleman M, Dodge R, McLean RR, Broadwell A, Kavanaugh A, Merola JF. Improvements in patient-reported outcomes through 6 months of guselkumab treatment in patients with active psoriatic arthritis: real-world data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. EULAR Congress, Vienna, Austria, June 12-15, 2024.

Armstrong AW, Feldman SR, Fitzgerald T, Alkousakis T, Sima A, Li A, Kang H, Ceja S, Khattri S, Stein Gold L. Patient-reported outcomes among plaque psoriasis patients initiating biologics in the CorEvitas Psoriasis Registry are similar regardless of extent of body surface area involvement. Maui Derm NP + PA Summer 2024, Colorado Springs, CO, June 19-22, 2024.

Baker JF, Bakewell C, Dikranian A, Lam G, O’Brien J, Moore PC, Yu M, Hur P, Masri KR. Characteristics and 6-month outcomes in patients with rheumatoid arthritis initiating infliximab biosimilar IFX-dyyb in a real-world setting. Rheumatol Ther. 2024, in press.

Enos CW, Yi JZ, Ormaza Vera A, McLean RR, Sima AP, Eckmann T, Van Voorhees AS. Racial/ethnic differences in biologic treatment patterns among psoriasis patients in the CorEvitas Psoriasis Registry. JAAD. 2024, in press.

Janak JC, Loughlin AM, Moore PC, Lemay CA, Mease PJ, Lebwohl M, Korzenik JR, Cross RK, Hudesman D. The burden of work productivity and activity impairment in patients with psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn’s disease. Dig Dis Sci. 2024, in press.

Lebwohl M, Strober B, Schrader A, Li AH, Eckmann T, Zhu B, Malatestinic WN, Birt J, Feely M, Blauvelt A. Six-month real-world study to assess the effectiveness of ixekizumab after switching from IL-23 inhibitors and other biologic therapies: the CorEvitas Psoriasis Registry. Drugs – Real World Outcomes. 2024, in press.

Jacqueline O’Brien, Sang Hee Park, Taylor Blachley, Maya Marchese, Nicole Middaugh, Keith Wittstock, Leslie R. Harrold. Disparities in burden of disease in patients with rheumatoid arthritis across racial and ethnic groups. Clinical Rheumatology 2024; doi: 10.1007/s10067-024-06869-9

Lebwohl M, Armstrong AW, Sima A, Gooderham M, Papp KA, Merola JF, Gottlieb AB, Napoli A, Zhuo J, Varga S, Strober B. The Registry of Psoriasis Health Outcomes (RePhlect): Characteristics of early adopters of deucravacitinib in the North American region. AAD, San Diego, CA, March 8-12, 2024.

Silverberg J, Augustin M, Eichenfield L, Lio P, Guttman-Yassky E, Reck Atwater A, Pierce E, Rueda MJ, Li A, Munoz Maldonado Y, Simpson E. A checklist to aid in identifying patients who are candidates for systemic therapy. Winter Clinical Dermatology Conference, Honolulu, HI, January 12-17, 2024.

Strober B, Zhong Y, Sima A, Beeghly A, Eckmann T, Balagula E, Zhuo J, Lebwohl M. Real-world application of International Psoriasis Council guidelines for prescribing systemic treatment to patients with psoriasis in North America. AAD, San Diego, CA, March 8-12, 2024.

Strober B, Zhong Y, Varga S, Zhuo J, Napoli A, Sima A, Beeghly A, Lebwohl M. Treatment discontinuation patterns in patients with psoriasis receiving apremilast in North America: a registry-based analysis. AAD, San Diego, CA, March 8-12, 2024.

Baker JF, Ali M, Bennett D, McLean RR, Munoz Maldonado Y, Yu M, Zueger P. Real-world use and outcomes in rheumatoid arthritis patients treated with upadacitinib: an analysis from the CorEvitas Registry. Rheumatol Ther. 2024, in press.

Baker JF, Bakewell C, Dikranian A, Lam G, O’Brien J, Moore PC, Yu M, Hur P, Masri KR. Characteristics and 6-month outcomes in patients with rheumatoid arthritis initiating infliximab biosimilar IFX-dyyb in a real-world setting. Rheumatol Ther. 2024, in press.

Broadwell A, Kavanaugh A, Merola JA. Improvements in patient-reported outcomes through six months of guselkumab treatment in patients with active psoriatic arthritis: real-world data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. ACR Open Rheumatol. 2024, in press.

Curtis JR, McLean RR, Lee IH, Mackey RH, Moore PC, Haubrich R, Greenberg JD, Wu A. Prevalence and factors associated with patient-clinician discordance among patients with rheumatoid arthritis initiating advanced therapy. ACR Open Rheumatol. 2024, in press.

Harrold LR, Wittstock K, Kelly S, Han X, Zhuo J, Schrader A, Middaugh N, Moore PC, Kaychuk V. Comparative effectiveness of abatacept versus TNF inhibitors in rheumatoid arthritis patients who are ACPA and shared epitope positive. Adv Rheumatol. 2024, in press. DOI: 10.1186/s42358-024-00352-4

Mease PJ, Ogdie A, Tesser J, Shiff NJ, Zhao RS, Chakravarty SD, Kelleman M, Dodge R, McLean RR, Simpson E, Lio P, Pierce E, Cronin A, McLean RR, Eckmann T, Reck Atwater A, Dawson Z, Silverberg JI. Impact of atopic dermatitis lesion locations and extent on patient burden: a real-world study. JEADV Clinical Practice. 2024, in press.

O’Brien J, Park SH, Blachley T, Marchese M, Middaugh N, Wittstock K, Harrold LR. Disparities in burden of disease in patients with RA across racial and ethnic groups. Clin Rheumatol. 2024, in press.

Silverberg JI, Cronin A, Jones EA, Dave SS, McLean RR, Greenberg J, Strober B, Bieber T, Gooderham M, Paller AS, Simpson EL. Characterization of disease burden, treatment and comorbidities in a large, real-world cohort of patients with atopic dermatitis: The CorEvitas Atopic Dermatitis Registry. JAAD International. 2024, in press.

2023

Pappas DA, O’Brien J, Moore PC, Dodge R, Germino R, Masri KR, Bingham CO, Cappelli LC. Treatment patterns and effectiveness of tofacitinib in patients initiating therapy for rheumatoid arthritis: results from the CorEvitas Rheumatoid Arthritis Registry. J Rheumatol. 2023, in press.

Strober B, Callis Duffin K, Lebwohl M, Sima A, Janak J, Patel M, Photowala H, Garg V, Bagel J. Impact of psoriasis disease severity and special area involvement on patient-reported outcomes in the real world: An analysis from the CorEvitas Psoriasis Registry. J Dermatological Treatment. 2023, in press

Mease PJ, Jones E, Sima A, Beaty S, Low R, Gomez B, Gurrola M, Lebwohl M. Patients with psoriatic arthritis at biologic therapy switch: the CorEvitas Psoriasis Registry. Fall Clinical Dermatology Conference, Las Vegas, NV, October 19-22, 2023.

Osiri M, Niamane R, Sima A, O’Brien J, Dodge R, Levent Gunay M, Sweet LL, Shelbaya A, Rammaoui J. Tofacitinib use in rituximab-experienced RA patients. APLAR, Chiang Mai, Thailand, December 7-11, 2023.

Simpson E, Fenske C, Dawson Z, Munoz Maldonado Y, Ho K, Li A, Callahan K. Evaluation of disease burden, patient characteristics, and associated treatment utilization among adults with atopic dermatitis, the CorEvitas Atopic Dermatitis Registry. Fall Clinical Dermatology Conference, Las Vegas, NV, October 19-22, 2023.

Silverberg JI, Pierce E, Feely M, Atwater AR, Schrader A, Jones R, Dave SS, Simpson E. Disease burden among patients with atopic dermatitis treated with systemic therapy for 4-12 months: results from the CorEvitas Atopic Dermatitis Registry. J Dermatolog Treat. 2023;34(1):2246601

Silverberg JI, Shi VY, Alexis A, Pierce E, Cronin A, McLean RR, Roberts-Toler C, Rueda MJ, Atwater AR, Simpson E. Racial and ethnic differences in sociodemographic, clinical, and treatment characteristics among patients with atopic dermatitis in the United States and Canada: real-world data from the CorEvitas Atopic Dermatitis Registry. Dermatol Ther (Heidelb). 2023;13(9):2045-2061

Mease PJ, Blachley T, Malatestinic WN, Harrold LR, Dube B, Lisse JR, Bolce RJ, Hunter TM. Effectiveness of bDMARDs in ankylosing spondylitis patients by biologic use: experience from the CorEvitas PsA/SpA Registry. Curr Med Res Opin. 2023 Dec 5:1-9. [online ahead of print]

Mease PJ, Ogdie A, Tesser J, Shiff NJ, Lin I, Chakravarty SD, Kelleman M, Dodge R, McLean RR, Broadwell A, Kavanaugh A, Merola JF. Six-month persistence and multi-domain effectiveness of guselkumab in adults with psoriatic arthritis: real-world data from the CorEvitas Psoriatic Arthritis/ Spondyloarthritis Registry. Rheumatol Ther 2023; doi: 10.1007/s40744-023-00582-w

Armstrong AW, Fitzgerald TP, McLean RR, Teeple A, Uy JP, Olurinde M, Rowland K, Guo L, Shan Y, Callis Duffin K. Real-world effectiveness of 9-12 months of guselkumab therapy among patients with moderate-to-severe plaque psoriasis in the CorEvitas Psoriasis Registry. Dermatol Ther (Heidelb). 2023;13(2):629-640.

Gulliver WP, See K, Zhu B, Konicek BW, Harrison RW, McLean RR, Kerti SJ, Burge RT, Leonardi CL. Development of psoriasis assessment tools among patients in the CorEvitas Psoriasis Registry. Journal of Psoriasis and Psoriatic Arthritis. 2023;8(2):74-82

McLean RR, Sima AP, Beaty S, Jones EA, Low R, McClung L, Spitzer RL, Stark J, Armstrong A. Durability of near-complete skin clearance in patients with psoriasis using systemic biologic therapies: real-world evidence from the CorEvitas Psoriasis Registry. Dermatol Ther (Heidelb). 2023. doi: 10.1007/s13555-023-01028-5

McLean RR, Sima AP, Beaty S, Low R, Spitzer RL, Stark JL, Lesser E, Lee E, Armstrong A. Skin clearance is associated with reduced treatment failure in patients with psoriasis: real-world evidence from the CorEvitas Psoriasis Registry. Dermatol Ther (Heidelb). 2023 doi: 10.1007/s13555-023-01027-6

Strober B, Ferris K, Callis Duffin K, Janak JC, Sima AP, Eckmann T, Patel M, Photowala H, Garg V, Armstrong A. Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry. J Am Acad Dermatol. 2024;90(1):p82-90

Yu C, Wang G, Burge RT, Ye E, Dou G, Li J, Harrison RW, McLean RR, Kerti SJ, Bagel J. Outcomes of biologic use in Asian compared with non-Hispanic White adult psoriasis patients from the CorEvitas Psoriasis Registry. Dermatol Ther (Heidelb). 2023;13(1):187-206

Aripova N, Kremer JM, Reed GA, Pappas DA, Mikuls T. Anti-citrullinated protein antibody profiles predict changes in disease activity in patients with rheumatoid arthritis initiating biologics. Rheumatology. 2023, in press. Doi:10.1093/rheumatology/kead260

Bessette L, Movahedi M, Reed G, Kremer JM, Kane K, Keystone E. Does the type of failure and the choice of the second biologic influence response and persistence on medication in rheumatoid arthritis? J Clin Rheumatol. 2023, in press

Capelli LC, Reed G, Pappas GA, Kremer JM. A model to predict future biological or targeted synthetic DMARD switch at a subsequent clinic visit in rheumatoid arthritis. Rheumatol Ther. 2023, in press. Doi: 10.1007/s40744-023-00606-5

Dua AB, Ford K, Fiore S, Pappas DA, Janak JC, Blachley T, Roberts-Toler C, Emeanuru K, Kremer JK, Kivitz A. Clinical outcomes in patients with rheumatoid arthritis after switching between interleukin-6-receptor inhibitors and janus kinase inhibitors: findings from an observational study. Rheumatol Ther. 2023, in press.

Harrold LR, Wittstock K, Kelly S, Han X, Shan Y, Guo L, Moore PC, Khaychuk V. Comparative effectiveness of abatacept vs. tofacitinib in the subset of patients who are CCP+. Rheumatol Ther. 2023;10(3):575-587

Harrold LR, Zueger P, Nowell WB, Blachley T, Schrader A, Lakin PR, Curtis D, Stradford L, Venkatachalam S, Tundia N, Patel PA. A real-world effectiveness study using a mobile application to evaluate early outcomes with upadacitinib in rheumatoid arthritis. Rheumatol Ther. 2023 doi: 10.1007/s40744-023-00594-6

Matsson A, Solomon DH, Crabtree MM, Harrison RW, Litman HJ, Johansson FD. Patterns in the sequential treatment of patients with rheumatoid arthritis starting a biologic or targeted synthetic disease-modifying antirheumatic drug: 10-year experience from a US-based registry. ACR Open Rheumatology. 2023, in press

Pala O, Reed G, Pappas DA, Harrold LR, Kremer JM. The impact of disease activity on patient-reported subjective cognitive decline (SCD) in patients with rheumatoid arthritis. Exploration of Musculoskeletal Disease. 2023;1:228-40

Pappas DA, O’Brien J, Guo L, Shan Y, Baker JF, Kricorian G, Stryker S, Collier DH. Treatment patterns and clinical outcomes in patients with rheumatoid arthritis initiating etanercept, adalimumab, or Janus kinase inhibitor as first-line therapy: results from the real-world CorEvitas RA Registry. Arthritis Res Ther. 2023;25(1):166

Solomon DH, Guan H, Johansson FD, Santacroce L, Malley W, Guo L, Litman H. Assessing clusters of comorbidities in rheumatoid arthritis: a machine learning approach. Arthritis Res Ther. 2023;25:224

Yoshida K, Harrold L, Middaugh N, Guan H, Stryker S, Karis E, Solomon D. Examining the potential direct cardiovascular benefit of tumor necrosis factor inhibitor in rheumatoid arthritis: natural and controlled direct effect analyses. Pharmacoepidemiol Drug Saf. 2023; 32(4):407-415

Yun H, Chen L, Roy JA, Greenberg J, Harrold LR, George MD, Curtis JR. Rheumatoid arthritis disease activity and hospitalized infection in a large US registry. Arthritis Care Res. 2023 https://doi.org/10.1002/acr.24984

Armstrong, A.W., Fitzgerald, T., McLean, R.R. et al. The Effectiveness of Guselkumab by BMI Category Among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry. Advances in Therapy (2023). https://doi.org/10.1007/s12325-023-02467-4

Curtis, Jeffrey R. MD, MS, MPH; Fiore, Stefano MD; Ford, Kerri Pharm D; Janak, Jud C. PhD; Chang, Hong PhD; Pappas, Dimitrios A. MD; Blachley, Taylor MS; Emeanuru, Kelechi MPH, CPH; Bykerk, Vivian P. MD. Meaningful Improvement and Worsening in Patients Who Do Not Achieve Low Disease Activity and Switch Therapy to a New Biologic or Targeted Disease-Modifying Antirheumatic Drug: Results From the CorEvitas RA Registry. JCR: Journal of Clinical Rheumatology 29(4):p e47-e51, June 2023. | DOI: 10.1097/RHU.0000000000001956. https://pubmed.ncbi.nlm.nih.gov/37000177/

Enos CW, Ramos VL, McLean RR, Lin TC, Dube B, Van Voorhees AS. Proportions of Biologic Discontinuation Among Psoriasis Patients with Metabolic Comorbidities. Journal of Psoriasis and Psoriatic Arthritis. 2023;8(1):7-10. doi:10.1177/24755303221131257. Link to Sage Journals.

Galvao RW, Curtis JR, Harrold LR, Wu Q, Xie F, George MD. Accuracy of administrative claims prescription fill data to estimate glucocorticoid use and dose in patients with rheumatoid arthritis [published online ahead of print, 2023 Jun 22]. Pharmacoepidemiol Drug Saf. 2023;10.1002/pds.5660. doi:10.1002/pds.5660

Jin JQ, Cronin A, Roberts-Toler C, Yeroushalmi S, Hadeler E, Spencer RK, Elhage KG, Gondo G, Wallace EB, Reddy SM, Han G, Kaffenberger J, Davis MS, Hakimi M, Scher JU, Armstrong AW, Bhutani T, McLean RR, Liao W, Sociodemographic and clinical characteristics associated with multiple biologic failure in psoriasis: a 2015-2022 prospective cohort analysis of the CorEvitas Psoriasis Registry, Journal of the American Academy of Dermatology (2023), https://doi.org/10.1016/j.jaad.2023.06.058.

Sebba, A., Bingham, C. O., Bykerk, V. P., Fiore, S., Ford, K., Janak, J. C., Pappas, D. A., Blachley, T., Dave, S. S., Kremer, J. M., Yu, M., & Choy, E. (2023). Comparative effectiveness of TNF inhibitor vs IL-6 receptor inhibitor as monotherapy or combination therapy with methotrexate in biologic-experienced patients with rheumatoid arthritis: An analysis from the CorEvitas RA Registry. Clinical rheumatology, 42(8), 2037–2051. https://doi.org/10.1007/s10067-023-06588-7

Wolf DC, Naegeli AN, Moore PC, Janak JC, Crabtree MM, Shan M, Hunter TM, Sontag A, Cross RK, Change in Urgency Status Among Ulcerative Colitis Patients: Understanding a Potential Unmet Patient Need from the CorEvitas Inflammatory Bowel Disease Registry, Gastro Hep Advances (2023), doi: https://doi.org/10.1016/j.gastha.2023.03.024.

Yamanaka H, Kishimoto M, Nishijima N, Yamashita K, Matsushima J, O’Brien J, Blachley T, Eliot M, Margolin Z, Dave SS, Tanaka Y. Socioeconomic impact of treatment with biological disease-modifying antirheumatic drugs in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2023 Jan 11;roac160. doi: 10.1093/mr/roac160. Online ahead of print.

Yu C, Wang G, Burge RT, Ye E, Dou G, Li J, Harrison RW, McLean RR, Kerti SJ, Bagel J. Outcomes of Biologic Use in Asian Compared with Non-Hispanic White Adult Psoriasis Patients from the CorEvitas Psoriasis Registry. Dermatol Ther (Heidelb). 2023 Jan;13(1):187-206. doi: 10.1007/s13555-022-00843-6. Epub 2022 Nov 16. PMID: 36385699

Yun, H., Chen, L., Roy, J.A., Greenberg, J., Harrold, L.R., George, M.D. and Curtis, J.R. (2023), Rheumatoid Arthritis Disease Activity and Hospitalized Infection in a Large US Registry. Arthritis Care Res. https://doi.org/10.1002/acr.24984

2022

Armstrong AW, Fitzgerald T, McLean RR, Teeple A, Uy JP, Olurinde M, Rowland K, Guo L, Shan Y, Callis Duffin K. Effectiveness of Guselkumab Therapy among Patients with Plaque Psoriasis with Baseline IGA Score ≥ 2 in the CorEvitas Psoriasis Registry. Dermatol Ther (Heidelb). 2022 Dec 9. doi: 10.1007/s13555-022-00865-0.

Baker JF, Reed G, Kremer J. Weight Fluctuation and the Risk of Cardiovascular Events in Patients With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2022 Feb;74(2):229-235. doi: 10.1002/acr.24469. Epub 2022 Jan 5. PMID: 33002323

Baker JF, Reed G, Poudel DR, Harrold LR, Kremer JM. Obesity and Response to Advanced Therapies in Rheumatoid Arthritis.  Arthritis Care Res (Hoboken). 2022 Feb 10. doi: 10.1002/acr.24867.  PMID: 35143117

Cross R, Sauk J, Zhuo J, Harrison R, Kerti S, Emeanuru K, O’Brien J, Ahmad H, Sreih A, Nguyen J, Horst S, Hudesman D. Poor Patient-reported Outcomes and Impaired Work Productivity in Patients With Inflammatory Bowel Disease in Remission. Gastro Hep Advances. 2022;1:927-935, doi: https://doi.org/10.1016/ j.gastha.2022.07.003.

Curtis JR, Kremer JM, Reed G, John AK, Pappas DA. TNFi Cycling Versus Changing Mechanism of Action in TNFi-Experienced Patients: Result of the Corrona CERTAIN Comparative Effectiveness Study. ACR Open Rheumatol. 2022 Jan;4(1):65-73. doi: 10.1002/acr2.11337. Epub 2021 Nov 5. PMID: 34741435

Enos CW, Ramos V, McLean RR, Lin TC, Foster N, Dube B, Van Voorhees AS. Cardiometabolic multimorbidity is common among patients with psoriasis and is associated with poorer outcomes compared to those without comorbidity. J Dermatolog Treat. 2022 Nov;33(7):2975-2982. doi: 10.1080/09546634.2022.2089329. Epub 2022 Jul 6. PMID 35737885

Enos CW, Yi JZ, McLean RR, Sima AP, Kohl EA, Eckmann T, Van Voorhees AS. Similar response to biologic therapy across racial and ethnic groups among patients with psoriasis enrolled in the CorEvitas Psoriasis Registry.  J Am Acad Dermatol. 2022 May 26;S0190-9622(22)00881-7. doi: 10.1016/j.jaad.2022.05.038.  PMID: 35643239

CW, Ramos V, McLean RR, Lin TC, Foster N, Dube B, Van Voorhees AS. Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6-months: a prospective analysis in the Corrona Psoriasis Registry.  J Am Acad Dermatol. 2022 Jan;86(1):68-76. doi: 10.1016/j.jaad.2021.06.883. Epub 2021 Jul 10. PMID: 34256035

Enos CW, O’Connell K, Harrison RW, McLean RR, Dube B, Van Voorhees AS. Regional Variation in DLQI 0/1 within the CorEvitas Psoriasis Registry 6-months following Biologic Initiation. SKIN The Journal of Cutaneous Medicine, 6(1), 41–43. https://doi.org/10.25251/skin.6.1.7

Enos CW, O’Connell KA, Harrison RW, McLean RR, Dube B, Van Voorhees AS. Geographic Patterns in Psoriasis: An Observational Study of CorEvitas Psoriasis Registry. Journal of Psoriasis and Psoriatic Arthritis. 2022;7(3):122-131. doi:10.1177/24755303221081799

Fan Y, Delgado-Aros S, Valdecantos WC, Janak JC, Moore PC, Crabtree MM, Stidham RW. Characteristics of Patients with Crohn’s Disease With or Without Perianal Fistulae in the CorEvitas Inflammatory Bowel Disease Registry. Dig Dis Sci. 2022 Apr 25. doi: 10.1007/s10620-022-07491-y.  PMID: 35467311

Hansen KE, Mortezavi M, Nagy E, Wang C, Connell CA, Radi Z, Litman HJ, Adami G, Rossini M. Fracture in clinical studies of tofacitinib in rheumatoid arthritis. Ther Adv Musculoskelet Dis 2022, Vol. 14: 1–13 DOI: 10.1177/1759720X221142346

Harrold LR, Connolly SE, Wittstock K, Zhuo J, Kelly S, Lehman T, Shan Y, Rebello S, Guo L, Khaychuk V. Baseline Anti-Citrullinated Protein Antibody Status and Response to Abatacept or Non-TNFi Biologic/Targeted-Synthetic DMARDs: US Observational Study of Patients with RA. 2022 Apr;9(2):465-480. doi: 10.1007/s40744-021-00401-0. Epub 2021 Dec 23. PMID: 34940957

Lockshin B, Harrison RW, McLean RR, Crabtree MM, Konicek BW, Zhu Baojin, Malatestinic  WN, Atiya B, Murage MJ, Burge RT. Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry. Dermatol Ther (Heidelb). 2022 Dec;12(12):2797-2815. doi: 10.1007/s13555-022-00834-7. Epub 2022 Nov 4. PMID 36331713

Mease PJ, Ogdie A, Chakravarty SD, Shiff NJ, Lin I, McLean RR. Clinical Characteristics of Registry Participants with Psoriatic Arthritis Initiating Guselkumab: An Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. Drugs Real World Outcomes. 2022 Dec;9(4):617-628. doi: 10.1007/s40801-022-00326-2. Epub 2022 Oct 15. PMID: 36243860

Mease PJ, Blachley T, Dube B, McLean RR, Kim N, Hur P, Ogdie A. Effectiveness of 6-month Use of Secukinumab in Patients With Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. J Rheumatol. 2022 Jul;49(7):700-706.doi:10.3899/ jrheum.211033. Epub 2022 Apr 15. PMID 35428716

Mease PJ, Chakravarty SD, McLean RR, Blachley T, Kawashima T, Lin I, Kavanaugh A, Ogdie A. Treatment Responses in Patients With Psoriatic Arthritis Axial Disease According to Human Leukocyte Antigen-B27 Status: An Analysis From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. ACR Open Rheumatol 2022 Feb 26. doi: 10.1002/acr2.11416. PMID: 35218320

Ogdie A, Harrison RW, McLean RR, Lin TC, Lebwohl M, Strober BE, Zhuo J, Patel V, Mease PJ. Prospective cohort study of psoriatic arthritis risk in patients with psoriasis in a real-world psoriasis registry. J Am Acad Dermatol. 2022 Dec;87(6):1303-1311. doi: 10.1016/j.jaad.2022.07.060. Epub 2022 Aug 17. PMID: 35987397

Ogdie A, Blachley T, Lakin PR, Dube B, McLean RR, Hur P, Mease P. Evaluation of Clinical Diagnosis of Axial Psoriatic Arthritis (PsA) or Elevated Patient-reported Spine Pain in CorEvitas’ PsA/Spondyloarthritis Registry. J Rheumatol. 2021 Dec 1;jrheum.210662. doi: 10.3899/jrheum. PMID: 34853090

Padula AS, Pappas DA, Fiore A, Blachley TS, Ford K, Emeanuru K, Kremer JM. The effect of targeted rheumatoid arthritis therapeutics on systemic inflammation and anemia: analysis of data from the CorEvitas RA registry. Arthritis Res Ther. 2022 Dec 21;24(1):276. doi: 10.1186/s13075-022-02955-y.

Pappas DA, Brittle C, Concoff A, Holman AJ, Takasugi D, Kremer JM. Perspectives on applying immuno-autonomics to rheumatoid arthritis: results from an online rheumatologist survey. Rheumatol Int. 2022 Sep;42(9):1555-1564. doi: 10.1007/s00296-022-05122-3. Epub 2022 Apr 21. PMID 35449236

Strober B, Patil D, McLean RR, Moore-Clingenpeel M, Guo N, Levi E, Lebwohl M. Impact of secukinumab on patient-reported outcomes in biologic-naive patients with psoriasis in a US real-world setting. J Dermatolog Treat 2022 Dec;33(8):3178-3187. doi: 10.1080/09546634.2022.2116266. Epub 2022 Sep 5. PMID: 36026543

Strober B, Patil D, McLean RR, Moore-Clingenpeel M, Guo N, Levi E, Lebwohl M. Utilization Trends and Impact of Secukinumab Treatment on Clinical Outcomes in Biologic-Naive Patients with Psoriasis in a US Real-World Setting. Dermatol Ther (Heidelb). 2022 Jun;12(6):1351-1365. doi: 10.1007/s13555-022-00740-y. Epub 2022 May 13. PMID: 35551619

Walsh JA, Duffin KC, Van Voorhees AS, Chakravarty SD, Fitzgerald T, Teeple A, Rowland K, UY J, McLean RR, Malley W, Cronin A, Merola JF. Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas’ Psoriasis Registry. Dermatol Ther (Heidelb). 2021 Nov 25. doi: 10.1007/s13555-021-00637-2.  PMID: 34822121

Yoshida K, Harrold LR, Middaugh N, Guan H, Stryker S, Karis E,  Solomon DH. Examining the Potential Direct Cardiovascular Benefit of Tumor-Necrosis Factor Inhibitor in Rheumatoid Arthritis: Natural and Controlled Direct Effect Analyses. Pharmacoepidemiol Drug Saf 2022. DOI: 10.1002/pds.5546.  PMID: 36129396

Yoshida K, Harrold LR, Middaugh N, Guan H, Stryker S. Karis E, Solomon DH. Time-Varying Association of Rheumatoid Arthritis Disease Activity to Subsequent Cardiovascular Risk. ACR Open Rheumatol. 2022 Jul;4(7):587-595. doi: 10.1002/acr2.11432. Epub 2022 Apr 10. PMID: 35403

Yun H, Chen L, Roy JA, Greenberg J, Harrold LR, George MD, Curtis JR. Rheumatoid arthritis disease activity and hospitalized infection in a large U.S. registry. Arthritis Care Res (Hoboken). 2022 Jul 22. doi: 10.1002/acr.24984.  PMID: 35866713

Yun H, Chen L, Roy JA, Greenberg J, Harrold LR, George MD, Curtis JR. Reply to letter to the editor from Dr. Boers re: Rheumatoid arthritis disease activity and hospitalized infection in a large U.S. registry. Arthritis Care Res (Hoboken). 2022 Dec 18. doi: 10.1002/acr.25075.

2021

Callis Duffin K, Mason MA, Gordon K, Harrison RW, Crabtree MM, Guana A, Germino R, Lebwohl M. Characterization of Patients with Psoriasis in Challenging-to-Treat Body Areas in the Corrona Psoriasis Registry. Dermatology 2021;237(1):46-55. doi: 10.1159/000504841. Epub 2020 Jan 21. PMID: 31962340

Cohen S, Wells AF, Curtis JR, Dhar R, Mellors T, Zhang L, Withers JB, Jones A, Ghiassian SD, Wang M, Connolly-Strong E, Rapisardo S, Gatalica Z, Pappas DA, Kremer JM, Saleh A, Akmaev VR.  A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor-α Inhibitors: The NETWORK-004 Prospective Observational Study. Rheumatol Ther. 2021 Jun 19;1-18. doi: 10.1007/s40744-021-00330-y. Online ahead of print. PMID: 34148193

Cohen SB, Greenberg JD, Harnett J, Madsen A, Smith TW, Gruben D, Zhang R, Lukic T, Woolcott J, Dandreo KJ, Litman HJ, Blachley T, Lenihan A, Chen C, Rivas JL, Dougados M. Real-World Evidence to Contextualize Clinical Trial Results and Inform Regulatory Decisions: Tofacitinib Modified-Release Once-Daily vs Immediate-Release Twice-Daily for Rheumatoid Arthritis. Adv Ther. 2021 Jan;38(1):226-248. doi: 10.1007/s12325-020-01501-z. Epub 2020 Oct 9. PMID: 33034006

Curtis JR, Kremer JM, Reed G, John AK, Pappas DA. TNFi Cycling Versus Changing Mechanism of Action in TNFi-Experienced Patients: Result of the Corrona CERTAIN Comparative Effectiveness Study. ACR Open Rheumatol. 2021 Nov 5. doi: 10.1002/acr2.11337. Online ahead of print. PMID: 34741435

Curtis JR, Palmer JL, Reed GW, Greenberg J, Pappas DA, Harrold LR, Kremer JM. Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis. Arthritis Care Res (Hoboken) 2021 Aug;73(8):1114-1124. doi: 10.1002/acr.24253. PMID: 32374918

Enos CW, O’Connell KA, Harrison RW, McLean RR, Dube B, Van Voorhees AS. Psoriasis Severity, Comorbidities, and Treatment Response Differ among Geographic Regions in the United States. JID Innovations (2021);1:100025 doi:10.1016/j.xjidi.2021.100025

Gottlieb AB, Merola JF, Cirulli J, Williams CC, Linowski GJ, Paris M, Litman HJ, Guo N, Emeanuru K, McLean RR, Cronin A, Strober B. Characteristics of Patients with Psoriasis Treated with Apremilast in the Corrona Psoriasis Registry. Dermatol Ther (Heidelb). 2021 Jan 21. doi: 10.1007/s13555-020-00479-4. Epub 2021 Jan 21. PMID: 33475970

Harrold LR, Bryson J, Lehman T, Zhuo J, Gao S, Han X, Schrader A, Rebello S, Pappas DA, Somers T, Kremer JM. Association Between Baseline Anti-cyclic Citrullinated Peptide Antibodies and 6-Month Clinical Response Following Abatacept or TNF Inhibitor Treatment: A Real-World Analysis of Biologic-Experienced Patients with RA. Rheumatol Ther. 2021 Jun;8(2):937-953. doi: 10.1007/s40744-021-00310-2. Epub 2021 May 28.PMID: 34047953

Johansson FD, Collins JE, Yau V, Guan H, Kim SC, Losina E, Sontag D, Stratton J, Trinh H, Greenberg J, Solomon DH. Predicting Response to Tocilizumab Monotherapy in Rheumatoid Arthritis: A Real-World Data Analysis Using Machine Learning. J Rheumatol. 2021 May 1:jrheum.201626. doi: 10.3899/jrheum.201626. Online ahead of print. PMID: 33934070

Kremer JM, Pappas DA, Kane K, Greenberg J, Harrold L, Feathers VL, Shadick N, Weinblatt ME, Reed G. The Clinical Disease Activity Index (CDAI) and the Routine Assessment of Patient Index Data3 (RAPID3) for Achievement of Treatment Strategies. J Rheumatol 2021 Dec;48(12):1776-1783. doi: 10.3899/jrheum.200692. Epub 2020 Dec 15. PMID: 33323534

Kremer JM, Reed G, Pappas DA, Kane K, Feathers VL, Weinblatt ME, Shadick N, Greenberg J, Harrold LR. Dr. Kremer et al reply. J Rheumatol. 2021 Oct 15;jrheum.210992. doi: 10.3899/jrheum.210992. Online ahead of print. PMID: 34654733

Kremer JM, Bingham CO, Cappelli LC, Greenberg JD, Madsen AM, Geier J, Rivas JL, Onofrei AM, Barr CJ, Pappas DA, Litman HJ, Dandreo KJ, Shapiro AB, Connell CA, Kavanaugh A. Postapproval Comparative Safety Study of Tofacitinib and Biological Disease‐Modifying Antirheumatic Drugs: 5‐Year Results from a United States–Based Rheumatoid Arthritis Registry. ACR Open Rheumatol. 2021 Mar;3(3):173-184. doi: 10.1002/acr2.11232. Epub 2021 Feb 11. PMID: 33570260

Lockshin B, Cronin A, Harrison RW, McLean RR, Anatale-Tardiff L, Burge R, Zhu B, Malatestinic WN, Atiya B, Murage MJ, Gallo G, Strober B, Van Voorhees A. Drug Survival of Ixekizumab, TNF Inhibitors, and Other IL-17 Inhibitors in Real-World Patients With Psoriasis: The Corrona Psoriasis Registry. Dermatol Ther. 2021 Jan 25;e14808. doi: 10.1111/dth.14808. Epub 2021 Feb 15. PMID: 33491259

Mease PJ, Stryker S, Liu M, Salim B, Rebello S, Gharaibeh M, Collier DH.Treatment patterns in rheumatoid arthritis patients newly initiated on biologic and conventional synthetic disease-modifying antirheumatic drug therapy and enrolled in a North American clinical registry. Arthritis Res Ther. 2021 Sep 8;23(1):236. doi: 10.1186/s13075-021-02599-4. PMID: 34496952

Mease PJ, Liu M, Rebello S, Hua W, McLean RR, Hur P, Ogdie A. Disease Characteristics, Quality of Life, and Work Productivity by Enthesitis Site: Real- World Data From the US Corrona Psoriatic Arthritis/Spondyloarthritis Registry.  J Rheumatol. 2021 Mar;48(3):367-375. doi: 10.3899/jrheum.191117. Epub 2020 Jun 1.  PMID: 32482647

Mease PM, Liu M, Rebello S, McLean RR, Dube B, Glynn M, Hur P, Ogdie A. Association of Nail Psoriasis With Disease Activity Measures and Impact in Psoriatic Arthritis: Data From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. J Rheumatol. 2021. Apr;48(4):520-526. doi: 10.3899/jrheum.190923. Epub 2020 Oct 15. PMID: 33060307

Mease PJ, Etzel CJ, Huster W, Armstrong A, Muram T, Lisse J, Rebello S, Dodge R, Murage MJ, Greenberg JD, Malatestinic W. Evaluation of changes in skin and joint outcomes and associated treatment changes in PsA: Experience from the Corrona PsA/SpA Registry.  J Rheumatol. 2021 Mar;48(3):376-384. doi: 10.3899/jrheum.190422. Epub 2020 May 1. PMID: 32358158

Mease PJ, McLean RR, Dube B, Liu M, Rebello S, Glynn M, Yi E, Park Y, Ogdie A. Dr. Mease et al reply. J Rheumatol. 2021 Dec;48(12):1891-1892. doi: 10.3899/jrheum.210750. Epub 2021 Sep 1. PMID: 34470796

Mease P, Liu M, Rebello S, McLean R, Blessing D, Glynn M, Yi E, Park Y, Ogdie A. Comparison of Men and Women With Axial Spondyloarthritis in the US-Based Corrona Psoriatic Arthritis/Spondyloarthritis Registry. J Rheumatol. 2021 Oct;48(10):1528-1536. doi: 10.3899/jrheum.201549. Epub 2021 Apr 15.PMID: 33858974

Ocon AJ, Reed G, Pappas DA, Curtis JR, Kremer JM. Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis. Ann Rheum Dis. 2021 Dec;80(12):1522-1529. doi: 10.1136/annrheumdis-2021-220577. Epub 2021 Jul 2. PMID: 34215644

Ogdie A, Hur P, Liu M, Rebello S, McLean RR, Dube B, Glynn M, Mease PH. Effect of Multidomain Disease Presentations on Patients With Psoriatic Arthritis in theCorrona Psoriatic Arthritis/Spondyloarthritis Registry. J Rheumatol. 2021 May;48(5):698-706. doi: 10.3899/jrheum.200371. Epub 2020 Oct 1. PMID: 33004532

Ogdie A, Liu M, Glynn M, Emeanuru K, Harrold L, Richter S, Guerette B, Mease PJ. Descriptive Comparisons of the Impact of Apremilast and Methotrexate Monotherapy in Oligoarticular Psoriatic Arthritis: the Corrona Psoriatic Arthritis/Spondyloarthritis Registry Results. J Rheumatol. 2021 May;48(5):693-697. doi: 10.3899/jrheum.191209. Epub 2020 Nov 15. PMID: 33191289

Pappas DA, St John G, Etzel CJ, Fiore S, Blachley T, Kimura T, Punekar R, Emeanuru K, Choi J, Boklage S, Kremer JM. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study. Ann Rheum Dis. 2021 Jan;80(1):96-102. doi: 10.1136/annrheumdis-2020-217209. Epub 2020 Jul 21. PMID: 32719038

Pappas DA, Litman HJ, Lesperance T, Kricorian G, Karis E, Rebello S, Hua W, Accortt NA, Stryker S. Persistence on biologic DMARD monotherapy after achieving rheumatoid arthritis disease control on combination therapy: retrospective analysis of Corrona registry data. Rheumatol Int. 2021 Feb;41(2):381-390. doi: 10.1007/s00296-020-04667-5. Epub 2020 Sep 2. PMID: 32876744

Pappas D, Blachley T, Best JH, Zlotnick S, Reiss W, Emeanuru K, Kremer JM. Durability of Response to Tocilizumab Therapy in Rheumatoid Arthritis: Data from the US-Based Corrona Rheumatoid Arthritis Registry. Rheumatol Ther. 2021 Mar;8(1):467-481. doi: 10.1007/s40744-021-00285-0. Epub 2021 Feb 25. PMID: 33630272

Pappas DA, Brittle C, Mossell JE III, Withers JB, Lim-Harashima J, Kremer JM. Perceived clinical utility of a test for predicting inadequate response to TNF inhibitor therapies in rheumatoid arthritis: results from a decision impact study. Rheumatol Int. 2021 Mar;41(3):585-593. doi: 10.1007/s00296-020-04746-7. Epub 2020 Nov 30. PMID: 33258003

Petro AD, Dougherty J, England BR, Sayles H, Duryee MJ, Hunter CD, Kremer JM, Pappas DA, Robinson WH, Curtis JR, Thiele GM, Mikuls TR. Associations between an expanded autoantibody profile and treatment responses to biologic therapies in patients with rheumatoid arthritis. Int Immunopharmacol. 2021 Feb;91:107260. doi:10.1016/j.intimp.2020.107260. Epub 2020 Dec 23. PMID: 33360371

Shahriari, N, Mattessich S, Lin TC, Litman HJ, McLean RR, Dube B, Shahriari M. Assessing the change in disease severity based on depressive symptoms in real-world psoriasis patients. J Comp Eff Res. 2021 Nov;10(16):1215-1224. doi: 10.2217/cer-2021-0106. Epub 2021 Sep 29. PMID: 34585596

Shahriari N, Lin TC, Litman HJ, Dube B, McLean RR, Shahriari M. Characterization Of Real-World Psoriasis Patients With And Without A History Of Depression: The Corrona Psoriasis Registry.J Am Acad Dermatol. 2021 May;84(5):1444-1447. doi: 10.1016/j.jaad.2020.06.994. Epub 2020 Jun 27. PMID: 32603721

Solomon DH, Xu C, Collins J, Kim SC,  Losina E, Yau V, Johansson FD. The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy. Arthritis Res Ther . 2021 Jan 14;23(1):26. doi: 10.1186/s13075-020-02408-4. PMID: 33446261

Strober B, Kotowsky N, Medeiros R, Mackey RH, Harrold LR, Valdecantos WC, Flack M, Golembesky AK, Lebwohl M. Unmet Medical Needs in the Treatment and Management of Generalized Pustular Psoriasis Flares: Evidence from a Survey of Corrona Registry Dermatologists. Dermatol Ther (Heidelb). 2021 Apr;11(2):529-541. doi: 10.1007/s13555-021-00493-0. Epub 2021 Feb 27. PMID: 33638115

Van Voorhees AS, Mason MA, Harrold LR, Guo N, Guana A, Tian H, Herrera V, Strober BE. Characterization of insufficient responders to anti-tumor necrosis factor therapies in patients with moderate to severe psoriasis: real-world data from the US Corrona Psoriasis Registry.  J Dermatolog Treat. 2021 May;32(3):302-309. doi: 10.1080/09546634.2019.1656797. Epub 2019 Oct 3. PMID: 31581919

Van Voorhees AS, Mason MA, Harrold LR, Guo N, Guana A, Tian H, Herrera V, Strober BE. Characterization of insufficient responders to ustekinumab in patients with moderate-to-severe psoriasis in the US Corrona Psoriasis Registry. J Dermatolog Treat. 2021 Dec;32(8):907-915. doi: 10.1080/09546634.2020.1720586. Epub 2020 Feb 27.

Winthrop KL, Citera G, Gold D, Henrohn D, Connell CA, Shapiro AB, Shi H, Onofrei AM, Pappas DA, Schulze-Koops H. Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry. Ann Rheum Dis. 2021 Jan;80(1):134-136. doi: 10.1136/annrheumdis-2020-218992. Epub 2020 Oct 12. PMID: 33046447

Wu JJ, Kearns DG, Lin TC, Chat VS, Litman HJ, Dube B, McLean RR. Characterization of non-responders to interleukin-17 inhibitors in moderate to severe psoriasis patients enrolled in the Corrona ® Psoriasis Registry. J Eur Acad Dermatol Venereol. 2021 Aug;35(8):e531-e533. doi: 10.1111/jdv.17270. Epub 2021 Apr 27. PMID: 33834554

Wu JJ, Schrader A, McLean RR, Valdecantos W, Etzel C, Singh R. Improvement in Body Surface Area is Associated with Better Quality of Life Among Patients with Psoriasis in the Corrona Psoriasis Registry. J Am Acad Dermatol. 2021 Jun;84(6):1715-1717. doi: 10.1016/j.jaad.2020.08.039. Epub 2020 Aug 13. PMID: 32798582

Wu AJ, Harrison RW, Zhu B, Goldblum OM, Malatestinic WN, Burge R, Murage MJ. Understanding characteristics of patients newly initiating ixekizumab: Findings from the Corrona Psoriasis Registry. J Comp Eff Res. 2021 Feb;10(2):157-167. doi: 10.2217/cer-2020-0113. Epub 2020 Dec 23. PMID: 33355477

2020

Baker JF, Reed G, Kremer J. Weight Fluctuation and the Risk of Cardiovascular Events in Patients with Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2020 Oct 1. doi: 10.1002/acr.24469. Online ahead of print. PMID: 33002323

Bergman MJ, Kivitz AJ, Pappas DA, Kremer JM, Zhang L, Jeter A, Withers JB. Clinical Utility and Cost Savings in Predicting Inadequate Response to Anti-TNF Therapies in Rheumatoid Arthritis. Rheumatol Ther. 2020 Dec;7(4):775-792. doi: 10.1007/s40744-020-00226-3. Epub 2020 Aug 14. PMID: 32797404

Enos CW, O’Connell KA, Harrison RW, McLean RR, Dube B, Van Voorhees AS. Geographic Variations in Biologic Therapy and Disease Characteristics: A Pilot-Study in the Corrona Psoriasis Registry. J Drugs Dermatol. 2020 Nov 1;19(11):1119-1122. doi: 10.36849/JDD.2020.5366. PMID: 33196741

Harrold LR, Shan Y, Rebello S, Kramer N, Connolly SE, Alemao E, Kelly S, Kremer JM, Rosenstein ED. Disease activity and patient-reported outcomes in patients with rheumatoid arthritis and Sjögren’s syndrome enrolled in a large observational US registry.Rheumatol Int. 2020 Aug;40(8):1239-1248. doi: 10.1007/s00296-020-04602-8. Epub 2020 May 24. PMID: 32449040

Harrold LR, Shan Y, Rebello R, Kramer N, Connolly SE, Alemao E, Kelly S, Kremer JM, Rosenstein ED. Prevalence of Sjögren’s syndrome associated with rheumatoid arthritis in the United States: an observational study from the Corrona registry. Clin Rheumatol. 2020 Jun;39(6):1899-1905. doi: 10.1007/s10067-020-05004-8. Epub 2020 Mar 4. PMID: 32130579

Harrold LR, Shan Y, Connolly SE, Alemao E, Rebello S, Guo L, Kremer JM. Association among anti-citrullinated protein antibody status, erosive disease and healthcare resource utilization in patients with rheumatoid arthritis. Curr Med Res Opin. 2020 Feb;36(2):337-342. doi: 10.1080/03007995.2019.1680354. Epub 2019 Oct 24. PMID: 31612736

Harrold LR, Patel PA, Griffith J, Litman HJ, Feng H, Schlacher CA, Kremer JM. Assessing disease severity in bio-naïve patients with RA on treatment with csDMARDs: insights from the Corrona Registry.Clin Rheumatol. 2020 Feb;39(2):391-400. doi: 10.1007/s10067-019-04727-7. Epub 2019 Oct 21. PMID: 31637609

Harrold LR, Griffith J, Zueger P, Litman HJ, Gershenson B, Islam SS, Barr CJ, Guo D, Fay J, Greenberg JD. Long-term, Real-world Safety of Adalimumab in Rheumatoid Arthritis: Analysis of a Prospective US-Based Registry. J Rheumatol. 2020 Jul 1;47(7):959-967. doi: 10.3899/jrheum.190260. Epub 2019 Aug 1. PMID: 31371657

Kremer JM, Reed G, Pappas DA, Harrold LR, Kane K, Greenberg J, Winthrop K. Hydroxychloroquine and the risk of respiratory infections among RA patients. RMD Open. 2020 Nov;6(3):e001389. doi: 10.1136/rmdopen-2020-001389. PMID: 33161375

Lee YC, Lu B, Guan H, Greenberg JD, Kremer J, Solomon DH. Physician Prescribing Patterns and Risk for Future Chronic Opioid Use among Patients with Rheumatoid Arthritis: A Prospective Observational Cohort Study. Arthritis Rheumatol. 2020 Jul;72(7):1082-1090. doi: 10.1002/art.41240. PMID: 32103630

Mease P, Charles-Schoeman C, Cohen S, Fallon L, Woolcott J, Yun H, Kremer J, Greenberg J, Malley W, Onofrei A, Kanik KS, Graham D, Wang C, Connell C, Valdez H, Hauben M, Hung E, Madsen A, Jones TV, Curtis JR. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, events reported in the tofacitinib rheumatoid arthritis, events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development psoriasis and psoriatic arthritis development programmes and from real-world data. Ann Rheum Dis. 2020 Nov;79(11):1400-1413. doi: 10.1136/annrheumdis-2019-216761. Epub 2020 Aug 5. PMID: 32759265

Mease PJ, Liu M, Rebello S, Hua W, McLean RR, Yi E, Park Y, Ogdie A.  Characterization of Patients With Axial Spondyloarthritis by Enthesitis Presence: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. ACR Open Rheumatol. 2020 Jul;2(7):449-456. doi: 10.1002/acr2.11154. Epub 2020 Jul 6. PMID: 32627974

Mellors T, Withers JB, Ameli A, Jones A, Wang M, Zhang L, Sanchez HN, Santolini M, Valle ID, Sebek M, Cheng F, Pappas D, Kremer JM, Curtis JR, Johnson KJ, Saleh A, Ghiassian SD, Akmaev VR. Clinical Validation of a Blood-Based Predictive Test for Stratification of Response to Tumor Necrosis Factor Inhibitor Therapies in Rheumatoid Arthritis Patients. Network and Systems Medicine Volume 3.1, 2020 DOI: 10.1089/nsm.2020.000. Accepted June 18, 2020

Merola JF, Chada PL, Siegel M, Bagel J, Evans C, Lockshin B, Mason M, Guo N, McLean RR, Greenberg JD, Van Voorhees AS. The National Psoriasis Foundation Psoriasis Treatment Targets in Real World Patients: Prevalence and Association with Patient Reported Outcomes in the Corrona Psoriasis Registry.  J Eur Acad Dermatol Venereol. 2020 Sep;34(9):2051-2058. doi: 10.1111/jdv.16274. Epub 2020 Jun 9. PMID: 32027420

Owensby JK, Chen L, O’Beirne R, Ruderman EM, Harrold LR, Melnick JA, Safford MM, Curtis JR, Danila MI. Patient and Rheumatologist Perspectives Regarding Challenges to Achieving Optimal Disease Control in Rheumatoid Arthritis.  Arthritis Care Res (Hoboken). 2020 Jul;72(7):933-941. doi: 10.1002/acr.23907. PMID: 31008566

Pappas DA, St John G, Etzel CJ, Fiore S, Blachley T, Kimura T, Punekar R, Emeanuru K, Choi J, Boklage S, Kremer JM. Response to ‘Correspondence on ‘Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study’’ by Zheng et al. Ann Rheum Dis. 2020 Nov 11;annrheumdis-2020-218907. doi: 10.1136/annrheumdis-2020-218907. Online ahead of print. PMID: 33177102

Pappas DA, Shan Y, Lesperance T, Kricorian G, Karis E, Rebello S, Hua W, Accortt NA, Stryker S. Maintenance of Sustained Low Disease Activity or Remission in Patients With Rheumatoid Arthritis Treated With Etanercept Monotherapy: Results from the Corrona Registry. ACR Open Rheumatol 2020 Oct;2(10):588-594. doi: 10.1002/acr2.11168. Epub 2020 Sep 29. PMID: 32990361

Pappas DA, Blachley T, Zlotnick S, Best J, Emeanuru K, Kremer JM. Methotrexate Discontinuation and Dose Decreases After Therapy With Tocilizumab: Results From the Corrona Rheumatoid Arthritis Registry. Rheumatol Ther. 2020 Jun;7(2):357-369. doi: 10.1007/s40744-020-00200-z. Epub 2020 Mar 30. PMID: 32232740

Pappas DA, Etzel CJ, Crabtree M, Blachley T, Best J, Zlotnick S, Kremer JM. Effectiveness of Tocilizumab in Patients With Rheumatoid Arthritis is Unaffected by Comorbidity Burden or Obesity: Data From a US Registry. J Rheumatol. 2020 Oct 1;47(10):1464-1474. doi: 10.3899/jrheum.190282. Epub 2020 Jan 15. PMID: 31941801

Shahriari M, Harrison RW, Burge R, Lin CY, Malatestinic WN, Goldblum OM, McLean RR, Crabtree MM, O’Brien J, Grace EL, Murage MJ. Disease response and patient-reported outcomes among initiators of ixekizumab. J Dermatolog Treat. 2020 Dec 2;1-9. doi: 10.1080/09546634.2020.1853023. Online ahead of print. PMID: 33267635

Solomon DH, Paynter NP, Guan H, Kremer JM. External Validation of a Risk Score for Major Toxicity Among Nonsteroidal Anti-Inflammatory Drug Users: Real-World Application.  ACR Open Rheumatol. 2020 May;2(5):269-275. doi: 10.1002/acr2.11134. Epub 2020 Apr 21. PMID: 32314877

Strober BE, Germino R, Guana A, Greenberg JD, Litman HJ, Guo N, Lebwohl M.  US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry.  J Dermatolog Treat. 2020 Jun;31(4):333-341. doi: 10.1080/09546634.2019.1603361. Epub 2019 Apr 29. PMID: 31035822

2019

Bonomo L, Abittan BJ, Hashim PW, Karki C, Mason M, Lebwohl M. Combination Use of Systemic Therapies in Psoriasis: Baseline Characteristics from the Corrona Psoriasis Registry. JDrugs Dermatol. 2019 Aug 1;18(8):731-740. PMID: 31424705

Cohen SB, Kremer JM, Dandreo KJ, Reed GW, Magner R, Shan Y, Kafka S, DeHoratius RJ, Ellis L, Parenti D. Outcomes of infliximab dose escalation in patients with rheumatoid arthritis. Clin Rheumatol. 2019 Sep;38(9):2501-2508. doi: 10.1007/s10067-019-04543-z. Epub 2019 May 2. PMID: 31049762

Curtis JR, Flake DD, Weinblatt ME, Shadick NA, Ostergaard M, Hetland ML, Brahe CH, Hwang YG, Furst DE, Strand V, Etzel CJ, Pappas DA, Wang X, Hwahg CC, Sasso EH, Gutin A, Hitraya E, Lanchbury JS. Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritis. Rheumatology (Oxford) 2019 May 1;58(5):874-883. doi: 10.1093/rheumatology/key367. PMID: 30590790

Farutin V, Prod’homme T, McConnell K, Washburn N, Halvey P, Etzel CJ, Guess J, Duffner J, Getchell K, Meccariello R, Gutierrez B, Honan C, Zhao G,  Cilfone NA, Gunay NS, Hillson JL, DeLuca DS, Saunders KC, Pappas DA, Greenberg JD, Kremer JM, Manning AM, Ling LE and Capila I. Molecular profiling of rheumatoid arthritis patients reveals an association between innate and adaptive cell populations and response to anti-tumor necrosis factor.Arthritis Res Ther. 2019 Oct 23;21(1):216. doi: 10.1186/s13075-019-1999-3. PMID: 31647025

Guan Y, Zhang H, Quang D, Wang Z, Parker SCJ, Pappas DA, Kremer JM, Zhu F. Machine Learning to Predict Anti–Tumor Necrosis Factor Drug Responses of Rheumatoid Arthritis Patients by Integrating Clinical and Genetic Markers.Arthritis Rheumatol. 2019 Dec;71(12):1987-1996. doi: 10.1002/art.41056. Epub 2019 Nov 4. PMID: 31342661

Harrold LR, Litman HJ, Connolly SE, Alemao E, Kelly S, Rebello S, Hua W, Kremer JM. Comparative Effectiveness of Abatacept versus Tumour Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis who are Anti-CCP Positive in the United States Corrona Registry. Rheumatol Ther. 2019 Jun;6(2):217-230. doi: 10.1007/s40744-019-0149-3. Epub 2019 Mar 13. PMID: 30868550

Lee YC, Kremer J, Guan H, Greenberg J, Solomon DH.  Chronic Opioid Use in Rheumatoid Arthritis: Prevalence and Predictors.  Arthritis Rheumatol. 2019 May;71(5):670-677. doi: 10.1002/art.40789. Epub 2019 Mar 6. PMID: 30474933

Lillegraven S, Greenberg JD, Reed GW, Saunders K, Curtis JR, Harrold L, Hochberg MC, Pappas DA, Kremer JM, Solomon DH.  Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis.  PLoS One. 2019 Jan 23;14(1):e0210459. doi: 10.1371/journal.pone.0210459. eCollection 2019. PMID: 30673733

Mease PJ, Liu M, Rebello S, Kang H, Yi E, Park Y, Greenberg JD.  Comparative Disease Burden in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis: Data from Two Corrona Registries.  Rheumatol Ther. 2019 Dec;6(4):529-542. doi: 10.1007/s40744-019-00172-9. Epub 2019 Sep 16. PMID: 31529278

Mease PJ, Accortt NA, Rebello S, Etzel CJ, Harrison RW, Aras GA, Gharaibeh MF, Greenberg JD, Collier DH.   Persistence of tumor necrosis factor inhibitor or conventional synthetic disease-modifying antirheumatic drug monotherapy or combination therapy in psoriatic arthritis in a real-world setting.  Rheumatol Int. 2019 Sep;39(9):1547-1558. doi: 10.1007/s00296-019-04345-1. Epub 2019 Jul 18. PMID: 31321485

Mease PJ, Karki C, Liu M, Li Y, Gershenson B, Feng H, Hur P, Greenberg JD.  Discontinuation and Switching Patterns of Tumor Necrosis Factor Inhibitors (TNFis) in TNFi-Naive and –Experienced Patients With Psoriatic Arthritis.  RMD Open 2019  Apr 24;5(1):e000880. doi: 10.1136/rmdopen-2018-000880. eCollection 2019. PMID: 31168408

Mease PJ, Palmer JB, Hur P, Strober BE, Lebwohl M, Karki C, Reed GW, Etzel CJ, Greenberg JD, Helliwell PS. Utilization of the validated Psoriasis Epidemiology Screening Tool (PEST) to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross-sectional analysis from the US-based Corrona Psoriasis Registry. J Eur Acad Dermatol Venereol. 2019 May;33(5):886-892. doi: 10.1111/jdv.15443. Epub 2019 Mar 5. PMID: 30663130

Mease PJ, Etzel CJ, Huster WJ, Muram T, Armstrong A, Lisse J, Rebello S, Dodge R, Mwangi MJ, Greenberg J, Malatestinic W. Understanding the association between skin involvement and joint activity in patients with psoriatic arthritis: experience from the Corrona Registry. RMD Open. 2019 May 24;5(1):e000867. doi: 10.1136/rmdopen-2018-000867. eCollection 2019. PMID: 31245045

Ogdie A, Palmer JL, Greenberg J, Curtis JR, Harrold LR, Solomon DH, Kavanaugh A, Kremer JM, Mease PJ.  Predictors of Achieving Remission among Patients with Psoriatic Arthritis Initiating a Tumor Necrosis Factor Inhibitor.  J Rheumatol. 2019 May;46(5):475-482. doi: 10.3899/jrheum.171034. Epub 2019 Jan 15. PMID: 30647182

Pappas DA, Rebello S, Liu M, Schenfeld J, Li Y, Collier DH, Accortt NA.  Therapy With Biologic Agents After Diagnosis of Solid Malignancies: Results From the Corrona Registry.  J Rheumatol. 2019 Nov;46(11):1438-1444. doi: 10.3899/jrheum.171457. Epub 2019 Apr 1. PMID: 30936285

Pappas DA, Etzel CJ, Zlotnick S, Best J, Blachley T, Kremer JM. Patterns of Prednisone Use in Patients with Rheumatoid Arthritis Initiating Treatment with Tocilizumab in Routine US Clinical Practice. Rheumatol Ther. 2019 Sep;6(3):421-433. doi: 10.1007/s40744-019-0162-6. Epub 2019 Jun 25. PMID: 31240499

Reed GW, Gerber RA, Shan Y, Takiya L, Dandreo KJ, Gruben D, Kremer J, Wallenstein G. Real-World Comparative Effectiveness of Tofacitinib and Tumor Necrosis Factor Inhibitors as Monotherapy and Combination Therapy for Treatment of Rheumatoid Arthritis.  Rheumatol Ther. 2019 Nov 9. doi: 10.1007/s40744-019-00177-4. Online ahead of print. PMID: 31707603

Strober B, Greenberg J, Karki C, Mason M, Guo N, Hur P, Herrera V, Feng L, Lebwohl M.  Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life, and work productivity among US patients: real-world data from the Corrona Psoriasis Registry. BMJ Open. 2019 Apr 20;9(4):e027535. doi: 10.1136/bmjopen-2018-027535. PMID: 31005939

2018

Accortt NA, Lesperance T, Liu M, Rebello S, Trivedi M, Li Y, Curtis JR.  Impact of Sustained Remission on the Risk of Serious Infection in Patients With Rheumatoid Arthritis.  Arthritis Care Res (Hoboken). 2018 May;70(5):679-684. doi: 10.1002/acr.23426. Epub 2018 Mar 11. PMID: 28960869

Alemao E, Litman HJ, Connolly SE, Kelly S, Hua W, Rosenblatt L, Rebello S, Kremer JM, Harrold LR.  Do Poor Prognostic Factors in Rheumatoid Arthritis Affect Treatment Choices and Outcomes? Analysis of a US Rheumatoid Arthritis Registry.  J Rheumatol. 2018 Oct;45(10):1353-1360. doi: 10.3899/jrheum.171050. Epub 2018 Jul 1. PMID: 29961696

Curtis JR, Xie F, Chen L, Greenberg JD, Zhang J.  Evaluation of a Methodological Approach to Define An Inception Cohort of Rheumatoid Arthritis Patients Using Administrative Data.  Arthritis Care Res (Hoboken). 2018 Oct;70(10):1541-1545. doi: 10.1002/acr.23533. Epub 2018 Sep 4. PMID: 29409118

Curtis JR, Greenberg JD, Harrold LR, Kremer JM, Palmer JL.  Influence of obesity, age, and comorbidities on the multi-biomarker disease activity test in rheumatoid arthritis.  Semin Arthritis Rheum. 2018 Feb;47(4):472-477. doi: 10.1016/j.semarthrit.2017.07.010. Epub 2017 Aug 2. PMID: 28947312

Harrold LR, Reed GW, Best J, Zlotnick S, Kremer JM.  Real-world Comparative Effectiveness of Tocilizumab Monotherapy vs. Tumor Necrosis Factor Inhibitors with Methotrexate in Patients with Rheumatoid Arthritis.  Rheumatol Ther. 2018 Dec;5(2):507-523. doi: 10.1007/s40744-018-0127-1. Epub 2018 Oct 6. PMID: 30293218

Harrold LR, Reed GW, John A, Barr CJ, Soe K, Magner R, Saunders KC, Ruderman EM, Haselkorn T, Greenberg JD, Gibofsky A, Harrington JT, Kremer JM.  A Cluster-Randomized Trial of a Behavioral Intervention to Incorporate a Treat-to-Target Approach to Care of US Patients With Rheumatoid Arthritis.  Arthritis Care Res (Hoboken). 2018 Mar;70(3):379-387. doi: 10.1002/acr.23294. Epub 2018 Feb 6. PMID: 28544704

Harrold LR, Litman HJ, Connolly SE, Kelly S, Hua W, Alemao E, Rosenblatt L, Rebello S, Kremer JM.  Effect of Anticitrullinated Protein Antibody Status on Response to Abatacept or Antitumor Necrosis Factor-α Therapy in Patients with Rheumatoid Arthritis: A US National Observational Study.  J Rheumatol. 2018 Jan;45(1):32-39. doi: 10.3899/jrheum.170007. Epub 2017 Nov 1. PMID: 29093151

Harrold LR, Litman HJ, Saunders KC, Dandreo KJ, Gershenson B, Greenberg JD, Low R, Stark J, Suruki R, Jaganathan S, Kremer JM, Yassine M.  One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry. Arthritis Res Ther. 2018 Jan 2;20(1):2. doi: 10.1186/s13075-017-1496-5. PMID: 29329557

Harrold LR, Stolshek BS, Rebello S, Collier DH, Mutebi A, Wade SW, Malley W, Greenberg JD, Etzel CJ.  Rebound in Measures of Disease Activity and Symptoms in Corrona Registry Patients with Psoriatic Arthritis Who Discontinue Tumor Necrosis Factor Inhibitor Therapy after Achieving Low Disease Activity.  J Rheumatol. 2018 Jan;45(1):78-82. doi: 10.3899/ jrheum.161567. Epub 2017 Oct 1. PMID: 28966209

Kavanaugh A, Singh R, Karki C, Etzel CJ, Kremer JM, Greenberg JD, Griffin J.  Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis.  Clin Rheumatol. 2018 Aug;37(8):2275-2280. doi: 10.1007/s10067-018-4140-0. Epub 2018 Jun 4. PMID: 29869112

Larmore CJ, Boytsov NN, Gaich CL, Zhang X, Araujo AB, Rebello S, Salim BA, Reed GW, Harrold LR. Examination of Patient-Reported Outcomes in Association with TNF-Inhibitor Treatment Response: Results from a US Observational Cohort Study.  Rheumatol Ther. 2018 Jun;5(1):215-229. doi: 10.1007/s40744-017-0092-0. Epub 2018 Jan 10. PMID: 29322372

Mease PJ, van der Heijde D, Karki C, Palmer JB, Liu M, Pandurengan R, Park Y, Greenberg JD.  Characterization of Patients With Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis in the US-Based Corrona Registry.  Arthritis Care Res (Hoboken). 2018 Nov;70(11):1661-1670. doi: 10.1002/acr.23534. Epub 2018 Oct 8. PMID: 29409123

Mease PJ, Karki C, Liu M, Kavanaugh A, Ritchlin CT, Huynh DH, Palmer JB, Greenberg JD.  Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry.  RMD Open. 2018 Apr 25;4(1):e000638. doi: 10.1136/rmdopen-2017-000638. eCollection 2018. PMID: 29707232

Mease PJ, Palmer JB, Liu M, Kavanaugh A, Pandurengan R, Ritchlin CT, Karki C, Greenberg JD.  Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis: Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. J Rheumatol. 2018 Oct;45(10):1389-1396. doi: 10.3899/jrheum.171094. Epub 2018 Jul 1. PMID: 29961691

Mease PJ, van der Heijde D, Karki C, Liu M, Park Y, Greenberg JD.  Tumor Necrosis Factor Inhibitor Discontinuation in Patients with Ankylosing Spondylitis:  An Observational Study From the US-Based Corrona Registry.  Rheumatol Ther. 2018 Dec;5(2):537-550. doi: 10.1007/s40744-018-0129-z. Epub 2018 Oct 23. PMID: 30353387

O’Dell JR, Cohen SB, Thorne JC, Kremer J.  Treatment of rheumatoid arthritis in the USA: premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate.  Open Access Rheumatol. 2018 Jul 3;10:97-101. doi: 10.2147/OARRR.S169152. eCollection 2018. PMID: 30013407

Pappas DA, Nyberg F, Kremer JM, Lampl K, Reed GW, Horne L, Ho M, Onofrei A, Malaviya AN Rillo OL, Radominski SC, Gal J, Gibofsky A, Popkova TV, Laurindo L, Kerzberg EM, Zahora R, Pons-Estel BA, Curtis JR, Furst DE, Greenberg JD.  Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: a multinational cross-sectional study.  Clin Rheumatol. 2018 Sep;37(9):2331-2340. doi: 10.1007/s10067-018-4113-3. Epub 2018 Apr 25. PMID: 29696436

Pappas DA,  Gerber RA, Litman HJ, Gruben D, Geier J, Hua WD, Chen C, Li Y, Kremer JM, Andrews JS, Bourret JA.  Delayed Treatment Acceleration in Patients with Rheumatoid Arthritis Who Have Inadequate Response to Initial Tumor Necrosis Factor Inhibitors: Data from the Corrona Registry. Am Health Drug Benefits. 2018 May;11(3):148-158. PMID: 29910846

Strober B, Karki C, Mason M, Guo N, Holmgren SH, Greenberg JD, Lebwohl M.   Characterization of disease burden, comorbidities and treatment use in a large US based cohort: Results from the Corrona Psoriasis Registry. J Am Acad Dermatol. 2018 Feb;78(2):323-332. doi: 10.1016/j.jaad.2017.10.012. Epub 2017 Oct 16. PMID: 29051036

Strober B.  Commentary: The Corrona-National Psoriasis Foundation Psoriasis Registry: A new collaborative approach for postapproval registries.  J Am Acad Dermatol. 2018 Feb;78(2):333-335. doi: 10.1016/j.jaad.2017.10.011. Epub 2017 Oct 16. PMID: 29042231

Yamanaka H, Kishimoto M, Pappas DA, Greenberg JD, Kremer JM, Tanaka Y.  Design characteristics of the Corrona Japan rheumatoid arthritis registry. Mod Rheumatol. 2018 Jan;28(1):95-100. doi: 10.1080/14397595.2017.1317383. Epub 2017 Apr 27. PMID: 28448195

2017

Anandarajah AP, El-Taha M, Peng C.  The Relationship between Focal and Generalized Bone Loss in Rheumatoid Arthritis.  Curr Rheumatol Rev. 2017;13(2):152-157. doi: 10.2174/1573397112666160909094403. PMID: 27632985

Cappelli LC, Palmer JL, Kremer J, Bingham CO 3rd.  Tocilizumab treatment leads to improvement in disease activity regardless of CCP status in rheumatoid arthritis.  Semin Arthritis Rheum. 2017 Oct;47(2):165-169. doi: 10.1016/j.semarthrit.2017.03.024. Epub 2017 Apr 1. PMID: 28477897

Cui J, Diogo D, Stahl EA, Canhao H, Mariette X, Greenberg JD, Okada Y, Pappas DA, Fulton RS, Tak PP, Nurmohamed MT, Lee A, Larson DE, Kurreeman F, Deluca TL, O’Laughlin M, Fronick CC, Fulton LL, Mardis ER, van der Horst-Bruinsma IE, Wolbink GJ, Gregersen PK, Kremer JM, Crusius JB, de Vries N, Huizinga TW, Fonseca JE, Miceli-Richard C, Karlson EW, Coenen MJ, Barton A, Plenge RM, Raychaudhuri S. Brief Report: The Role of Rare Protein-Coding Variants in Anti-Tumor Necrosis Factor Treatment Response in Rheumatoid Arthritis.  Arthritis Rheumatol. 2017 Apr;69(4):735-741. doi: 10.1002/art.39966. PMID: 27788309

Curtis JR, Chen L, Greenberg JD, Harrold L, Kilgore ML, Kremer JM, Solomon DH, Yun H. The clinical status and economic savings associated with remission among patients with rheumatoid arthritis: leveraging linked registry and claims data for synergistic insights. Pharmacoepidemiol Drug Saf. 2017 Mar;26(3):310-319. doi: 10.1002/pds.4126. Epub 2016 Dec 28. PMID: 28028867

Harrold LR, John A, Reed GW, Haselkorn T, Karki C, Li Y, Best J, Zlotnick S, Kremer JM, Greenberg JD. Impact of Tocilizumab Monotherapy on Clinical and Patient-Reported Quality-of-Life Outcomes in Patients with Rheumatoid Arthritis.  Rheumatol Ther. 2017 Dec;4(2):405-417. doi: 10.1007/s40744-017-0081-3. Epub 2017 Sep 21. PMID: 28936808

Harrold LR, John A, Best J, Zlotnick S, Karki C, Li Y, Greenberg JD, Kremer JM.  Impact of rituximab on patient-reported outcomes in patients with rheumatoid arthritis from the US Corrona Registry.  Clin Rheumatol. 2017 Sep;36(9):2135-2140. doi: 10.1007/s10067-017-3742-2. Epub 2017 Jul 17. PMID: 28718043

Harrold LR, Etzel CJ, Gibofsky A, Kremer JM, Pillinger MH, Saag K, G Schlesinger N, Terkeltaub R, Cox V, Greenberg JD.  Sex differences in gout characteristics: tailoring care for women and men. BMC Musculoskelet Disord. 2017 Mar 14;18(1):108. doi: 10.1186/s12891-017-1465-9. PMID: 28292303

Harrold LR, Stolshek BS, Rebello S, Collier DH, Mutebi A, Wade SW, Malley W, Greenberg JD, Etzel CJ.  Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry. Clin Rheumatol. 2017 Apr;36(4):895-901. doi: 10.1007/s10067-017-3593-x. Epub 2017 Mar 7. PMID: 28271234

Harrold LR, Litman HJ, Connolly SE, Kelly S, Hua W, Alemao E, Rosenblatt L, Rebello S, Kremer JM.  A window of opportunity for abatacept in RA: is disease duration an independent predictor of low disease activity/remission in clinical practice?  Clin Rheumatol. 2017 Jun;36(6):1215-1220. doi: 10.1007/s10067-017-3588-7. Epub 2017 Mar 1. PMID: 28251392

Huynh DH, Boyd TA, Etzel CJ, Cox V, Kremer J, Mease P, Kavanaugh A.  Persistence of low disease activity after tumour necrosis factor inhibitor (TNFi) discontinuation in patients with psoriatic arthritis.  RMD Open. 2017 Jan 16;3(1):e000395. doi: 10.1136/rmdopen-2016-000395. eCollection 2017. PMID: 28123783

Kavanaugh A, Keystone E, Greenberg JD, Reed GW, Griffith JM, Friedman AW, Saunders KC, Ganguli A.  Benefit of biologics initiation in moderate versus severe rheumatoid arthritis: evidence from a United States registry.  Rheumatology (Oxford). 2017 Jul 1;56(7):1095-1101. doi: 10.1093/rheumatology/kex042. PMID: 28340006

Mease PJ, Karki C, Palmer JB, Etzel CJ, Kavanaugh A, Ritchlin CT, Malley W, Herrera V, Tran M, Greenberg JD.  Clinical and Patient-reported Outcomes in Patients with Psoriatic Arthritis (PsA) by Body Surface Area Affected by Psoriasis: Results from the Corrona PsA/Spondyloarthritis Registry.  J Rheumatol. 2017 Aug;44(8):1151-1158. doi: 10.3899/jrheum.160963. Epub 2017 Jun 15. PMID: 28620063

Mease PJ, Karki C, Palmer JB, Etzel CJ, Kavanaugh A, Ritchlin CT, Malley W, Herrera V, Tran M, Greenberg JD.  Clinical Characteristics, Disease Activity, and Patient-Reported Outcomes in Psoriatic Arthritis Patients With Dactylitis or Enthesitis: Results From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry.  Arthritis Care Res (Hoboken). 2017 Nov;69(11):1692-1699. doi: 10.1002/acr.23249. PMID: 28376239

Mease PJ, Lesperance T, Liu M, Collier DH, Mason M, Deveikis S, Accortt NA.  Changes in Treatment Patterns in Patients with Psoriatic Arthritis Initiating Biologic and Nonbiologic Therapy in a Clinical Registry.  J Rheumatol. 2017 Feb;44(2):184-192. doi: 10.3899/jrheum.160343. Epub 2017 Jan 15. PMID: 28089969

Pappas DA, Kremer JM, Griffith J, Reed G, Salim B, Karki C, Garg V.  Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry.  Rheumatol Ther. 2017 Dec;4(2):375-389. doi: 10.1007/s40744-017-0077-z. Epub 2017 Aug 24. PMID: 28840531

Reed GW, Collier DH, Koenig AS, Saunders KC, Pappas DA, Litman HJ, Kremer JM, Kotak S.  Clinical and demographic factors associated with change and maintenance of disease severity in a large registry of patients with rheumatoid arthritis. Arthritis Res Ther. 2017 Apr 27;19(1):81. doi: 10.1186/s13075-017-1289-x. PMID: 28449692

Strand V, Miller P, Williams SA, Saunders K, Grant S, Kremer J.  Discontinuation of Biologic Therapy in Rheumatoid Arthritis: Analysis from the Corrona RA Registry.Rheumatol Ther. 2017 Dec;4(2):489-502. doi: 10.1007/s40744-017-0078-y. Epub 2017 Aug 22. PMID: 28831751

Yamanaka H, Askling J, Berglind N, et al. Infection rates in patients from five rheumatoid arthritis (RA) registries: contextualising an RA clinical trial programme. RMD Open. 2017 Oct 10;3(2):e000498. doi: 10.1136/rmdopen-2017-000498. eCollection 2017. PMID: 29081988

2016

Askling J, Berglind N, Franzen S, Frisell T, Garwood C, Greenberg JD, Ho M, Holmqvist M, Horne L, Inoue E, Michaud K, Nyberg F, Pappas DA, Reed G, Tanaka E, Tran TN, Verstappen SMM, Yamanaka H, Wesby-van Swaay E, Symmons D.  How comparable are rates of malignancies in patients with rheumatoid arthritis across the world? A comparison of cancer rates, and means to optimise their comparability, in five RA registries.  Ann Rheum Dis. 2016 Oct;75(10):1789-96. doi: 10.1136/annrheumdis-2015-208105. Epub 2015 Nov 30.

Boytsov N, Harrold LR, Mason MA, Gaich CL, Zhang X, Larmore CJ, Rebello S, Araujo AB.  Increased healthcare resource utilization in higher disease activity levels in initiators of TNF-inhibitors among US rheumatoid arthritis patients.Curr Med Res Opin. 2016 Dec;32(12):1959-1967. Epub 2016 Aug 25.

Curtis JR, Bharat A, Chen L, Greenberg JD, Harrold L, Kremer JM, Sommers T, Pappas D. Agreement between Rheumatologist and Patient-reported Adherence to Methotrexate in a US Rheumatoid Arthritis Registry.J Rheumatol. 2016 Jun;43(6):1027-9. doi: 10.3899/jrheum.151136. Epub 2016 May 1.

Franke L, el Bannoudi H, Jansen DT, Kok K, Trynka G, Diogo D, Swertz M, Fransen K, Knevel R, Gutierrez-Achury J, Ärlestig L, Greenberg JD, Kremer J, Pappas DA, Kanterakis A, Weersma RK, van der Helm-van Mil AH, Guryev V, Rantapää-Dahlqvist S, Gregersen PK, Plenge RM, Wijmenga C, Huizinga TW, Ioan-Facsinay A, Toes RE, Zhernakova A.  Association analysis of copy numbers of FC-gamma receptor genes for rheumatoid arthritis and other immune-mediated 

phenotypes.  Eur J Hum Genet. 2016 Feb;24(2):263-70. doi: 10.1038/ejhg.2015.95.

Greenberg JD, Palmer JB, Li Y, Herrera V, Tsang Y, Liao M. Healthcare Resource Use and Direct Costs in Patients with Ankylosing Spondylitis and Psoriatic Arthritis in a Large US Cohort. J Rheumatol. 2016 Jan;43(1):88-96. doi: 10.3899/jrheum.150540. Epub 2015 Dec 1.

Harrold LR, Reed GW, Solomon DH, Curtis JR, Liu M, Greenberg JD, Kremer JM. Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry. Arthritis Res Ther. 2016 Dec 1;18(1):280.

Harrold L, Reed G, Kremer J, Curtis J, Solomon D, Hochberg M, Kavanaugh A, Saunders K, Shan Y, Spruill T, Pappas D, Greenberg J. Identifying factors associated with concordance with the American College of Rheumatology rheumatoid arthritis treatment recommendations. Arthritis Res Ther. 2016;18:94. doi: 10.1186/s13075-016-0992-3.

Harrold LR, Reed GW, Karki C, Magner R, Shewade A, John A, Kremer JM, Greenberg JD. Risk of infection associated with subsequent biologic use after rituximab: Results from a national rheumatoid arthritis patient registry. Arthritis Care Res (Hoboken). 2016 Dec;68(12):1888-1893. doi: 10.1002/acr.22912.

Herrinton LJ, Harrold L, Salman C, Liu L, Goldfien R, Asgari M, Gelfand JM, Wu JJ, Curtis JR. Population Variations in Rheumatoid Arthritis Treatment and Outcomes, Northern California, 1998-2009. Perm J. 2016 Winter;20(1):4-12. doi: 10.7812/TPP/15-028. Epub 2015 Dec 21.

Kremer JM.  The Corrona US registry of rheumatic and autoimmune diseases.  Clin Exp Rheumatol. 2016 Sep-Oct;34(5 Suppl 101):S96-S99. Epub 2016 Oct 19.

Michaud K, Berglind N, Franzén S, Frisell T, Garwood C, Greenberg JD, Ho M, Holmqvist M, Horne L, Inoue E, Nyberg F, Pappas DA, Reed G, Symmons D, Tanaka E, Tran TN, Verstappen SMM, Wesby-van Swaay E, Yamanaka H, Askling J.  Can rheumatoid arthritis (RA) registries provide contextual safety data for modern RA clinical trials? The case for mortality and cardiovascular disease. Ann Rheum Dis. 2016 Oct;75(10):1797-805. doi: 10.1136/annrheumdis-2015-208698. Epub 2016 Feb 8.

Pappas DA, John A, Curtis JR, Reed GW, Karki C, Magner R, Kremer JM, Shewade A, Greenberg JD.  Dosing of Intravenous Tocilizumab in a Real-World Setting of Rheumatoid Arthritis — Analyses From the Corrona Registry.  Rheumatol Ther. 2016 Jun;3(1):103-115. doi: 10.1007/s40744-016-0028-0. Epub 2016 Feb 8.

Rathbun AM, Harrold LR, Reed GW.  A Prospective Evaluation of the Effects of Prevalent Depressive Symptoms on Disease Activity in Rheumatoid Arthritis Patients Treated With Biologic Response Modifiers.  Clin Ther. 2016 Jul;38(7):1759-1772.e3. doi: 10.1016/j.clinthera.2016.06.007. Epub 2016 Jun 29.

Schlesinger N, Etzel C, Greenberg J, Kremer J, Harrold LR.  Gout Prophylaxis Evaluated According to the 2012 American College of Rheumatology Guidelines: Analysis from the CORRONA Gout Registry. J. Rheumatol. 2016 May;43(5):924-30. doi: 10.3899/jrheum.150345. Epub 2016 Mar 15.

Shrestha A, Bahce-Altuntas A, Mowrey W, Broder A.  Active peripheral inflammation is associated with pro-atherogenic lipid profile in psoriatic arthritis.  Semin Arthritis Rheum. 2016 Dec;46(3):286-290. doi: 10.1016/j.semarthrit.2016.05.011. Epub 2016 Jun 2.

Sieberts SK, Zhu F, García-García J, Stahl E, Pratap A, Pandey G, Pappas D, Aguilar D, Anton B, Bonet J, Eksi R, Fornés O, Guney E, Li H, Marín MA, Panwar B, Planas-Iglesias J, Poglayen D, Cui J, Falcao AO, Suver C, Hoff B, Balagurusamy VS, Dillenberger D, Neto EC, Norman T, Aittokallio T, Ammad-Ud-Din M, Azencott CA, Bellón V, Boeva V, Bunte K, Chheda H, Cheng L, Corander J, Dumontier M, Goldenberg A, Gopalacharyulu P, Hajiloo M, Hidru D, Jaiswal A, Kaski S, Khalfaoui B, Khan SA, Kramer ER, Marttinen P, Mezlini AM, Molparia B, Pirinen M, Saarela J, Samwald M, Stoven V, Tang H, Tang J, Torkamani A, Vert JP, Wang B, Wang T, Wennerberg K, Wineinger NE, Xiao G, Xie Y, Yeung R, Zhan X, Zhao C; Members of the Rheumatoid Arthritis Challenge Consortium, Greenberg J, Kremer J, Michaud K, Barton A, Coenen M, Mariette X, Miceli C, Shadick N, Weinblatt M, de Vries N, Tak PP, Gerlag D, Huizinga TW, Kurreeman F, Allaart CF, Louis Bridges S Jr, Criswell L, Moreland L, Klareskog L, Saevarsdottir S, Padyukov L, Gregersen PK, Friend S, Plenge R, Stolovitzky G, Oliva B, Guan Y, Mangravite LM, Bridges SL, Criswell L, Moreland L, Klareskog L, Saevarsdottir S, Padyukov L, Gregersen PK, Friend S, Plenge R, Stolovitzky G, Oliva B, Guan Y, Mangravite LM.  Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis.  Nat Commun. 2016 Aug 23;7:12460. doi: 10.1038/ncomms12460.

Strand V, Greenberg JD, Griffith J, Bao Y, Saunders KC, Garg V, Li G, Ganguli A. Impact of Treatment With Biologic Agents on the Use of Mechanical Devices Among Rheumatoid Arthritis Patients in a Large US Patient Registry. Arthritis Care Res, 2016 68: 914–921. doi: 10.1002/acr.22784.

2015

Diogo D, Bastarache L, Liao KP, Graham RR, Fulton RS, Greenberg JD, Eyre S, Bowes J, Cui J, Lee A, Pappas DA, Kremer JM, Barton A, Coenen MJ, Franke B, Kiemeney LA, Mariette X, Richard-Miceli C, Canhão H, Fonseca JE, de Vries N, Tak PP, Crusius JB, Nurmohamed MT, Kurreeman F, Mikuls TR, Okada Y, Stahl EA, Larson DE, Deluca TL, O’Laughlin M, Fronick CC, Fulton LL, Kosoy R, Ransom M, Bhangale TR, Ortmann W, Cagan A, Gainer V, Karlson EW, Kohane I, Murphy SN, Martin J, Zhernakova A, Klareskog L, Padyukov L, Worthington J, Mardis ER, Seldin MF, Gregersen PK, Behrens T, Raychaudhuri S, Denny JC, Plenge RM.  TYK2 protein-coding variants protect against rheumatoid arthritis and autoimmunity, with no evidence of major pleiotropic effects on non-autoimmune complex traits.  PLoS One. 2015 Apr 7;10(4):e0122271. doi: 10.1371/journal.pone.0122271. eCollection 2015.

Harrold LR, Reed GW, Kremer JM, Curtis JR, Solomon DH, Hochberg MC, Greenberg JD. The comparative effectiveness of abatacept versus anti-tumor necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumor necrosis factor. Ann Rheum Dis 2015 Feb;74(2):430-6. doi: 10.1136/annrheumdis-2013-203936.

Harrold LR, Reed GW, Magner R, Shewade A, John A, Greenberg JD, Kremer JM. Comparative effectiveness and safety of rituximab versus subsequent anti-tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti-tumor necrosis factor therapies in the United States Corrona registry. Arthritis Res Ther 2015;17:256. doi: 10.1186/s13075-015-0776-1.

Harrold LR, Reed GW, Shewade A, Magner R, Saunders KC, John A, et al. Effectiveness of rituximab for the treatment of rheumatoid arthritis in patients with prior exposure to anti-TNF: Results from the CORRONA registry.  J Rheumatol. 2015 Jul;42(7):1090-8. doi: 10.3899/jrheum.141043. Epub 2015 May 1.

Kaushik P, Solomon DH, Greenberg JD, Anderson JT, Reed G, Pala O, Sumbul-Yuksel B, Kadam P, Kremer JM; CORRONA investigators. Subcutaneous nodules are associated with cardiovascular events in patients with rheumatoid arthritis: results from a large US registry.

Clin Rheumatol. 2015 Oct;34(10):1697-704. doi: 10.1007/s10067-015-3032-9. Epub 2015 Aug 5.

Kavanaugh A, Lee SJ, Curtis JR, Greenberg JD, Kremer JM, Soto L, Etzel CJ, Cox V, Yoshida K, Reed GW, Solomon DH. Discontinuation of tumor necrosis factor inhibitors In rheumatoid arthritis patients in low disease activity: persistent benefits. 2015 Jun;74(6):1150-5. doi: 10.1136/annrheumdis-2014-206435.

Kim K, Bang SY, Lee HS, Cho SK, Choi CB, Sung YK, Kim TH, Jun JB, Yoo DH, Kang YM, Kim SK, Suh CH, Shim SC, Lee SS, Lee J, Chung WT, Choe JY, Shin HD, Lee JY, Han BG, Nath SK, Eyre S, Bowes J, Pappas DA, Kremer JM, Gonzalez-Gay MA, Rodriguez-Rodriguez L, Ärlestig L, Okada Y, Diogo D, Liao KP, Karlson EW, Raychaudhuri S, Rantapää-Dahlqvist S, Martin J, Klareskog L, Padyukov L, Gregersen PK, Worthington J, Greenberg JD, Plenge RM, Bae SC.  High-density genotyping of immune loci in Koreans and Europeans identifies eight new rheumatoid arthritis risk loci.  Ann Rheum Dis. 2015 Mar;74(3):e13. doi: 10.1136/annrheumdis-2013-204749. Epub 2014 Feb 14.

Lee SH, Byrne EM, Hultman CM, Kähler A, Vinkhuyzen AA, et al.New data and an old puzzle: the negative association between schizophrenia and rheumatoid arthritis.  Int J Epidemiol. 2015 Oct;44(5):1706-21.

Mease PJ, Collier DH, Saunders KC, Li G, Kremer JM, Greenberg JD. Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results form the Corrona registry. RMD Open. 2015 Dec 30;1(1):e000181. doi: 10.1136/rmdopen-2015-000181. eCollection 2015.

Nyberg F, Askling F, Berglind N, Franzen S, Ho M, Holmqvist, Horne L, Lampl K, Michaud K,  Pappas D, Reed G, Symmons D, Tanaka E, Tran T, Verstappen S, Wesby-van Swaay E, Yamanaka H, Greenberg JD.  Using epidemiological registry data to provide background rates as context for adverse events in a rheumatoid arthritis drug development program: a coordinated approach.  Pharmacoepidemiol Drug Saf. 2015 Nov;24(11):1121-32. doi: 10.1002/pds.3854. Epub 2015 Aug 25.

Pappas DA, Hooper MM, Kremer JM, Reed GW, Shan Y, Wenkert D, Greenberg JD, Curtis JR. Herpes zoster reactivation in patients with rheumatoid arthritis: Analysis of disease characteristics and disease modifying anti-rheumatic drugs. Arthritis Care Res (Hoboken). 2015 Nov 24; 67(12). doi: 10.1002/acr.22628.

Pappas D, Kent J, Greenberg J, Mason M, Kremer J, Holt R. Delays in Initiation of Disease-Modifying Therapy in Rheumatoid Arthritis Patients: Data from a US-Based Registry. 

Rheumatol Ther. 2015 Dec;2(2):153-164. Epub 2015 Sep 29.

Pappas DA, Reed GW, Saunders KC, John A, Shewade A, Greenberg JD, Kremer JM. Characteristics associated with biologic monotherapy use in biologic-naive patients with rheumatoid arthritis in a US registry population.  Rheumatol Ther. 2015 Jun;2(1):85-96. Epub 2015 Jan 27.

Rathbun AM, Harrold LR, Reed GW. Temporal associations between the different domains of rheumatoid arthritis disease activity and the onset of patient-reported depressive symptoms.Clin Rheumatol.2015 Apr;34(4):653-63. doi: 10.1136/annrheumdis-2013-203936.

Rathbun AM, Harrold LR, Reed GW. Temporal effect of depressive symptoms on the longitudinal evolution of rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken).  2015 May;67(6):765-75. doi: 10.1002/acr.22515.

Solomon DH, Greenberg J, Curtis JR, Liu M, Farkouh ME, Tsao P, Kremer JM, Etzel CJ. Derivation and internal validation of an expanded cardiovascular risk prediction score for rheumatoid arthritis (ERS-RA): A CORRONA registry study. Arthritis Rheumatol. 2015 May;67(8):1995-2003. doi: 10.1002/art.39195.

Solomon DH, Reed GW, Kremer JM, Curtis JR, Farkouh ME, Harrold LR, Hochberg MC, Tsao P, Greenberg JD. Disease activity in rheumatoid arthritis and the risk of cardiovascular events.Arthritis Rheumatol. 2015 Jun;67(6):1449-55. doi: 10.1002/art.39098.

Verstappen SM, Askling J, Berglind N, Franzen S, Frisell T, Garwood C, Greenberg JD, Holmqvist M, Horne L, Lampl K, Michaud K, Nyberg F,  Pappas DA, Reed G, Symmons DP, Tanaka E, Tran TN, Yamanaka H, Ho M. Methodological Challenges When Comparing Demographic and Clinical Characteristics of International Observational Registries.  Arthritis Care Res (Hoboken). 2015 Dec;67(12):1637-45. doi: 10.1002/acr.22661.

Yarwood A, Han B, Raychaudhuri S, Bowes J, Lunt M, Pappas DA, Kremer J, Greenberg JD, Plenge R; Rheumatoid Arthritis Consortium International (RACI), Worthington J, Barton A, Eyre S.  A weighted genetic risk score using all known susceptibility variants to estimate rheumatoid arthritis risk. Ann Rheum Dis 2015 Jan;74(1):170-6. doi: 10.1136/annrheumdis-2013-204133.

Yoshida K, Radner H, Mjaavatten MD, Greenberg JD, Kavanaugh A, Kishimoto M, Matsui K, Okada M, Reed GW, Saeki Y, Tohma S, Kremer J, Solomon DH. Incidence and predictors of biological antirheumatic drug discontinuation attempts among rheumatoid arthritis patients in remission: a Corrona and NinJa collaborative cohort study. J Rheumatol. 2015 Dec;42(12):2238-46. doi: 10.3899/jrheum.150240. Epub 2015 Nov 1.

2014 

Curtis JR, Chen L, Bharat A, Delzell E, Greenberg JD, Harrold L, Kremer JM, Setoguchi S, Solomon DH, Xie F, Yun H. Linkage of a de-identified United States rheumatoid arthritis registry with administrative data to facilitate comparative effectiveness research. Arthritis Care Res (Hoboken) 2014 Dec; 66(12):1790-8. doi: 10.1002/acr.22377.

Curtis JR, Wright NC, Xie F, Chen L, Zhang J, Saag KG, Bharat A, Kremer J, Cofield S, Winthrop K, Delzell E. Use of health plan combined with registry data to predict clinical trial recruitment. Clin Trials 2014 Feb;11(1):96-101.doi: 10.1177/1740774513512185.

Gross RL, Schwartzman-Morris JS, Krathen M A, Reed GW, Chang H, Saunders KC, Fisher MC, Greenberg JD, Putterman C, Mease PJ, Gottlieb AB, Kremer JM, Broder A. A comparison of malignancy incidence among psoriatic and rheumatoid arthritis patients in a large US cohort. Arthritis Rheumatol (Hoboken) 2014 Mar 3;66(6):1472-81.  doi: 10.1002/art.38385.

Harrold LR, Reed GR, Harrington TJ, Barr CJ, Saunders KC, Gibofsky A, Greenberg JD, John A, Devenport J, Kremer JM. The rheumatoid arthritis Treat-To-Target trial: A cluster randomized trial within the Corrona rheumatology network. BMC Musculoskelet Disord 2014 Nov 21;15:389. doi: 10.1186/1471-2474-15-389.

Kay J, Morgacheva O, Messing SP, Kremer JM, Greenberg JD, Reed GW, Gravallese EM, Furst DE. Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year. Arthritis Res Ther 2014 February 3;16(1):R40. doi: 10.1186/ar4469.

Labitigan M, Bahce-Altuntas A, Kremer JM, Reed G, Greenberg JD, Jordan N, Putterman C, Broder A.  Higher rates and clustering of abnormal lipids, obesity, and diabetes in psoriatic arthritis compared with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2014 Apr;66(4):600-7. doi: 10.1002/acr.22185.

Okada Y, Diogo D, Greenberg JD, Mouassess F, Achkar WA, Fulton RS, Denny JC, Gupta N, Mirel D, Gabriel S, Li G, Kremer JM, Pappas DA, Carroll RJ, Eyler AE, Trynka G, Stahl EA, Cui J, Saxena R, Coenen MJ, Guchelaar HJ, Huizinga TW, Dieudé P, Mariette X, Barton A, Canhão H, Fonseca JE, de Vries N, Tak PP, Moreland LW, Bridges SL Jr, Miceli-Richard C, Choi HK, Kamatani Y, Galan P, Lathrop M, Raj T, De Jager PL, Raychaudhuri S, Worthington J, Padyukov L, Klareskog L, Siminovitch KA, Gregersen PK, Mardis ER, Arayssi T, Kazkaz LA, Plenge RM. Integration of sequence data from a consanguineous family with genetic data from an outbred population identifies PLB1 as a candidate rheumatoid arthritis risk gene. PLoS One 2014 Feb 10;9(2):e87645. doi: 10.1371/journal.pone.0087645. eCollection 2014.

Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K, Kochi Y, Ohmura K, Suzuki A, Yoshida S, Graham RR, Manoharan A, Ortmann W, Bhangale T, Denny JC, Carroll RJ, Eyler AE, Greenberg JD, Kremer JM, Pappas DA, Jiang L, Yin J, Ye L, Su DF, Yang J, Xie G, Keystone E, Westra HJ, Esko T, Metspalu A, Zhou X, Gupta N, Mirel D, Stahl EA, Diogo D, Cui J, Liao K, Guo MH, Myouzen K, Kawaguchi T, Coenen MJ, van Riel PL, van de Laar MA, Guchelaar HJ, Huizinga TW, Dieudé P, Mariette X, Bridges SL Jr, Zhernakova A, Toes RE, Tak PP, Miceli-Richard C, Bang SY, Lee HS, Martin J, Gonzalez-Gay MA, Rodriguez-Rodriguez L, Rantapää-Dahlqvist S, Arlestig L, Choi HK, Kamatani Y, Galan P, Lathrop M; RACI consortium.; GARNET consortium., Eyre S, Bowes J, Barton A, de Vries N, Moreland LW, Criswell LA, Karlson EW, Taniguchi A, Yamada R, Kubo M, Liu JS, Bae SC, Worthington J, Padyukov L, Klareskog L, Gregersen PK, Raychaudhuri S, Stranger BE, De Jager PL, Franke L, Visscher PM, Brown MA, Yamanaka H, Mimori T, Takahashi A, Xu H, Behrens TW, Siminovitch KA, Momohara S, Matsuda F, Yamamoto K, Plenge RM.  Genetics of rheumatoid arthritis contributes to biology and drug discovery.  Nature. 2014 Feb 20;506(7488):376-81. doi: 10.1038/nature12873.

Pappas D, Kremer J, Reed G, Greenberg J, Curtis J. Design characteristics of the CORRONA CERTAIN study: a comparative effectiveness study of biologic agents for rheumatoid arthritis patients. BMC Musculoskelet Disord 2014 April 1;15:113. doi: 10.1186/1471-2474-15-113.

Rathbun AM, Harrold LR, Reed GW. A description of patient- and rheumatologist-reported depression symptoms in an American rheumatoid arthritis registry population.Clin Exp Rheumatol. 2014 Jul-Aug;32(4):523-32.

Solomon DH, Kremer JM, Fisher M, Curtis JR, Furer V, Hochberg MC, Reed G, Tsao P, Greenberg JD. Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum 2014 Feb;43(4):489-97. doi: 10.1016/j.semarthrit.2013.08.003. Epub 2013 Sep 5.

2013

Curtis JR, Shan Y, Harrold L Zhang J, Greenber JD, Reed GW. Patient perspectives on achieving T2T goals: A critical examination of patient reported outcomes. Arthritis Care Res (Hoboken) 2013 Oct;65(10):1707-12. doi: 10.1002/acr.22048.

Dewitt, EM, Li Y, Curtis JR, Glick HA, Greenberg JD, Anstrom KJ, Kremer JM, Reed G, Schulman KA, Reed SD. Comparative effectiveness of nonbiologic  versus biologic disease modifying antirheumatic drugs for rheumatoid arthritis. J Rheumatol 2013 Feb; 40(2):127-36. doi: 10.3899/jrheum.120400.

Diogo D, Kurreeman F, Stahl EA, Liao KP, Gupta N, Greenberg JD, Rivas MA, Hickey B, Flannick J, Thomson B, Guiducci C, Ripke S, Adzhubev I, Barton A, Kremer JM, Aldfredsson L; Consortium of Rheumatology Researchers of North America; Rheumatoid Arthritis Consortium International, Sunyaev S, Martin J, Zhernakova A, Bowes J, Eyre S, Siminovitch KA, Gregersen PK, Worthington J, Klareskog L, Padyukov L, Raychaudhuri S, Plenge RM.  Rare, low-frequency, and common varients in the protein-coding sequence of biological candidate genes from GWASs contribute to risk of rheumatoid arthritis.  Am J Hum Genet 2013 Jan 10;92(1):15-27. doi: 10.1016/j.ajhg.2012.11.012.

Greenberg JD, Spruill TM, Shan Y, Reed G, Kremer JM, Potter J, Yazici Y, Ogedegbe G, Harrold LR. Racial and ethnic disparities in disease activity in patients with rheumatoid arthritis. Am J Med 2013 Dec; 126(12):1089-98. doi: 10.1016/j.amjmed.2013.09.002.

McAllister K, Yarwood A, Bowes J, Orozco G, Viatte S, Diogo D, Hocking LJ, Steer S, Wordsworth P, Wilson AG, Morgan AW; UK Rheumatoid Arthritis Genetics Consortium; Rheumatoid Arthritis Consortium International, Kremer J, Pappas D, Gregersen P, Klareskog L, Plenge R, Barton A, Greenberg J, Worthington J, Eyre S. Brief Report: Identification of BACH2 and RAD51B as Rheumatoid Arthritis Susceptibility Loci in a Meta-Analysis of Genome-Wide Data. Arthritis Rheum 2013 Dec;65(12):3058-62. doi: 10.1002/art.38183.

Navarro-Millán I, Chen L, Greenberg JD, Pappas DA, Curtis JR. Predictors and persistence of new-onsetclinical remission in rheumatoid arthritis patients. Semin Arthritis Rheum 2013 Oct;43(2):137-43. doi: 10.1016/j.semarthrit.2013.02.002.

Pappas DA, Oh C, Plenge RM, Kremer JM, Greenberg JD. Association of rheumatoid arthritis risk alleles with response to anti-TNF biologics: results from the CORRONA registry and meta-analysis. Inflammation 2013 Apr;36(2):279-84. doi: 10.1007/s10753-012-9544-4.

Ranganath VK,  Maranian P, Elashoff DA, Woodworth, T, Khanna D, Hahn T, Sakisian C, Kremer JM, Furst DE, Paulus HE. Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis. Rheumatology (Oxford) 2013 Oct;52(10):1809-17.doi: 10.1093/rheumatology/ket224.

Sarsour K, Greenberg JD, Johnston JA, Nelson DR, O’Brien LA, Oddoux  C, Ostrer H, Pearlman A, Reed G.  The role of the FcGRIIIa polymorphism in modifying the association between treatment and outcome in patients with rheumatoid arthritis treated with rituximab versus TNF-α antagonist therapies.Clin Exp Rheumatol 2013 Mar- Apr 3;31(2):189-94.

2012

Fisher MC, Furer V, Hochberg MC, Greenberg JD, Kremer JM, Curtis JR, Reed G, Harrold L, Solomon DH. Malignancy validation in a United States registry of rheumatoid arthritis patients. BMC Musculoskelet Disord 2012 May 31;13:85. doi: 10.1186/1471-2474-13-85.

Fisher MC, Hochberg MC, El-Taha M, Kremer JM, Peng C, Greenberg JD; CORRONA Investigators. Smoking, smoking cessation, and disease activity in a large cohort of patients with rheumatoid arthritis. J Rheumatol 2012 May;39(5):904-9. doi: 10.3899/jrheum.110852.

Greenberg JD, Reed G, Decktor D, Harrold L, Furst D, Gibofsky A, Dehoratius R, Kishimoto M, Kremer JM; CORRONA Investigators. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis 2012 Jul;71(7):1134-42.doi: 10.1136/annrheumdis-2011-150573.

Harrold LR, Harrington JT, Curtis JR, Furst DE, Bentley MJ, Shan Y, Reed G, Kremer J, Greenberg JD. Prescribing practices in a US cohort of rheumatoid arthritis patients before and after publication of the American College of Rheumatology treatment recommendations. Arthritis Rheum 2012 Mar;64(3):630-8.doi: 10.1002/art.33380.

Jawaheer D, Messing S, Reed G, Ranganath VK, Kremer JM, Louie JS, Khanna D, Greenberg JD, Furst DE. Significance of sex in achieving sustained remission in the Consortium of Rheumatology Researchers of North America cohort of rheumatoid arthritis patients. Arthritis Care Res 2012 Dec; 64(12):1811-8. doi: 10.1002/acr.21762.

Solomon DH, Mercer E, Kavanaugh A. Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis. Arthritis Rheum 2012 January; 64(1): 21-32. doi: 10.1002/art.30653.

2011

Anandarajah AP, El-Taha M, Peng C, Reed G, Greenberg JD,  Ritchlin CT. Association between focal erosions and generalized bone loss in psoriatic arthritis. Ann Rheum Dis 2011 Jul;70(7):1345-7. doi: 10.1136/ard.2010.148452.

Askling J, Dixon W. Influence of biological agents on cardiovascular disease in rheumatoid arthritis. Ann Rheum Dis. 2011 Apr;70(4):561-2. doi: 10.1136/ard.2010.142174.

Au K, Reed GW, Curtis JR, Kremer JM, Greenberg JD, Strand V, Furst DE. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis 2011 May;70(5):785-791. doi: 10.1136/ard.2010.128637.

Furst DE, Pangan AL, Harrold LR, Chang H, Reed G, Kremer JM, Greenberg JD. Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: results from the consortium of rheumatology researchers of North America registry. Arthritis Care Res (Hoboken) 2011 Jun;63(6):856-64.  doi: 10.1002/acr.20452.

Greenberg JD, Kremer JM, Curtis JR, Hochberg MC, Reed GW, Tsao P, Farkouh ME, Nasir A, Setoguchi S, Solomon DH.  Tumor necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 2011 Apr;70(4):576-582. doi: 10.1136/ard.2010.129916.

Zhang J, Shan Y, Reed G, Kremer J, Greenberg JD, Baumgartner S, Curtis JR: Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: experience from a large U.S. cohort. Arthritis Care Res (Hoboken)2011 Dec;63(12):1672-1679. doi: 10.1002/acr.20643.

2010

Bentley MJ, Greenberg JD, Reed GW. A modified rheumatoid arthritis disease activity score without acute-phase reactants (mDAS28) for epidemiological research. J Rheumatol. 2010 Aug 1;37(8):1607-14. doi: 10.3899/jrheum.090831.

Curtis JR, Beukelman T, Onofrei A, Strand V, Greenberg JD, Reed G, Kremer JM. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide.  Ann Rheum Dis. 2010 Jan;69(1):43-7. doi: 10.1136/ard.2008.101378.

Curtis JR, Chen L, Harrold LR, Narongroeknawin P, Reed G, Solomon DH. Physician preference motivates the use of anti-tumor necrosis factor therapy independent of clinical disease activity. Arthritis Care Res (Hoboken) 2010 Jan 15;62(1):101-7. doi: 10.1136/ard.2008.101378.

Curtis JR, Jain A, Askling J, Bridges SL Jr, Carmona L, Dixon W, Finckh A, Hyrich K, Greenberg JD, Kremer J, Listing J, Michaud K, Mikuls T, Shadick N,Solomon DH, Weinblatt ME, Wolfe F, Zink A. A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum 2010 Aug;40(1):2-14 e11. doi: 10.1016/j.semarthrit.2010.03.003.

Greenberg JD, Reed G, Kremer JM, Tindall E, Kavanaugh A, Zheng C, Bishai W, Hochberg M. Association of methotrexate and tumor necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis. 2010 Feb;69(2):380-6. doi: 10.1136/ard.2008.089276.

Reddy S, Anandarajah A, Fisher M, Mease P, Greenberg J, Kremer J, Reed G, Chen R, Messing S, Kaukenien, K, Ritchlin CT. Comparative analysis of disease activity measures using biologic agents, BMI, radiographic features, and bone density in psoriatic arthritis and rheumatoid arthritis patients followed in a large US disease registry. J Rheum 2010 Dec; 37(12):2566-72. doi: 10.3899/jrheum.100483.

Sokolove J, Strand V, Greenberg JD, Curtis JR, Kavanaugh A, Kremer JM, Anofrei A, Reed R, Calabrese L, Hooper M, Baumgertner S, and Furst D. Risk of elevated liver enzymes associated with TNF inhibitor utilization in patients with rheumatoid arthritis. Ann Rheum Dis 2010 Sep; 69(9):1612-7. doi: 10.1136/ard.2009.

Solomon DH, Kremer JM, Curtis JR, Hochberg M, Reed G, Tsao P, Farkouh M, Setoguch S, and Greenberg JD. Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis 2010 Nov;69(11):1920-5. doi: 10.1136/ard.2009.122226.

2009

Aizer J, Reed G, Onofrei A, Harrison MJ. Predictors of bone density testing in patients with rheumatoid arthritis. Rheumatology Int. 2009 Jun;29(8):897-905. doi: 10.1007/s00296-008-0804-4. Epub 2008 Dec 21.

Coulson KA, Reed G, Gilliam BE, Kremer JM, Pepmueller PH. Factors influencing fracture risk, T score, and management of osteoporosis in patients with rheumatoid arthritis in the Consortium of Rheumatology Researchers of North America (CORRONA) registry. J Clin Rheumatol. 2009 Jun;15(4):155-60. doi: 10.1097/RHU.0b013e3181a5679d.

Curtis JR, Patkar NM, Jain A, Greenberg J, Solomon DH. Validity of physician-reported hospitalized infections in an observational U.S. arthritis registry. Rheumatology (Oxford) 2009 October; 48(10):1269-72. doi: 10.1093/rheumatology/kep205.

Furst D, Chang H, Greenberg J, Ranganath V, Reed G, Ozturk Z, Kremer JM. Prevalence of low hemoglobin levels and associations with other disease parameters in rheumatoid arthritis patients: Evidence from the CORRONA registry. Clin Exp Rheumatol 2009 Jul-Aug;27(4): 560-6.

Greenberg JD, Fisher MC, Kremer JM, Chang H, Rosenstein ED, Kishimoto M, Lee S, Yazici Y, Kavanaugh A,  Abramson SB.  The COX-2 inhibitor market withdrawals and prescribing patterns by rheumatologists in patients with gastrointestinal and cardiovascular risk. Clin Exp Rheumatol. 2009 May-Jun; 27(3):395-401.

Greenberg JD, Harrold LR, Bentley MJ, Kremer JM, Reed G. Strand V. Evaluation of composite measures of treatment response without acute phase reactants in patients with rheumatoid arthritis. Rheumatology (Oxford) 2009 June; 48(6):686-90. doi: 10.1093/rheumatology/kep054.

Kremer JM, Greenberg JD. Interpreting registry derived drug studies: does societal context matter? Arthritis Rheum 2009 Nov; 60(11):3155-7. doi: 10.1002/art.24880.

Lee SJ, Chang H, Yazici Y, Greenberg JD, Kremer JM,  Kavanaugh A.  Utilization trends of tumor necrosis factor inhibitors among rheumatoid arthritis patients in a United States observational cohort study. J Rheumatol 2009 Aug; 36(8):1611-7. doi: 10.3899/jrheum.080889.

2008

Greenberg JD, Kishimoto M, Strand V, Cohen SB, Olenginski TP, Harrington JT, Kafka SP, Reed G, Kremer JM.  TNF antagonist responsiveness in a United States rheumatoid arthritis cohort. Am J Med 2008 Jun;121(6):532-8. doi: 10.1016/j.amjmed.2008.02.018.

Kremer JM, Gibofsky A, Greenberg JD.  The role of drug and disease registries in rheumatic disease epidemiology. Cur Opin Rheumatol. 2008 Mar;20(2):123–130. doi: 10.1097/BOR.0b013e3282f50eb1.

Ranganath VK, Paulus HE, Onofrei A, Khanna D, Reed G, Elashoff DA, Kremer JM, Furst DE. Functional improvement after patients with rheumatoid arthritis start a new disease modifying antirheumatic drug (DMARD) associated with frequent changes in DMARD: the CORRONA database. J Rheumatol 2008 Oct;35(10):1966-71.

2006

Greenberg JD, Bingham CO, Abramson SB, Reed G, Kishimoto M, Hinkle K, Kremer JM.  Assessment of coxib utilization by rheumatologists for nonsteroidal antiinflammatory drug gastroprotection prior to the coxib market withdrawals. Arthritis Rheum 2006 Aug;55(4):543-50.

Kremer JM.  The CORRONA Database. Autoimmun Rev 2006 Jan;5(1):46-54.

Tutuncu Z, Reed G, Kremer JM, Kavanaugh A.  Do patients with older-onset rheumatoid arthritis receive less aggressive treatment? Ann Rheum Dis2006 Sep;65(9):1226-1229.

2005

Greenberg JD, Bingham CO, Abramson SB, Reed G, Seibaldt R, Kremer JM.  Effect of cardiovascular comorbidities and concomitant aspirin use on selection of cyclooxgenase inhibitor among rheumatologists. Arthritis Rheum. 2005 Feb;53:12-17.

Kremer JM.  The CORRONA Database. Ann Rheum Dis 2005 Nov;64(Suppl4):iv37-41.

Kremer JM.  The CORRONA Database. Clin Exp Rheumatol 2005 Sep-Oct;23(5 Suppl 39):172-7.

2003

Sebaldt RJ, Kremer JM. CANDOO and CANOAR, CORRONA and more: advancing therapeutics through layered-in clinical data collection and feedback at the point of care. J Rheumatol2003 Nov;30(11):2308-2311.

PUBLISHED ABSTRACTS

Hawaii Derm Seminar 2023

Silverberg J, Shi VY, Alexis A, Pierce E, Cronin A, McLean RR, Roberts-Toler C, Rueda MJ, Atwater AR, Simpson EL. Racial and Ethnic Differences in Sociodemographic and Treatment Characteristics Among Patients with Atopic Dermatitis in the United States: Real-world Data from CorEvitas Registry. Hawaii Derm Seminar, February 2023.

Revolutionizing Atopic Dermatitis (RAD) Virtual Conference 2023

Silverberg JI, Gooderham M, Calimlim B, Grada A, Munoz Maldonado Y, Li A, Crabtree MM, Simpson E. Real-world effectiveness of upadacitinib in moderate-to-severe atopic dermatitis (AD): Results from cross-sectional analyses of the CorEvitas AD Registry. Revolutionizing Atopic Dermatitis (RAD) Virtual Conference, December 10, 2023

ACG 2023

Cross RK, Griffith J, Kujawski MR, Beeghly A, Middaugh N, Moore P, Choi CJ, Gurrola M, Sharma D. Corticosteroid use among patients with Crohn’s disease and ulcerative colitis on advanced therapy from the CorEvitas Inflammatory Bowel Disease Registry. ACG 2023, Vancouver, BC, Canada, October 20-25, 2023.

MSMilan 2023

Daniel Kantor, Jacqueline O’Brien Wendi Malley, Mousumi Biswas, Diego Silva, Erik DeBoer, Zachary Margolin, Carla Roberts-Toler, Robert Zivadinov, Michael Dwyer, Niels Bergsland, Peter M. Wahl, Aaron Miller. Linking imaging and clinical data in a real-world setting: first findings from the qMRI sub-study in CorEvitas MS Registry. ECTRIMS-ACTRIMS Meeting, Milan, Italy, October 11-13, 2023.

ENAR Spring Conference 2023

Sima AP, Maldonado YM, Pugach O. Addressing the Impact of Group Imbalance on Standardized Effect Size Measures in Real-World Evidence Studies. ENAR Spring Conference, Nashville, TN, March 19-22, 2023.

ICPE 2023

Loughlin AM, Pugach O, Roberts-Toler C, Lakin P, Harrold LR, Litman H, Sheffield KM, Shan M, Faries DE, Cui ZL. Evaluation of methods for building a hybrid real-world (RW) control arm for baricitinib Phase IIB randomized controlled trial (RCT) in patients with rheumatoid arthritis (RA). ICPE, Halifax, Nova Scotia, August 23-27, 2023.

Pugach O, Sheffield KM, Loughlin AM, Shan M, Faries D, Roberts-Toler C, Lakin P, Cui ZL, Harrold LR, Litman H. Evaluation of methods for building a hybrid real-world (RW) control arm for baricitinib phase IIB randomized controlled trial (RCT) in patients with rheumatoid arthritis (RA). ICPE, Halifax, NS, Canada, August 23-27, 2023

ACR Convergence 2023

Mease PJ, Ogdie A, Tesser J, Shiff NJ, Lin I, Chakravarty SD, Kelleman M, Dodge R, McLean RR, Broadwell A, Kavanaugh A, Merola JF. Improvements in patient-reported outcomes through 6 months of guselkumab treatment in patients with active psoriatic arthritis: Real-world data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry. ACR Convergence, San Diego, CA, November 10-15, 2023.

Ogdie AR, Song C, Middaugh N, Marchese M, Eliot M, Beaty S, Low R, Mease PJ. Durability of response among psoriatic arthritis (PsA) patients using b/tsDMARDs in the CorEvitas PsA/Spondyloarthritis (SpA) Registry. ACR Convergence, San Diego, CA, November 10-15, 2023.

Fukui S, Winkelmayer W, Tedeschi S, Marrugo J, Guan H, Harrold L, Litman H, Shinozaki, Solomon D. The relationship between disease activity of rheumatoid arthritis and kidney function. ACR Convergence, San Diego, CA, November 10-15, 2023

CCR West 2023

Mease PJ, Ogdie A, Tesser J, Shiff NJ, Lin I, Chakravarty SD, Kelleman M, Dodge R, McLean RR, Broadwell A, Kavanaugh A, Merola JF. Six-month persistence and multi-domain effectiveness of guselkumab in adults with psoriatic arthritis: real-world data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. CCR West 2023, San Diego, CA, September 7-10, 2023.

Philip J. Mease, Alexis Ogdie, John Tesser, Natalie J. Shiff, Iris Lin, Soumya D. Chakravarty, Mike Kelleman, Rhiannon Dodge, Robert R. McLean, Aaron Broadwell, Arthur Kavanaugh, Joseph F. Merola. Six-Month Persistence and Multi-Domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. CCR West, San Diego, September 7-10, 2023. Encore poster

Pappas DA, O’Brien J, Kelleman M, Guo L, Shan Y, Baker JF,  Kricorian G, Stryker S, Collier D. Outcomes in Patients with Rheumatoid Arthritis Initiating Monotherapy with Etanercept, Adalimumab, or Janus Kinase Inhibitors. CCR East, Destin, FL, May 4-7, 2023

Maui Derm 2023

Mease PJ, Ogdie A, Tesser J, Shiff NJ, Lin I, Chakravarty SD, Kelleman M, Dodge R, McLean RR, Broadwell A, Kavanaugh A, Merola JF. Six-month persistence and multi-domain effectiveness of guselkumab in adults with psoriatic arthritis: real-world data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. Maui Derm NP+PA Fall 2023, Asheville, NC, September 27-30, 2023.

Philip J. Mease, Alexis Ogdie, John Tesser, Natalie J. Shiff, Iris Lin, Soumya D. Chakravarty, Mike Kelleman, Rhiannon Dodge, Robert R. McLean, Aaron Broadwell, Arthur Kavanaugh, Joseph F. Merola. Six-Month Persistence and Multi-Domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. Maui Derm NP + PA, Colorado Springs, CO, June 21-24, 2023

Philip J. Mease, Alexis Ogdie, John Tesser, Natalie J. Shiff, Iris Lin, Soumya D. Chakravarty, Mike Kelleman, Rhiannon Dodge, Robert R. McLean, Aaron Broadwell, Arthur Kavanaugh, Joseph F. Merola. Six-Month Persistence and Multi-Domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. Maui Dermatology Conference, Maui, HI, January 23-27, 2023

Armstrong AW, Ferris LK, Callis Duffin K, Janak JC, Sima AP, Eckmann T, Patel M, Photowla H, Garg V, Strober BE. Long Term Real-World Treat-to-Target Skin Clearance and Maintenance of Response with Risankizumab in Patients with Moderate to Severe Psoriasis from the CorEvitas Psoriasis Registry. Maui Derm, Maui, HI, January 23-27, 2023.

Sociedad Española de Reumatología (SER) 2023

Ogdie A, McLean RR, Blachley T, Middaugh N, Mittal M, Clewell J, Ciecinski S, Mease P. The Impact of Second-Line Therapeutic on Disease Control After Discontinuation of First Line TNF Inhibitor in Patients with PsA: Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. Sociedad Española de Reumatología (SER), Seville, Spain, May 9-12, 2023.

RhAPP 2023

Philip J. Mease, Alexis Ogdie, John Tesser, Natalie J. Shiff, Iris Lin, Soumya D. Chakravarty, Mike Kelleman, Rhiannon Dodge, Robert R. McLean, Aaron Broadwell, Arthur Kavanaugh, Joseph F. Merola. Six-Month Persistence and Multi-Domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. RhAPP, Phoenix, September 21-23, 2023. Encore poster.

RNS Conference 2023

Philip J. Mease, Alexis Ogdie, John Tesser, Natalie J. Shiff, Iris Lin, Soumya D. Chakravarty, Mike Kelleman, Rhiannon Dodge, Robert R. McLean, Aaron Broadwell, Arthur Kavanaugh, Joseph F. Merola. Six-Month Persistence and Multi-Domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. RNS Conference, Austin, TX, August 2-5, 2023. Encore poster.

RWCS 2023

Philip J. Mease, Alexis Ogdie, John Tesser, Natalie J. Shiff, Iris Lin, Soumya D. Chakravarty, Mike Kelleman, Rhiannon Dodge, Robert R. McLean, Aaron Broadwell, Arthur Kavanaugh, Joseph F. Merola. Six-Month Persistence and Multi-Domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. RWCS, Maui, HI, February 15 – 18, 2023.

State of Texas Association of Rheumatologists (STAR) Conference

Philip J. Mease, Alexis Ogdie, John Tesser, Natalie J. Shiff, Iris Lin, Soumya D. Chakravarty, Mike Kelleman, Rhiannon Dodge, Robert R. McLean, Aaron Broadwell, Arthur Kavanaugh, Joseph F. Merola. Six-Month Persistence and Multi-Domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. State of Texas Association of Rheumatologists (STAR) Conference, Houston, TX, February 3-5, 2023.

AAD 2023

Armstrong AW, Ferris LK, Callis Duffin K, Janak JC, Sima AP, Eckmann T, Patel M, Photowla H, Garg V, Strober BE. Long Term Real-World Treat-to-Target Skin Clearance and Maintenance of Response with Risankizumab in Patients with Moderate to Severe Psoriasis from the CorEvitas Psoriasis Registry. AAD, New Orleans, Louisiana, March 17-21, 2023. Encore poster.

Strober BE, Ferris LK, Callis Duffin K, Janak JC, Sima AP, Eckmann T, Patel M, Photowla H, Garg V, Armstrong AW. Long Term Real-World Patient-Reported Outcomes with Risankizumab in Patients with Moderate to Severe Psoriasis from the CorEvitas Psoriasis Registry. AAD, New Orleans, Louisiana, March 17-21, 2023. Encore poster

Yeroushalmi S, Cronin A, Roberts-Toler C, Gondo G, Wallace E, Reddy S, Han G, Kaffenberer J, Bhutani T, McLean RR, Liao W. Identification of Demographic and Clinical Features Associated with Multi-Biologic Failure in the CorEvitas Psoriasis Registry. AAD, New Orleans, Louisiana, March 17-21, 2023

Enos C, Munoz Maldonado Y, Kang HJ, McLean RR, Van Voorhees A. Diabetes is associated with worse response to biologics at 12-months among patients with plaque psoriasis in the CorEvitas Psoriasis Registry. AAD, New Orleans, Louisiana, March 17-21, 2023

Congreso Colombiano de Dermatologia 2023

Armstrong AW, Ferris LK, Callis Duffin K, Janak JC, Sima AP, Eckmann T, Photowala H, Patel M, Garg V, Strober BE. Real-World Treat-to-Target Skin Clearance with Risankizumab in Patients with Moderate to Severe Psoriasis from the CorEvitas Psoriasis Registry. Congreso Colombiano de Dermatologia, Pereiro, Colombia, February 23-26, 2023. Encore poster.

EADV Congress 2023

Armstrong AW, Ferris LK, Callis Duffin K, Sima A, Eckmann T, Beeghly A, Patel M, Photowala H, Garg V, Strober BE.  Real-world achievement of absolute Psoriasis Area and Severity Index thresholds with persistent 18-month rizankizumab use in patients with moderate to severe psoriasis from a North American registry. EADV Congress, Berlin, Germany, October 11-14, 2023

Lebwohl M, Armstrong AW, Sima A, Gooderham M, McLean R, Papp K, Merola J, Gottlieb AB, Kisa R, Napoli A, Zhuo J, Varga S, Strober B. The Registry of Psoriasis Health Outcomes: a longitudinal real-world collaboration study (RePhlect) – North American Registry design. EADV Congress, Berlin, Germany, October 11-14, 2023

Park SH, Zhong Y, Sima A, Patel V, Zhuo J, Roberts-Toler C, Becker B, Hovland S, Strober B. Association of patient-reported disease burden and treatment switching among patients with plaque psoriasis on nonbiologic systemic therapy. EADV Congress, Berlin, Germany, October 11-14, 2023.

Clinical Dermatology Conference

Lebwohl M, Strober B, Schrader A, Li AH, Eckmann T, Zhu B, Malatestinic WN, Birt J, Feely M, Blauvelt A. 6-month real world study to assess the effectiveness of ixekizumab after switching from other biologic therapies: the CorEvitas Psoriasis Registry. Fall Clinical Dermatology Conference, Las Vegas, NV, October 19-22, 2023

Park SH, Zhong Y, Sima A, Patel V, Zhuo J, Roberts-Toler C, Becker B, Hovland S, Strober B. Association of patient-reported disease burden and treatment switching among patients with plaque psoriasis on nonbiologic systemic therapy. Winter Clinical Dermatology Conference, Kohala Coast, HI, January 13-17, 2023

Park SH, Zhong Y, Sima A, Patel V, Zhuo J, Roberts-Toler C, Becker B, Hovland S, Strober B. Association of patient-reported disease burden and treatment switching among patients with plaque psoriasis on nonbiologic systemic therapy. Winter Clinical Dermatology Conference, Miami, FL, February 17-20, 2023

EULAR 2023

Philip J. Mease, Eric Jones, Adam Sima, Silky Beaty, Robert Low, Braulio Gomez, Marie Gurrola, Mark Lebwohl. Patients with Psoriatic Arthritis at Biologic Therapy Switch: The CorEvitas Psoriasis Registry. EULAR 2023, Milan, Italy, May 31-June 3, 2023

Krueger WS, Harrold LR, Sima A, Eckmann T, Kilpatrick RD. Characteristics of first-line upadacitinib initiators and factors contributing to prescribing upadacitinib as first-line b/tsDMARD. EULAR 2023, May 31-June 3, 2023. AB0445

National Psoriasis Foundation Dermatology Residents and Rheumatology Fellows Meeting on Psoriatic Disease

Park SH, Zhong Y, Sima A, Patel V, Zhuo J, Roberts-Toler C, Becker B, Hovland S, Strober B. Association of patient-reported disease burden and treatment switching among patients with plaque psoriasis on nonbiologic systemic therapy. National Psoriasis Foundation Dermatology Residents and Rheumatology Fellows Meeting on Psoriatic Disease, Washington, DC, October 7-8, 2023

AAD 2022

Armstrong AW, Ferris LK, Duffin KC, Janak JC, Sima A, Eckmann T, Photowala H, Patel M, Garg V, Strober BE. Real-World Treat-to-Target Skin Clearance with Risankizumab in Patients With Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry.  AAD 2022, Boston, MA, March 25-29, 2022. EPoster

Strober BE, Ferris LK, Duffin KC, Janak JC, Sima A, Eckmann T, Patel M, Photowala H, Garg V, Armstrong AW. Real-World Patient-Reported Outcomes with Risankizumab in Patients With Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry. AAD 2022, Boston, MA, March 25-29, 2022. EPoster and Oral Presentation

Ogdie A, Strober B, Lebwohl M, Cronin A, Kang HJ, Middaugh N, O’Brien J, Jardon S, Richter S, Mease PJ. Relationship Between Skin Involvement and Disease Burden in Patients With Mild to Moderate Plaque Psoriasis: Real-World Findings From CorEvitas’ Psoriasis Registry. AAD 2022, Boston, MA, March 25-29, 2022. EPoster and Oral Presentation

Lio P, Simpson E, Pierce E, Cronin A, McLean R, Dave SS, Kovacik A, Feely M, Silverberg J. Impact of Atopic Dermatitis Lesion Locations on Patient Burden: A Real-world Study. AAD 2022, Boston, MA, March 25-29, 2022. EPoster

Russo G, Sima AP, Janak JC, Kohl EA, Lesser E, Marushchak O, Lebwohl M. Factors Impacting Drug Survival for Currently FDA-approved Biologic Therapies for Psoriasis at One-Year of Treatment. AAD 2022, Boston, MA, March 25-29, 2022. Oral Presentation

ACTRIMS Forum

Harrold LR, Cohen L, Cronin A, Benett JL, Levy M, Weinshenker B. Wingerchuk D, Lewis K, Cook LJ, Blascke TF, Smith TJ, Yeaman MR, Pappas DA. SPHERES: Innovative Registry Addressing the New Era of NMOSD Therapy. ACTRIMS Forum, West Palm Beach, FL, February 24-26, 2022. Poster

RWCS 2022

Mease PJ, Ogdie A, Chakravarty SD, Shiff NJ, Lin I, Malley W, McLean RR, Spitzer RL, Kavanaugh A, Merola JF. Characteristics of Real-World Psoriatic Arthritis Patients Initiating Guselkumab: Findings from the CorEvitas PsA/SpA Registry. RWCS, Maui, HI, February 16-19, 2022. Encore. Abstract

Crohn’s & Colitis 2022

Wolf DC, Naegeli AN, Moore PC, Janak JC, Crabtree MM, Shan M, Hunter TM, Sontag A, Cross RK. Change in Urgency Status Among Ulcerative Colitis Patients: Understanding the Impact of Treatment Changes From The CorEvitas Inflammatory Bowel Disease Registry. C&C Congress 2022, Virtual, January 20-22, 2022. Encore. Poster

Winter Clinical Derm 2022

Strober B, Cronin A, Lin TC, O’Brien J, Kang HJ, Jardon S, Richter S, Khilfeh I, Lebwohl M. Analysis of Real-world Systemic-Naive Patients With Mild or Moderate vs Severe Plaque Psoriasis: Patient Characteristics and Disease Burden Findings From CorEvitas’ Psoriasis Registry. WCD, Kauai, HI, January 14-19, 2022. Encore. Poster

ACR Convergence 2021

Mease P, McLean R, Blachley T, Marchese M, Anatale-Tardiff L, Saffore CD, Quach D, Biljan A, Ogdie A. Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported Outcome Measures Among Patients with Ankylosing Spondylitis Treated with Biologic DMARDs. ACR, Virtual, November 5-9, 2021. Poster

Ogdie A, McLean R, Marchese M, Blachley T, Anatale-Tardiff L, Quach D, Saffore CD, Douglas K, Mease P. Impact of Achieving Minimal Disease Activity on Patient-Reported Outcome Measures and Disease Activity Among Patients with Psoriatic Arthritis Treated with Biologic and Targeted Synthetic DMARDs. ACR, Virtual, November 5-9, 2021. Poster

Ogdie-Beatty A, Strober B, Lebwohl M, Cronin A, Lin TC, Kang HJ, Middaugh N, O’Brien J, Jardon S, Richter S, Klyachkin Y, Mease PJ. Characterizing Musculoskeletal Disease Burden in Mild to Moderate Psoriasis Patients Suggestive of Comorbid PsA: Analysis of CorEvitas’ Psoriasis Registry. ACR, Virtual, November 5-9, 2021. Poster

Mease PJ, Blachley T, O’Brien J, Middaugh N, Kricorian G, Stryker S, Collier DH, Ogdie A. Real-World Efficacy of TNF Inhibitors for Treatment of Psoriatic Arthritis by Disease Domains: 6-Month Findings From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. ACR, Virtual, November 5-9, 2021. Poster

O’Brien J, Park SH, Blachley T, Marchese M, Middaugh N, Han X, Wittstock K, Harrold LR. Disparities in Burden of Disease in Patients With RA Across Racial and Ethnic Groups. ACR, Virtual, November 5-9, 2021. Poster

Sebba A, Bingham C, Bykerk V, Fiore S, Ford K, Janak JC, Pappas DA, Blachley T, Swapna D, Kremer JM, Yu M, Choy E. Comparative Effectiveness of TNF Inhibitor vs IL-6 Receptor Inhibitor as Monotherapy or Combination Therapy with Methotrexate in Patients with Rheumatoid Arthritis: Analysis from CorEvitas’ RA Registry. ACR, Virtual, November 5-9, 2021. Poster

Pappas DA, Reed G, Kane K, Curtis JR, Kremer JM. Effect of Biologic Agents on Lipids and Cardiovascular Risk in Rheumatoid Arthritis Patients. ACR, Virtual, November 5-9, 2021. Poster

Cohen S, Mellors T, Zhang L, Jones A, Connolly-Strong E, Pappas DA, Kremer JM, Withers JB, Akmaev VR. A Molecular Signature Response Classifier Predicts the Likelihood of Non-response to TNF Inhibitor Therapies in RA at 3 Months. ACR, Virtual, November 5-9, 2021. Poster

Curtis JR, Kremer JM, Pappas DA, Zhang L, Connolly-Strong E, Withers JB, Akmaev VR, Saleh A. Discontinuation of TNFi Treatment Among Rheumatoid Arthritis Patients with a Molecular Signature of Non-response to Tumor Necrosis Factor-ɑ Inhibitor Therapies. ACR, Virtual, November 5-9, 2021. Poster

Harrold L, Wittstock K, Kelly S, Park S, Han X, Shan Y, Roberts-Toler C, Middaugh N, Khaychuk V. Improvement in Clinical Disease Activity and Patient-Reported Outcomes After 6 Months of Treatment With Abatacept, Stratified by Line of Therapy, in Patients With RA: Results From a Large, US, National Observational Study. ACR, Virtual, November 5-9, 2021. Poster

Chao R, Reed G, Kremer J, Kavanaugh A. Disease Activity in Psoriatic Arthritis Patients with Enthesitis Across Different Therapies. ACR, Virtual, November 5-9, 2021. Poster

ACG 2021

Wolf DC, Naegeli AN, Moore PC, Janak JC, Crabtree MM, Shan M, Hunter TM, Sontag A, Cross RK. Change in Urgency Status Among Ulcerative Colitis Patients: Understanding a Potential Unmet Patient Need From CorEvitas’ Inflammatory Bowel Disease Registry.  ACG, Las Vegas, NV, October 22-27, 2021. EPoster and Poster

CMSC 2021

Kantor D, Bebo B, Wahl PM, Coyle PK, Fox EJ, Bermel RA, Riolo J, Silva D, Wright C, Malley W, Janak J, Miller A. Baseline Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients Enrolling in the US-Based Corrona MS Registry. CMSC 2021, Orlando, FL and Virtual, October 25-28, 2021. EPoster

Fall Clinical Derm 2021

Strober B, Patil D, McLean RR, Moore-Clingenpeel M, Guo N, Levi E, Lebwohl M. The Evolving Treatment Approach of Secukinumab in Biologic-Experienced and Biologic-Naive Patients With Psoriasis: Key Clinical and Patient Characteristics by Year of Treatment Initiation in a US-Based Registry. FCD 2021, Las Vegas, NV, October 21-24, 2021. EPoster

Strober B, Ferris LK, Callis Duffin K, Janak JC, Sima A, Eckmann T, Patel M, Photowala H, Garg V, Armstrong AW. Real-World  Effectiveness of Risankizumab in Patients With Moderate to Severe Psoriasis Using the CorEvitas Psoriasis Registry. FCD 2021, Las Vegas, NV, October 21-24, 2021. EPoster

AMCP Nexus 2021

Strober B, Callis Duffin K, Lebwohl M, Lin TC, Janak JC, Patel M, Photowala H, Vishvas Garg V, Bagel J. Indirect Costs Due to Work Productivity Loss in Patients With Psoriasis in the United States: Analysis of the CorEvitas Psoriasis Registry. AMCP Nexus 2021, Denver, CO, October 19-21, 2021. Poster

AOCD

Lockshin B, Harrison RW, McLean RR, Crabtree MM, Konicek BW, Zhu B, Malatestinic WN, Atiya B, Murage MJ, Russel Burge R.  Outcomes in Ixekizumab Patients following Exposure to Secukinumab and Other Biologics in the Corrona Psoriasis Registry. AOCD New Trends in Dermatology Virtual Meeting & Expo, October 7-10, 2021. Encore Poster

Maui Derm NP+PA 2021 – Fall

Strober B, Patil D, McLean R, Moore-Clingenpeel M, Guo N, Levi E, Lebwohl M. Impact of Secukinumab on Clinical and Patient-Reported Outcomes in Biologic-Naive Patients With Psoriasis in a US Real-World Setting.  Maui Derm NP+PA 2021 Fall, Asheville, NC, September 29 – October 2, 2021. Poster

EADV 2021

Strober B, Cronin A, Lin TC, O’Brien J, Kang HJ, Jardon S, Richter S, Khilfeh I, Lebwohl M. Analysis of Real-world Systemic-Naive Patients With Mild or Moderate vs Severe Plaque Psoriasis: Patient Characteristics and Disease Burden Findings From the Corrona Psoriasis Registry. EADV 2021, Vienna, Austria, September 29-October 2, 2021. EPoster

CCR-West 2021

Lockshin B, Harrison RW, McLean RR, Crabtree MM, Konicek BW, Zhu B, Malatestinic WN, Atiya B, Murage MJ, Burge R, Wenda R. Zick (Non-author presenter). Outcomes in Ixekizumab Patients following Exposure to Secukinumab and Other Biologics in the Corrona Psoriasis Registry. CCR-West 2021, San Diego, CA, September 18-21, 2021. EPoster

Innovations in Dermatology 2021 – Fall

Lockshin B, Harrison RW, McLean RR, Crabtree MM, Konicek BW, Zhu B, Malatestinic WN, Atiya B, Murage MJ, Burge R. Outcomes in ixekizumab patients following exposure to secukinumab and other biologics in the Corrona Psoriasis Registry. Innovations in Dermatology, Fall Virtual, September 17-20, 2021. EPoster

Strober B, Patil D, McLean RR, Moore-Clingenpeel M, Guo N, Levi E, Lebwohl M.

Secukinumab Provides Sustained Improvement on Clinical and Patient-Reported Outcomes Through 12 Months in Both Biologic-Naive and Biologic-Experienced Patients With Psoriasis in a US Real-World Setting. Innovations in Dermatology, Fall Virtual, September 17-20, 2021. EPoster

NPF Research Symposium 2021 

Enos CW, Yi JZ, McLean RR, Sima AP, Kohl EA, Eckmann T, Van Voorhees AS. Assessment of racial and ethnic differences in treatment response to biologic therapy among psoriasis patients enrolled in CorEvitas‘ Psoriasis Registry. NPF Research 2021, New York, NY, September 10, 2021. Poster

ISPE / ICPE 2021

Reed G, Schrader A, Madsen A, Saunders, Litman H, Geier J. Methods and practical considerations in use of an external control to assess potential drug risk. ICPE 2021, Virtual, August 21-25, 2021. EPoster

CCR-East 2021

Lockshin B, Harrison RW, McLean RR, Crabtree MM, Konicek BW, Zhu B, Malatestinic WN, Atiya B, Murage MJ, Burge R, Stenger KB (presenter). Outcomes in Ixekizumab Patients following Exposure to Secukinumab and Other Biologics in the Corrona Psoriasis Registry. CCR-East 2021, Destin, FL, August 12-15, 2021. EPoster

RNS Virtual 2021

Lockshin B, Harrison RW, McLean RR, Crabtree MM, Konicek BW, Zhu B, Malatestinic WN, Atiya B, Murage MJ, Burge R. Outcomes in Ixekizumab Patients following Exposure to Secukinumab and Other Biologics in the Corrona Psoriasis Registry. RNS Virtual 2021, August 4-7-2021, EPoster

SDPA Summer 2021

Strober B, Patil D, McLean R, Moore-Clingenpeel M, Guo N, Levi E, Lebwohl M. Impact of Secukinumab on Clinical and Patient-Reported Outcomes in Biologic-Naive Patients With Psoriasis in a US Real-World Setting. SDPA Summer 2021, Chicago, IL , July 22-25, 2021. EPoster

Florida Society of Rheumatology 2021

Lockshin B, Harrison RW, McLean RR, Crabtree MM, Konicek BW, Zhu B, Malatestinic WN, Atiya B, Murage MJ, Burge R. Outcomes in Ixekizumab Patients following Exposure to Secukinumab and Other Biologics in the Corrona Psoriasis Registry. FSR 2021, Lake Buena Vista, FL, July 9-11, 2021. EPoster

ECCO 2021

Wolf DC, Naegeli AN, Moore PC, Janak JC, Crabtree MM, Shan M, Hunter TM, Sontag A, Cross RK; Change in Urgency Status Among Ulcerative Colitis Patients: Understanding the Impact of Treatment Changes from the Corrona Inflammatory Bowel Disease. ECCO, Copenhagen, Denmark, July 7-10, 2010, EPoster

IFPA 2021

Gulliver W, See K, Zhu B, Malatestinic W, Konicek B, Harrison RW, McLean RR, Kerti S, Anatale-Tardiff L, Burge R, Leonardi C. Development and Validation of Optimal Psoriasis Assessment Tools (OPAT) Among Patients in the Corrona Psoriasis Registry. IFPA, Stockholm, Sweden, July 1-3, 2021, EPoster

Maui Derm NP+PA Summer 2021

Lockshin B, Harrison RW, McLean RR, Crabtree MM, Konicek BW, Zhu B, Malatestinic WN, Atiya B, Murage MJ, Burge R. Outcomes in Ixekizumab Patients following Exposure to Secukinumab and Other Biologics in the Corrona Psoriasis Registry. Maui Derm NP+PA Summer, Colorado Springs, CO, June 23-26, 2021. EPoster

SER 2021

Yoshida K, Guan H, Harrold LR, Solomon D. Potential direct effect of tumor-necrosis factor inhibitors on cardiovascular risk controlling for disease activity measure. SER, San Diego, CA, June 22-25, 2021. Poster

CSD Congress 2021 (Chinese Society of Dermatology)

Strober B, Kotowsky N, Medeiros RA, Foster N, Janak J, Valdecantos WC, Flack M, Duan S, Golembesky AK, Lebwohl M. Patient-reported outcomes from a large, North American-based cohort, highlight a greater disease burden for generalized pustular psoriasis versus plaque psoriasis: Real-world evidence from the Corrona Psoriasis Registry. CSD,  China, June 17-20, 2021. Poster

EULAR 2021

Curtis J, Fiore S, Ford K, Janak J, Chang H, Pappas DA, Blachley T, Emeanuru K, Bykerk V. Meaningful Improvement and Worsening in Patients Who Do Not Achieve LDA and Switch Therapy to a New Biologic or Targeted Therapy: Results from the CORRONA Registry. POS0594, June 2021 Volume 80 Supplement 1, DOI: 10.1136/annrheumdis-2021-eular.544.

Dua A, Ford K, Fiore S, Pappas DA, Janak J, Blachley T, Emeanuru K, Kremer J, Kivitz A. Disease Activity and Patients-Reported Outcomes After Switching Between IL-6 Receptor Inhibitors and JAK Inhibitors: An Analysis from the Corrona Registry. POS0606, June 2021 Volume 80 Supplement 1, DOI: 10.1136/annrheumdis-2021-eular.1298

Harrold L, Wittstock K, Kelly S, Park S, Han X, Shan Y, Roberts-Toler C, Middaugh N, Khaychuk V. Improvement in Clinical Disease Activity and Patient-Reported Outcomes after 6 Months of Treatment with Abatacept, Stratified by Line Of Therapy, in Patients with RA: Results from a large, US, National Observational Study. AB0202, June 2021 Volume 80 Supplement 1, doi.org/10.1136/annrheumdis-2021-eular.701

Kremer JM, Tundia N, McLean RR, Blachley T, Maniccia A, Pappas DA. Characteristics and six-month outcomes among real-world rheumatoid arthritis patients initiating upadacitinib: CorEvitas’ Rheumatoid Arthritis Registry. POS0435, June 2021 Volume 80 Supplement 1, DOI: 10.1136/annrheumdis-2021-eular.170

Mease PJ, Marchese M, McClean R, Blachley T, Anatale-Tardiff L, Saffore C, Lesser E, Ogdie A. Comparison of Baseline Disease Activity and Patient (Pt)-Reported Outcomes (PROs) Between Pts With Psoriatic Arthritis and Axial Involvement (Axial PsA) and Axial Spondyloarthritis (Axial SpA) From the Corrona PsA/SpA Registry. OP0049, June 2021 Volume 80 Supplement 1, DOI: 10.1136/annrheumdis-2021-eular.137

Yoshida K, Harrold LR, Middaugh N, Guan H, Stryker S, Karis E, Solomon DH. Time-varying influence of rheumatoid arthritis disease activity on subsequent cardiovascular risks. OP0101, June 2021 Volume 80 Supplement 1, DOI: 10.1136/annrheumdis-2021-eular.28

SDDS June 2021

Lockshin B, Harrison RW, McLean RR, Crabtree MM, Konicek BW, Zhu B, Malatestinic WN, Atiya B, Murage MJ, Burge R. Outcomes in Ixekizumab Patients following Exposure to Secukinumab and Other Biologics in the Corrona Psoriasis Registry. SDDS June 2011, San Diego, CA, June 11-13, 2021, EPoster

DDW 2021

Hudesman D, Mease P, Lebwohl M, Loughlin AM, Moore P, Janak J, Lemay CA, Korzenik J, Cross RK. The burden of work productivity and activity impairment in Crohn’s disease, ulcerative colitis, psoriasis and psoriatic arthritis.  DDW, Virtual, May 21-23, 2021. Session Title: IBD: Natural History and Outcomes (5/22/21). Poster of Distinction

SID 2021

Ogdie A, Harrison RW, McLean RR, Lin TC, Lebwohl M, Strober BE, Zhuo J, Patel V, Mease PJ. Psoriatic Arthritis Risk in Psoriasis Patients in the Corrona® Psoriasis Registry.  SID, Virtual, May 3-8, 2021, EPoster.

Enos C, Ramos VL, Lin TC, McLean RR, Foster N, Dube B, Van Voorhees AS. Proportions of biologic discontinuation among psoriasis patients with metabolic comorbidities. SID, Virtual, May 3-8, 2021, EPoster.

AAD 2021

Armstrong AW, Duffin KC, Fitzgerald T, Teeple A, Uy JP, Olurinde M, Rowland K, McLean RR, Guo L, Shan Y, Van Voorhees AS. Impact of guselkumab on quality of life and work productivity outcomes among patients with severe plaque psoriasis in the Corrona Psoriasis Registry. AAD VMX, Virtual, April 23-25, 2021, Poster

Armstrong AW, Duffin KC, Fitzgerald T, Teeple A, Uy JP, Olurinde M, Rowland K, McLean RR, Guo L, Shan Y, Van Voorhees AS. Effectiveness of guselkumab among patients with severe plaque psoriasis in the Corrona Psoriasis Registry. AAD VMX, Virtual, April 23-25, 2021, Poster

Enos CW, Ramos V, Lin T, McLean RR, Foster N, Dube B, Van Voorhees AS. Characteristics of Patients with Psoriasis Differ by Obesity Status and History of Metabolic Comorbidities. AAD VMX, Virtual, April 23-25, 2021, Poster

Enos CW, Ramos V, Lin T, McLean RR, Foster N, Dube B, Van Voorhees AS. Psoriatic Disease Characteristics by Metabolic Comorbidities among Patients with Psoriasis. AAD VMX, Virtual, April 23-25, 2021, Poster/Presentation

Lebwohl M, Kotowsky N, Medeiros RA, Nicole N, Janak J, Valdecantos WC, Flack M, Amanda K Golembesky AK, Strober B. Greater disease burden associated with palmoplantar pustulosis versus plaque psoriasis: Real-world evidence from the North American-based Corrona Psoriasis Registry. AAD VMX, Virtual, April 23-25, 2021, Poster

Strober B, Kotowsky N, Medeiros RA, Nicole N, Janak J, Valdecantos WC, Flack M, Amanda K Golembesky AK, Lebwohl M. Patient-reported outcomes from a large, North American-based cohort, highlight a greater disease burden for generalized pustular psoriasis versus plaque psoriasis: Real-world evidence from the Corrona Psoriasis Registry. AAD VMX, Virtual, April 23-25, 2021, Poster

Strober B, Cronin, C, Lin TC, O’Brien J, Emeauru K, Kang HJ, Nunez-Gomez N, Khilfeh I, Lebwohl M. Characteristics and Disease Burden in Patients With Mild to Moderate vs. Severe Plaque Psoriasis in Real-World Settings: Results From the Corrona Psoriasis Registry. AAD VMX, Virtual, April 23-25, 2021, Poster

AMCP 2021

Cohen SB, Shan Y, Litman HJ, McLean RR, Dandreo KJ, Gruben D, Germino R, Murray C, Kremer JM. Real-World Patterns of Methotrexate Withdrawal in Patients Receiving Tofacitinib: Results from the US Corrona RA Registry. AMCP, Virtual, April 12-16, 2021, EPoster

Innovations in Dermatology 2021 – Spring

Lockshin B, Harrison RW, McLean RR, Crabtree MM, Konicek BW, Zhu B, Malatestinic WN, Atiya B, Murage MJ, Burge R. Outcomes in ixekizumab patients following exposure to secukinumab and other biologics in the Corrona Psoriasis Registry. Innovations in Dermatology (Hawaii and Caribbean Derm), Virtual, March 16-20, 2021, EPoster

Strober B, Callis Duffin K, Lebwohl M, Lin TC, Janak J, Longcore M, Patel M, Photowala H, Garg V, Bagel J. Association of Psoriasis Disease Severity With Patient-Reported Outcomes Among US and Canadian Patients: Analysis of the Corrona Psoriasis Registry. Innovations in Dermatology (Hawaii and Caribbean Derm), Virtual, March 16-20, 2021, EPoster

CRA 2021 

Padula A, Pappas DA, Fiore S, Blachley T, Ford K, Emeanuru K, Kremer JM. The Effect of Targeted Rheumatoid Arthritis Therapeutics on Systemic Inflammation and Anemia.  Canadian Rheumatology Association (CRA), Virtual, February 24-26, 2021, EPoster

Maui Derm Connect 2021

Strober B, Lebwohl M, Kotowsky N, Medeiros RA, Mackey RH, Harrold LR, Valdecantos WC, Flack M, Golembesky AK. Perspectives on generalized pustular psoriasis treatment in North America: survey results from dermatologists in the Corrona Psoriasis Registry. Maui Derm, Maui, HI, January 25-29, 2021, EPoster

Winter Clinical Dermatology 2021

Strober B, Lebwohl M, Kotowsky N, Medeiros RA, Mackey RH, Harrold LR, Valdecantos WC, Flack M, Golembesky AK. Flare characteristics of generalized pustular psoriasis in North America: survey results from dermatologists in the Corrona Psoriasis Registry. Winter Clinical Derm, Maui, HI, January 15-20, 2021, EPoster

CDA 2021 – Chinese Dermatologist Association 

Gang W, Burge R, Erjia Y, Guanshen D, Harrison RW, McLean RR, Kerti J, Bagel J. Effectiveness of biologic therapy for psoriasis in Asian and Caucasian patients: A retrospective analysis from CorEvitas’ Psoriasis Registry. Chinese Dermatologist Association 17th Annual Meeting in China, Abstract

AIBD 2020 

Horst SN, Hudesman DP, Zhuo J, Harrison RW, Kerti SJ, Emeanuru K, Ahmad H, Sreih A, Nguyen J, Cross RK, Sauk JS. Factors Associated With Impaired Patient-Reported Outcomes and Work Productivity Among Patients With Ulcerative Colitis in Remission. Advances in Inflammatory Bowel Diseases (AIBD), December 10-12, 2020, Virtual, Poster

Hudesman DP, Sauk JS, Zhuo J, Harrison RW, Kerti SJ, Emeanuru K, Ahmad H, Sreih A, Nguyen J, Cross RK, Horst SN. Factors Associated with Impaired Patient-Reported Outcomes and Work Productivity Among Patients with Crohn’s Disease in Remission. Advances in Inflammatory Bowel Diseases (AIBD), December 10-12, 2020, Virtual, Poster

CSD 2020 – Chinese Society of Dermatology

Dou GS, Zhan LJ, Ye EJ, Burge RT, Sato M, Harrison RW, McLean RR, Anatale-Tardiff L, Crabtree MM, Bagel J. The real-world effectiveness of Ixekizumab among bio-experienced Asian patients with moderate to severe plaque psoriasis: 6-month analysis from the Corrona Psoriasis Registry. Chinese Society of Dermatology Conference, November 26-29, 2020, China, Podium Presentation

ACR Convergence 2020 

Curtis JR, Medeiros RA, Lee IH, Mackey RH, Haubrich R, Hao H, Greenberg JD, Wu A. Prevalence and Factors Associated with Patient-Physician Discordance Among RA Patients Initiating Advanced Therapy.Arthritis Rheumatol. 2020; 72 (suppl 10). Oral Presentation

Harrold L, Wittstock K, Kelly S, Xue H, Schrader A, Middaugh N, Moore P, Khaychuk V. The Comparative Effectiveness of Abatacept Versus TNF Inhibitors in Patients who are ACPA Positive and Have the Shared Epitope: Results From a US National Observational Study. Arthritis Rheumatol. 2020; 72 (suppl 10). Poster

Harrold L, Wittstock K, Kelly S, Xue H, Shan Y, Moore P, Guo L, Khaychuk V. The Comparative Effectiveness of Abatacept Versus Tofacitinib After 6 Months of Treatment in Patients With RA Who Were Anti-citrullinated Protein Antibody Positive at Baseline: Results From a US National Observational Study.Arthritis Rheumatol. 2020; 72 (suppl 10). Poster

Kishimoto M, Tanaka Y, Harrold LR, Onofrei A, Barr CJ, Agarwal E, Rivas JL, Sugiyama N, Greenberg JD, Yamanaka H. Real-World DMARD Experience and Outcomes in Japan: Safety.Arthritis Rheumatol. 2020; 72 (suppl 10). Poster

Mease P, Ogdie A, Blachley T, McLean R, Kawashima T, Sean, Soumya C, Iris. Clinical Characteristics of Psoriatic Arthritis Patients with Physician-Identified Spondylitis, According to HLA-B27 Status: An Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. Arthritis Rheumatol. 2020; 72 (suppl 10). Poster

Mease P, McLean R, Blachley T, Anatale-Tardiff L, Saffore C, Lovan C, Ogdie A. Impact of Skin Involvement on Disease Burden Among Patients with Psoriatic Arthritis: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. Arthritis Rheumatol. 2020; 72 (suppl 10). Poster

Mease P, McLean R, Blachley T, Anatale-Tardiff L, Saffore C, Zueger P, Ogdie A. Comparison of Disease Control Thresholds in Psoriatic Arthritis: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry.  Arthritis Rheumatol. 2020; 72 (suppl 10). Poster

Ogdie A, Blachley T, Emeanuru K, Richter S, Guerrette B, Mease P. Characteristics of Patients With Early Oligoarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/ Spondyloarthritis Registry. Arthritis Rheumatol. 2020; 72 (suppl 10). Poster

Tanaka Y, Yamanaka H, Harrold LR, Lin T, Agarwal E, Rivas JL, Sugiyama N, Greenberg JD, Kishimoto M. Real-World DMARD Experience and Outcomes in Japan: Effectiveness.Arthritis Rheumatol. 2020; 72 (suppl 10). Poster

Yamanaka H, Kishimoto M, Nakano K, Misaki K, Yamanishi Y, Dobashi H, Natsumeda M, Miyamoto T, Amano K, Sagawa A, Koido N, Harrold LR, Lin T, Greenberg JD, Tanaka Y. International comparison of Japanese and US Cross Country Utilization of RA Medications. Arthritis Rheumatol. 2020; 72 (suppl 10). Poster

Fall Clinical Derm 2020 

Armstrong AW, Duffin KC, Fitzgerald T, Teeple A, Uy JP, Olurinde M, Rowland K, McLean RR, Guo L, Shan Y, Van Voorhees AS.  Effectiveness of guselkumab by body mass index among patients with plaque psoriasis in the Corrona Psoriasis Registry.  FCD, Las Vegas, NV, October 29-November 1, 2020. Poster

EADV 2020 

Gottlieb AB, Harrison RW, McLean RR, Dube B, Merola JF. Utility of the PSAID12, a Patient Reported Outcome Measure for Psoriatic Arthritis, among patients in the Corrona Psoriasis Registry. EADV, Vienna, Austria, October 28-November 1, 2020. EPoster

Strober B, Lebwohl M, Kotowsky N, Medeiros RA, Mackey RH, Harrold LR, Valdecantos WC, Flack M, Golembesky AK. Perspectives on generalized pustular psoriasis treatment in North America: survey results from dermatologists in the Corrona Psoriasis Registry. EADV, Vienna, Austria, October 28-November 1, 2020. EPoster

Strober B, Lebwohl M, Kotowsky N, Medeiros RA, Mackey RH, Harrold LR, Valdecantos WC, Flack M, Golembesky AK.  Flare characteristics of generalized pustular psoriasis in North America: survey results from dermatologists in the Corrona Psoriasis Registry. EADV, Vienna, Austria, October 28-November 1, 2020. EPoster

ACG 2020 

Abraham BP, Hunter TM, Naegeli AN, Shan M, Sontag A, Moore PC, Mackey RH, Crabtree MM, Korzenik JR. Characteristics of Crohn’s Disease Patients in the Corrona Inflammatory Bowel Disease Registry on Biological or Conventional Therapy Differ by Disease Duration. ACG, Nashville, TN, October 23-28, 2020. Poster

Fan Y, Golembesky A, Delgado Aros S, Valdecantos W, Moore PC, Mackey RA, Crabtree MM, Stidham RW. Characteristics of Patients With Crohn’s Disease by History of Perianal Fistula Who Enrolled in the Corrona® Inflammatory Bowel Disease Registry. ACG, Nashville, TN, October 23-28, 2020. Poster

Sauk JS, Horst S, Hudesman DP, Zhuo J, Ahmad H, Sreih A, Harrison RW, Mackey RH, Crabtree MM, Emeanuru K, Cross RK. Real-World Treatment Patterns and Treatment Persistence Among Ulcerative Colitis and Crohn’s Disease Patients in the Corrona Inflammatory Bowel Disease National Registry. ACG, Nashville, TN, October 23-28, 2020. Poster

Wong G, Solon C, Reilly N, Harrison RW, Mackey RH, Anatale-Tardiff L, Kerti S. Characterizing Prior Healthcare Resource Utilization by Disease Severity in Ulcerative Colitis: Real World Data From the Corrona Inflammatory Bowel Disease Registry. ACG, Nashville, TN, October 23-28, 2020. Poster

Wong G, Solon C, Reilly N, Harrison RW, Mackey RH, Anatale-Tardiff L, Kerti S. Differences in Clinical Characteristics and Patient-Reported Outcomes of Recently Hospitalized vs Non-Hospitalized Ulcerative Colitis Patients: Real World Data From Corrona Inflammatory Bowel Disease Registry. ACG, Nashville, TN, October 23-28, 2020. Poster

Spanish Congress of Rheumatology 2020

Mease P, Liu M, Rebello S, McLean R, Dube B, Glynn M, Yi E, Park Y, Ogdie A. Comparison of Men and Women With Axial Spondyloarthritis in the US-Based Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry. Spanish Congress of Rheumatology, Madrid, Spain, October 22-25, 2020. Poster

UEGW 2020

Wolf DC, Naegeli AN, Shan M, Hunter TM, Sontag A, Moore PC, Mackey RH, Crabtree MM, Cross RK.  Characteristics of Ulcerative Colitis patients by urgency of defecation at enrollment in the Corrona Inflammatory Bowel Disease Registry. United European Gastroenterology Week, Amsterdam, October 11-13, 2020. EPoster

AMCP Nexus 2020 

Wong G, Solon C, Reilly N, Mackey RH, Anatale-Tardiff L, Kerti S, Harrison RW. Differences in Clinical Characteristics and Patient-Reported Outcomes of Recently Hospitalized Versus non-Hospitalized Crohn’s Disease Patients: Real-World Data from the Corrona Inflammatory Bowel Disease Registry. AMCP Nexus, Las Vegas, NV, October 20-23, 2020. EPoster

Wong G, Solon C, Reilly N, Mackey RH, Anatale-Tardiff L, Kerti S, Harrison RW. Characterizing Prior Healthcare Resource Utilization by Disease Severity in Crohn’s Disease: Real-World Data From the Corrona Inflammatory Bowel Disease Registry.  AMCP Nexus, Las Vegas, NV, October 20-23, 2020. EPoster

Maui Derm Connect 2020 

Van Voorhees AS, Harrison RW, Burge R, Malatestinic WN, Zhu B, Atiya B, Murage MJ, McLean RR, Crabtree M, O’Brien J, Lockshin B. Outcomes in ixekizumab initiators by prior biologic status in the Corrona® Psoriasis Registry. Maui Derm Connect, September 23-26, 2020, Live Streamed. EPoster

San Diego Dermatology Symposium 2020 

Van Voorhees AS, Harrison RW, Burge R, Malatestinic WN, Zhu B, Atiya B, Murage MJ, McLean RR, Crabtree M, O’Brien J, Lockshin B. Outcomes in ixekizumab initiators by prior biologic status in the Corrona® Psoriasis Registry.  SDDS, San Diego, CA, September 11-13, 2020. EPoster

ACTRIMS-ECTRIMS 2020 

Kantor D, Engmann NJ, Malley W, McLean RR, Cronin A, Dube B, Miller A. Characteristics of patients initiating ocrelizumab vs other disease-modifying therapies in a US national multiple sclerosis registry. ACTRIMS/ECTRIMS, Washington, DC, September 9-12, 2020. Poster

EULAR 2020 

Hunter T, Malatestinic W, Blachley T, Harrold L, Dube B, Glynn M, Lisse J, Bolce R, Mease P. Effectiveness of bDMARDs in AS and nr-axSpA patient populations: Experience from the Corrona Registry. June 2020 Volume 79 Supplement 1. DOI: 10.1136/annrheumdis-2020-eular.3318. Poster

Kremer JM, Winkler A, Tardiff-Anatale L, McLean R, Shan Y, Moore P, Tundia N, Suboticki J, Tesser J. Comparison of patients (pts) with rheumatoid arthritis (RA) among disease activity categories after 6 months of treatment with a tumour necrosis factor inhibitor (TNFi): Results from the Corrona® RA Registry. June 2020 Volume 79 Supplement 1. DOI: 10.1136/annrheumdis-2020-eular.1698. Poster

Mease P, Blachley T, Glynn M, Dube B, McLean RR, Kim N, Hur P, Ogdie A. Secukinumab Improves Clinical and Patient-Reported Outcomes at 6 Months Among Patients With Psoriatic Arthritis in the US-Based Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry. June 2020 Volume 79 Supplement 1. DOI: 10.1136/annrheumdis-2020-eular.1014. Poster

Ogdie A, Blachley T, Glynn M, Rebello S, Dube B, McLean RR, Hur P, Mease P. Comparison of Patients With Psoriatic Arthritis (PsA) and Investigator-Defined Axial PsA To Patients With PsA and Elevated Patient-Reported Spine Pain: Findings From the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry. June 2020 Volume 79 Supplement 1. DOI: 10.1136/annrheumdis-2020-eular.1072. Presentation

Ogdie A, Liu M, Glynn M, Emeanuru K, Harrold LR, Mohawk J, Richter S, Guerette B, Mease PJ. Burden Of Disease In Patients Initiating Apremilast Treatment: 2014-2019 Findings From The Corrona Psoriatic Arthritis/Spondyloarthritis Registry. June 2020 Volume 79 Supplement 1. DOI: 10.1136/annrheumdis-2020-eular.1537. Poster

Pappas DA, Blachley T, Zlotnick S, Best J, Emeanuru K, Kremer JM. Comparative Effectiveness of Tocilizumab in Combination With Methotrexate Versus Tumor Necrosis Factor Inhibitors (TNFis) in Combination With Methotrexate in Patients With Rheumatoid Arthritis With Prior Exposure to TNFis. June 2020 Volume 79 Supplement 1. DOI: 10.1136/annrheumdis-2020-eular.588. Poster

Pappas DA, Blachley T, Best J, Zlotnick S, Emeanuru K, Kremer JM. Persistence of Tocilizumab Therapy Among Patients With Rheumatoid Arthritis: Data From the US-Based Corrona Rheumatoid Arthritis Registry. June 2020 Volume 79 Supplement 1. DOI: 10.1136/annrheumdis-2020-eular.708. Poster

Pappas DA, Blachley T, Best J, Zlotnick S, Reiss W, Emeanuru K, Kremer JM. Durability of Response Among Patients With Rheumatoid Arthritis Initiating Tocilizumab: Data From the US-Based Corrona Rheumatoid Arthritis Registry. June 2020 Volume 79 Supplement 1. DOI: 10.1136/annrheumdis-2020-eular.571. Poster

SID 2020 

Enos C, O’Connell K, Harrison R, McLean R, Dube B, Bell S, Van Voorhees A. Regional differences in biologic treatment patterns and achievement of outcomes within the Corrona Psoriasis Registry across the US. SID, Scottsdale, AZ, May 13-16, 2020. Abstract

DDW 2020 

Cross R, Naegeli A, Dong Y, Arora V, Morris N, Malatestinic W, Kayhan C, Harrison R, Moore P, Mackey R, Lemay CA, Korzenik J. Disease Burden and Patient-Reported Outcome Measures among Ulcerative Colitis Patients According to Therapy at Enrollment into the Corrona IBD Registry. DDW, Chicago, IL, May 3-5, 2020. Poster

Horst SN, Hudesman D, Zhuo J, Harrison RW, Mackey RH, Crabtree MM, Emeanuru K, Ahmad H, Nguyen J, Sauk JS, Cross R. Poor Patient-Reported Outcomes were Observed in Patients in the Corrona Inflammatory Bowel Disease Registry, despite being in clinical remission. DDW, Chicago, IL, May 3-5, 2020. Poster

Hudesman D, Horst SN, Zhuo J, Mackey RH, Harrison RW, Crabtree MM, Emeanuru K, Ahmad H, Nguyen J, Sauk JS, Cross RK. Considerable work productivity loss in patients with inflammatory bowel disease both with active disease and in clinical remission. DDW, Chicago, IL, May 3-5, 2020. Poster

Sauk J, Cross RK, Abraham BP, Horst S, Hudesman D, Kochhar G, Stidham RR, Wolf D, Harrison RW, Mackey RH, Korzenik JR. Enrollment characteristics of Ulcerative Colitis and Crohn’s Disease patients in the Corrona® Inflammatory Bowel Disease Registry according to type of insurance.  DDW, Chicago, IL, May 3-5, 2020. Poster

AAN 2020 

Kantor D, Engmann N, Malley W, McLean R, Cronin A, Dube B, Miller A. Demographic, clinical and patient-reported characteristics of patients on ocrelizumab versus other disease-modifying therapies in the Corrona Multiple Sclerosis Registry.  AAN, Toronto, Ontario, Canada, April 25-May 1, 2020. Poster

Kantor D, Bebo B, Coyle PK, Fox EJ, Bermel RA, Greenberg JD, Malley W, McLean R, Rebello S, LaRocca N, Miller AE. Observed differences in characteristics of secondary-progressive multiple sclerosis and relapsing-remitting multiple sclerosis patients in the US-based Corrona MS Registry. AAN, Toronto, Ontario, Canada, April 25-May 1, 2020. Poster

AAD 2020 

Armstrong A, Strober B, Drew S, Cronin A, Jacobson A. Real-World Characteristics of Patients With Psoriasis Initiating Brodalumab: Findings From the Corrona Psoriasis Registry. AAD, Denver, CO, March 20-24, 2020. Poster

Armstrong AW, Uy JP, Rowland K, González-Rivera TT, Fitzgerald T, Teeple A, McLean RR, Guo L, Shan Y, Van Voorhees AS. Impact of guselkumab on quality of life and work productivity outcomes among patients with plaque psoriasis in the Corrona® Psoriasis Registry. AAD, Denver, CO, March 20-24, 2020. Poster

Bagel J, Behl A, Litman HJ, Medeiros RA, Guo N, Lebwohl M, Strober BE. Secukinumab Significantly Improves Clinical and Patient-Reported Outcomes Up to 18 Months of Follow-Up: Real-World Evidence From a US Psoriasis Registry. AAD, Denver, CO, March 20-24, 2020. Poster

Enos C, O’Connell K, Harrison RW, McLean RR, Dube B, Van Voorhees A. 2018 Geographic Variations in the Use of Biologic Therapy for Psoriasis in the Corrona PsO Registry. AAD, Denver, CO, March 20-24, 2020. Oral and Poster.  Also to be published in an online version of JAAD in late Spring 2020.

Lebwohl M, Kimmel G, Von Csiky-Sessoms S, Cronin A, Jacobson A. Real-World Disease Severity of Patients Receiving Brodalumab: Findings From the Corrona Psoriasis Registry. AAD, Denver, CO, March 20-24, 2020. Poster

Wu JJ, Lin TC, Litman HJ, Dube B, Kearns DG, Chat VS, McLean RR. Characterization of Non-Responders to IL-17 inhibitors in Moderate to Severe Psoriasis Patients Enrolled in the Corrona® Psoriasis Registry. AAD, Denver, CO, March 20-24, 2020. Poster

Hawaii Derm 2020 

Lockshin B, Cronin A, Harrison RW, McLean RR, Anatale-Tardiff L, Burge R, Zhu B, Malatestinic WN, Atiya B, Murage MJ, Strober B, Van Voorhees A. Drug survival of ixekizumab, other IL-17 inhibitors, and TNF inhibitors in real-world patients with psoriasis: the Corrona® Psoriasis Registry. Hawaii Dermatology Seminar, Maui, Hawaii, February 16-21, 2020. Poster

ACR 2019

Dore R, Antonova J, Harrold L, Chang L, Scherer E, Cronin A, Emeanuru K, Kremer J. Patient Characteristics, Treatment Patterns, and Treatment Persistency in Biologic DMARD-Experienced Rheumatoid Arthritis Patients in a US RA Registry[abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10).

Harrold L, Shan Y, Rebello S, Guo L, Connolly S, Zhuo J, Kelly S, Lehman T. Association Between Baseline Anti-citrullinated Protein Antibody Status and Response to Abatacept or Non-TNF Inhibitor Therapy in Patients with RA: Results from a US National Observational Study [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10).

Harrold L, Bryson J, Lehman T, Zhuo J, Gao S, Han X, Schrader A, Rebello S, Kremer J. Association Between Baseline Anti-CCP2 Antibody Concentration and Clinical Response After 6 Months of Treatment with Abatacept or a TNF Inhibitor in Biologic-Experienced Patients with RA: Results from a US National Observational Study [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10).

Johansson F, Collins J, Gale S, Guan H, Kim S, Losina E, Sontag D, Stratton J, Trinh H, Greenberg J, Solomon D. Predicting Remission in Rheumatoid Arthritis: External Validation for Tocilizumab Monotherapy Using Corrona Real World Data [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10).

Kremer J, Bingham C, Cappelli L, Greenberg J, Geier J, Madsen A, Chen C, Onofrei A, Barr C, Pappas D, Litman H, Dandreo K, Shapiro A, Connell C, Kavanaugh A. Post-Approval Comparative Safety Study of Tofacitinib and Biologic DMARDs: Five‑Year Results from a US-based Rheumatoid Arthritis Registry [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10).

Kremer J, Bingham C, Cappelli L, Greenberg J, Madsen A, Geier J, Rivas J, Onofrei A, Barr C, Pappas D, Litman H, Dandreo K, Shapiro A, Connell C, Kavanaugh A. Comparison of Malignancy and Mortality Rates Between Tofacitinib and Biologic DMARDs in Clinical Practice: Five-Year Results from a US-Based Rheumatoid Arthritis Registry [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10).

Mease P, Liu M, Rebello S, McLean R, Dube B, Glynn M, Yi E, Park Y, Ogdie A. Comparison of Men and Women with Axial Spondyloarthritis in the US-Based Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10).

Ogdie A, Liu M, Glynn M, Emeanuru K, Harrold L, Richter S, Guerette B, Mease P. Real-World Use of Apremilast in Combination with Biologic Therapy in Patients with Psoriatic Arthritis: Findings from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10).

Ogdie A, Liu M, Rebello S, Cronin A, Dube B, McLean R, Yi E, Hur P, Mease P. Characteristics of Patients with Seropositive or Seronegative Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis: Data from the US-Based Corrona Rheumatoid Arthritis and Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registries [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10).

Ogdie A, Liu M, Rebello S, Glynn M, Dube B, McLean R, Yi E, Park Y, Mease P. Clinical Characteristics and Treatment Profiles of Patients with Ankylosing Spondylitis Who Initiated Secukinumab and Other Biologics: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10).

Ogdie A, Liu M, Glynn M, Emeanuru K, Harrold L, Richter S, Guerette B, Mease P. Burden of Disease at Treatment Initiation Among Biologic-Naïve Patients with Oligoarticular versus Polyarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10).

Ogdie A, Hur P, Liu M, Rebello S, McLean R, Dube B, Glynn M, Mease P. Impact of Multidomain Disease Presentations on Overall Disease Burden Among Patients with Psoriatic Arthritis: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10).

Ogdie A, Hur P, Liu M, Rebello S, McLean R, Dube B, Glynn M, Mease P. Prevalence of Disease Domain Presentations Among Patients with Psoriatic Arthritis: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10).

Pappas D, Blachley T, Zlotnick S, Best J, Emeanuru K, Kremer J. Methotrexate Discontinuation and Dose Decreases After Therapy with Tocilizumab: Results from the Corrona Rheumatoid Arthritis Registry [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10).

Pappas D, Blachley T, Zlotnick S, Best J, Emeanuru K, Kremer J. Comparative Effectiveness of Tocilizumab in Combination with Methotrexate versus Tumor Necrosis Factor Inhibitors (TNFis) in Combination with Methotrexate in Patients with Rheumatoid Arthritis with Prior Exposure to TNFis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10).

Pappas D, Blachley T, Best J, Zlotnick S, Emeanuru K, Kremer J. Persistence of Tocilizumab Therapy Among Patients with Rheumatoid Arthritis: Data from the US-Based Corrona Rheumatoid Arthritis Registry [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10).

Las Vegas Dermatology Seminar 2019

Bagel J, Schrader A, McLean RR, Litman HJ, Chapman-Rothe N, Behl A, Guzman AK. Effectiveness of Secukinumab in Patients With Psoriasis in Challenging-to-Treat Areas: Real-World Evidence From the Corrona Psoriasis Registry.Las Vegas Dermatology Seminar 2019, November 7-9, 2019, Las Vegas, NV. Poster

Fall Clinical Derm 2019

Armstrong AW, Duffin KC, Uy JP, Rowland K, Gonzalez-Rivera TT, Fitzgerald T, Teeple A, McLean RR, Guo L, Shan Y, Van Voorhees AS. Effectiveness of guselkumab among patients with plaque psoriasis in the Corrona Psoriasis Registry. Fall Clinical Derm, Las Vegas, NV, October 17-20, 2019. Poster

EADV 2019

Callis-Duffin K, Merola JF, Walsh J, Uy J, Fitzgerald T, Teeple A, Rowland K, Chakravarty S, McLean R, Malley W, Cronin A, Van Voorhees AS. Patient reported outcomes among patients with psoriasis who initiated guselkumab in a large North American psoriasis registry. 28th EADV Congress.  9-13 October 2019. Madrid, Spain. E-Poster

Callis-Duffin K, Merola JF, Walsh J, Uy J, Fitzgerald T, Teeple A, Rowland K, Chakravarty S, McLean R, Malley W, Cronin A, Van Voorhees AS. Demographics and disease characteristics of patients with psoriasis who initiated guselkumab in a large North American psoriasis registry. 28th EADV Congress.  9-13 October 2019. Madrid, Spain. E-Poster

Gottlieb AB, Merola JF, McLean RR, Cirulli J, Mohawk J, Yang L, Litman HJ, Cronin A, Emeanuru K, Strober B.Characteristics of Psoriasis Patients and Use of Apremilast Classified by Psoriasis Severity and Disease Burden: Results From the Corrona Psoriasis Registry. 28th EADV Congress.  9-13 October 2019. Madrid, Spain. E-Poster

Gottlieb AB, Merola JF, McLean RR, Cirulli J, Mohawk J, Yang L, Litman HJ, Cronin A, Emeanuru K, Strober B.Real-World Efficacy of Apremilast in Patients With Psoriasis With and Without Comorbid Psoriatic Arthritis: Findings From the Corrona Psoriasis Registry. 28th EADV Congress.  9-13 October 2019. Madrid, Spain. E-Poster

Strober B, Zema CL, Holmes C, O’Brien J, Harrison RW, McLean RR, Lebwohl M. Reasons for drug discontinuation among psoriasis patients in the Corrona Psoriasis Registry. 28th EADV Congress.  9-13 October 2019. Madrid, Spain. E-Poster

Maui Derm NP+PA Fall 2019

Bagel J, Behl A, Chapman-Rothe N, Greenberg JD, Litman HJ, Guo N, Lebwohl M, Strober BE. Secukinumab Significantly Improves 6- and 12-Month Clinical and Patient-Reported Outcomes: Real-World Evidence From the Corrona Psoriasis Registry. Maui Derm NP+PA Fall, Asheville, NC, October 2-5, 2019. Poster

Congress of Clinical Rheumatology 2019

Walsh JA, Duffin KC, Van Voorhees AS, Chakravarty SD, Fitzgerald T, Rowland K, McLean RR, Malley W, Cronin A, Merola JF. Characteristics of Patients with Psoriasis and Concomitant Psoriatic Arthritis Prescribed Guselkumab in a Large North American Psoriasis Registry. CCR-W 2019, San Diego, CA, September 26-29, 2019. Poster

ECTRIMS 2019

Kantor D, Bebo B, Coyle PK, Fox EJ, Bermel RA, Greenberg JD, Malley W, McLean R, Rebello S, LaRocca N, Miller AE. Observed differences in characteristics of secondary-progressive multiple sclerosis and relapsing-remitting multiple sclerosis patients in the US-based Corrona MS Registry. 35th Congress of ECTRIMS, 11-13 September 2019, Stockholm Sweden. Poster

Kantor D, Bebo B, Coyle PK, Fox EJ, Bermel RA, Greenberg JD, Malley W, McLean R, Rebello S, LaRocca N, Miller AE. Baseline characteristics of patients with multiple sclerosis enrolled in the US-based Corrona MS Registry. 35th Congress of ECTRIMS, 11-13 September 2019, Stockholm Sweden. Poster

EULAR 2019

Danila M, Chen L, Owensby J, O’Beirne R, Melnick J, Ruderman E, Harrold L, Curtis J. Mitigating Medication Risk Aversion In The Confident Treatment Decisions For Living With Rheumatoid Arthritis Trial. Ann Rheum Dis, volume 78, supplement 2, year 2019, page A329. Poster

Dore R, Harrold L, Blachley T, Emeanuru K, Antonova J, Kremer J. Differences in patient characteristics and patterns of treatment by disease-modifying antirheumatic drugs (DMARD) in bDMARD naive versus experienced patients. Ann Rheum Dis, volume 78, supplement 2, year 2019, page A1141. Poster

Harrold L, Litman HJ, O’Brien J, Feng H, Schlacher C, Tundia N. Methotrexate Treatment Patterns In Advanced Therapy–Naïve Patients With Rheumatoid Arthritis: Clinical Characteristics And Outcomes Of Patients In The Corrona Registry. Ann Rheum Dis, volume 78, supplement 2, year 2019, page A747. Poster

Harrold L, Patel P, Zueger P, O’Brien J, Litman HJ, Feng H, McLean R. Treatment Utilisation Patterns Of Advanced Therapies In Psoriatic Arthritis. Ann Rheum Dis, volume 78, supplement 2, year 2019, page A910. Poster

Harrold LR, Shan Y, Rebello S, Kramer N, Connolly SE, Alemao E, Kelly S, Kremer JM, Rosenstein ED. Disease Activity and Patient Reported Outcomes in Patients with RA with Sjögren’s Syndrome Enrolled in a Large Observational US Registry.  Ann Rheum Dis, volume 78, supplement 2, year 2019, page A327. Poster

Kremer J, Bingham C, Cappelli L, Etzel C, Greenberg J, Geier J, Madsen A, Chen C, Onofrei A, Barr C, Pappas DA, Litman HJ, Dandreo KJ, Shapiro A, Connell CA,  Kavanaugh A. Post-Approval Comparative Safety Study Of Tofacitinib And Biologic Dmards: Five Year Results From A Us-Based Rheumatoid Arthritis Registry. Ann Rheum Dis, volume 78, supplement 2, year 2019, page A82. Presentation

Mease PJ, Liu M, Rebello S, McLean RR, Dube B, Glynn M, Yi E,  Park Y, Ogdie A. Comparison of Men and Women With Axial Spondyloarthritis in the US-Based Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry. Ann Rheum Dis, volume 78, supplement 2, year 2019, page A1230. Poster

Mease PJ, Hur P, Liu M, Rebello S, McLean RR, Dube B, Glynn M, Ogdie A. Characterization of Patients With Psoriatic Arthritis and Nail Psoriasis: Data From the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry. Ann Rheum Dis, volume 78, supplement 2, year 2019, page A1278. Poster

Mease PJ, Liu M, Rebello S, Hua W, McLean RR, Yi E, Park Y, Ogdie A. Characterization of Patients With Axial Spondyloarthritis by Presence of Enthesitis: Data From the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry. Ann Rheum Dis, volume 78, supplement 2, year 2019, page A1249. Poster

Ogdie A, Liu M, Rebello S, Glynn M, Dube B, McLean RR, Yi E, Park Y, Mease PJ. Clinical Characteristics and Treatment Profiles of Patients With Ankylosing Spondylitis Who Initiated Secukinumab and Other Biologics: Results From the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry. Ann Rheum Dis, volume 78, supplement 2, year 2019, page A484. Poster

Ogdie A, Liu M, Glynn M, Emeanuru K, Harrold LR, Richter S, Guerette B, Mease PJ. Burden Of Disease At Treatment Initiation Among Biologic-Naïve Patients With Oligoarticular Versus Polyarticular Psoriatic Arthritis In The Corrona Psoriatic Arthritis/Spondyloarthritis Registry. Ann Rheum Dis, volume 78, supplement 2, year 2019, page A1251. Poster

Ogdie A, Hur P, Liu M, Rebello S, McLean RR, Dube B, Glynn M, Mease PJ. Prevalence of Disease Domain Presentations Among Patients With Psoriatic Arthritis: Results From the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry. Ann Rheum Dis, volume 78, supplement 2, year 2019, page A922. Poster

Ogdie A, Hur P, Liu M, Rebello S, McLean RR, Dube B, Glynn M, Mease PJ. Impact of Multidomain Disease Presentations on Overall Disease Burden Among Patients With Psoriatic Arthritis: Results From the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry. Ann Rheum Dis, volume 78, supplement 2, year 2019, page A923. Poster

Pappas DA, Blachley T, Zlotnick S,  Best J, Emeanuru K, Kremer JM. Methotrexate Discontinuation and Dose Decreases After Therapy With Tocilizumab: Results From the Corrona Rheumatoid Arthritis Registry. Ann Rheum Dis, volume 78, supplement 2, year 2019, page A1150.  Poster

World Congress of Dermatology 2019

Merola JF, Gottlieb AB, McLean RR, Cirulli J, Williams C, Linowski GJ, Litman HJ, Guo N, Emeanuru K, Strober B. Real-World Efficacy of Apremilast in Patients With Moderate Plaque Psoriasis: Results From the Corrona Psoriasis Registry.  WCD 2019. Milan, Italy. June 10-15, 2019. Poster

NPF Cure Symposium 2019

Shahriari M, Harrison R, Burge R, Lin C, Malatestinic WN, Goldblum OM, Amato D, Crabtree M, Grace E, Murage MJ.  Disease Response Outcomes Among Ixekizumab Patients: Findings from the Corrona Registry. NPF Cure Symposium. Seattle, WA. May 30-31, 2019. Poster

Shahriari M, Crabtree M, Burge R, Lin C, Malatestinic WN, Goldblum OM, Amato D, O’Brien J, Grace E, Murage MJ. Patient-Reported Outcomes and Response to Treatment for Patients Initiating Ixekizumab: Findings from the Corrona Registry.  NPF Cure Symposium. Seattle, WA. May 30-31, 2019. Poster

SPIN 2019 

Grace E, Zhu B, Malley W, O’Brien J, Magner R, Agada N, Gallo G, Bhutani T.  Safety Events Occurring Among Patients Exposed To Ixekizumab In The Corrona Psoriasis Registry.  SPIN 2019, April 25-27, 2019, Paris, France.  Poster

AAD 2019

Bagel J, Germino R, Guana A, Herrera V, Greenberg JD, Litman HJ, Guo N, Lebwohl M,  Strober B.  Secukinumab Significantly Improves Disease Severity and Patient-Reported Outcomes Up to 1 Year of Follow-Up: Real -World Analyses from the Corrona Psoriasis Registry.  AAD 2019, March 1-5, 2019, Washington, DC.  Poster

Bagel J, Germino R, Guana A, Herrera V, Greenberg JD, Litman HJ, Guo N, Lebwohl M,  Strober B.  Reasons for Secukinumab Initiation and Discontinuation Among Patients with Psoriasis.  AAD 2019, March 1-5, 2019, Washington, DC.  Poster

Merola JF, Gottlieb AB, McLean RR, Cirulli J, Williams CC, Linowski GJ, Litman HJ, Guo N, Emeanuru K, Strober B.  Real-World Efficacy of Apremilast in Patients With Moderate Plaque Psoriasis: Results From the Corrona Psoriasis Registry.  AAD 2019, March 1-5, 2019, Washington, DC.  Poster

Shahriari M, Harrison R, Burge R, Lin C, Malatestinic WN, Goldblum OM, Amato D, Crabtree M, Grace E, Murage MJ.  Disease Response Outcomes Among Ixekizumab Patients: Findings from the Corrona Registry.  AAD 2019, March 1-5, 2019, Washington, DC.  Poster

Shahriari M, Crabtree M, Burge R, Lin C, Malatestinic WN, Goldblum OM, Amato D, O’Brien J, Grace E, Murage MJ.  Patient-Reported Outcomes and Response to Treatment for Patients Initiating Ixekizumab: Findings from the Corrona Registry.  AAD 2019, March 1-5, 2019, Washington, DC.  Poster

Hawaii Derm Seminar 2019

Shahriari M, Harrison RW, Burge R, Lin C, Malatestinic WN, Amato D, O’Brien J, Crabtree M, Grace E, Murage MJ.  Patient Characteristics and Treatment Patterns for Patients Initiating Ixekizumab: Findings from the Corrona Registry.  Hawaii Derm Seminar (SDEF).  Waikoloa Village, HI.  17-22 February 2019.  Poster

Psoriasis National Congress 2019

Bagel J, Germino R, Guana A, Herrera V, Greenberg JD, Litman HL, Guo N, Lebwohl M, Strober BE, Guillermo Guinea.  Secukinumab clinical and patient-reported outcomes after 1 year of follow-up: Real-world analyses from the Corrona Psoriasis Registry.  Congreso Nacional de Psoriasis 2019. Madrid, Spain. 18-19 January 2019.  Poster

Las Vegas Dermatology 2018

Bagel J, McLean RR, Schrader A, Litman HJ, Guana A, Germino R, Guzman A. Impact of Secukinumab on Patient Reported Outcomes in Patients with Psoriasis in Challenging-to-Treat Areas: Real World Data from the Corrona Psoriasis Registry. Las Vegas Dermatology Seminar. Las Vegas, NV. 1-3 November 2018. Poster

Callis Duffin K, McLean RR, Gordon K, Harrison RW, Crabtree MM, Guana A, Germino R, Lebwohl M. Prevalence of Psoriatic Arthritis and Challenging-to-Treat Areas Among Patients With Psoriasis Who Initiated Biologic Therapy in the Corrona Psoriasis Registry. Las Vegas Dermatology Seminar. Las Vegas, NV. 1-3 November 2018. Poster

AMCP Nexus 2018

Mease PJ, Gershenson B, Hur P, Greenberg JD. Discontinuation and Switching Patterns of Tumor Necrosis Factor Inhibitor (TNFi) Therapy in TNFi-Naive and TNFi-Experienced Patients With Psoriatic Arthritis in the US Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry. AMCP Nexus 2018. 22-25, October 2018. Orlando, FL. Poster

Mease PJ, Liu M, Rebello S, Kang H, Park Y, Greenberg JD. Comparative Disease Burden of Patients With Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis: Data From the Corrona Rheumatoid Arthritis and Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registries. AMCP Nexus 2018. 22-25, October 2018. Orlando, FL. Poster

ACR 2018

Cohen S, Litman HJ, Chen C, Lukic T, Madsen A, Takiya L, Dandreo KJ, Blachley T, Greenberg J. Clinical Effectiveness of Tofacitinib 11mg Once Daily (QD) Versus Tofacitinib 5mg Twice Daily (BID) in the Corrona US RA Registry [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10).

Curtis JR, Palmer JL, Reed GW, Greenberg J, Pappas DA, Harrold LR, Kremer J. Real-World Outcomes Associated with Triple Therapy Vs. TNFi Combo Therapy: Results from the Corrona Registry [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10).

Danila MI, Chen L, Owensby JK, O’Beirne R, Melnick JA, Ruderman EM, Harrold LR, Curtis JR. Mitigating Medication Risk Aversion in the Confident Treatment Decisions for Living with Rheumatoid Arthritis Trial [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10).

Harrold LR, Griffith J, Litman HJ, Feng H, Schlacher CA, Kremer J. Disease Severity Among Bio-Naive RA Patients on Csdmards [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). Poster

Harrold LR, Griffith J, Litman HJ, Gershenson B, Islam S, Barr CJ, Guo D, Zueger P, Fay J, Greenberg J. Long-Term, Real-World Safety of Adalimumab in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). Poster

Harrold LR, Guo L, Connolly SE, Alemao E, Rebello S, Shan Y, Kremer J. Association between Anti-Citrullinated Protein Antibody Status, Erosive Disease and Healthcare Resource Utilization in Patients with RA [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). Poster

Harrold LR, Shan Y, Rebello S, Kramer N, Connolly SE, Alemao E, Kelly S, Curtice T, Kremer J, Rosenstein E. Prevalence of Sjögren’s Syndrome in Patients with RA Enrolled in a Large Observational US Registry [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). Poster

Kremer J, Cappelli LC, Etzel CJ, Greenberg J, Geier J, Madsen A, Chen C, Onofrei A, Barr CJ, Pappas DA, Dandreo KJ, Shapiro A, Connell CA, Kavanaugh A. Real-World Data from a Post-Approval Safety Surveillance Study of Tofacitinib Vs Biologic Dmards and Conventional Synthetic Dmards: Five-Year Results from a US-Based Rheumatoid Arthritis Registry [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10).

Kremer J, Palmer JL, Reed GW, Pappas DA, Harrold LR, Greenberg J, Curtis JR. Clinical and Sociodemographic Characteristics of Patients with Rheumatoid Arthritis (RA) Starting Triple Therapy and a Combination of a TNF Inhibitor and Methotrexate from a Large US Registry [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10).

Lee YC, Lu B, Guan H, Greenberg J, Kremer J, Solomon D. Physician Opioid Prescribing Patterns and Risk for Chronic Opioid Use Among Rheumatoid Arthritis Patients [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10).

Mease PJ, Liu M, Rebello S, Hua W, McLean RR, Hur P, Ogdie A. Disease Characteristics, Quality of Life, and Work Productivity By Enthesitis Sites: Real-World Data from the US Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10).

Mease PJ, Liu M, Rebello S, Kang H, Park Y, Greenberg J. Comparative Disease Burden of Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis: Data from the Corrona Rheumatoid Arthritis and Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registries [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10).

Mikuls TR, Bath A, England BR, Duryee MJ, Hunter CD, Kremer J, Pappas DA, Robinson WH, Curtis JR, Thiele GM. Expanded Autoantibody Profiles Predict Treatment Response to Biologic Therapy in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10).

Ogdie A, Liu M, Rebello S, Glynn M, Hur P, Mease PJ. Clinical Characteristics and Treatment Profile of Patients with Psoriatic Arthritis Who Initiated Secukinumab and Other Biologics: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10).

Pappas DA, Etzel CJ, Crabtree M, Best JH, Zlotnick S, Kremer J. Impact of Comorbidity Burden and Obesity on the Effectiveness of Tocilizumab in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). Poster

Pappas DA, Shan Y, Lesperance T, Rebello S, Karis E, Kricorian G, Hua W, Accortt NA, Stryker S. Persistence in Low Disease Activity or Remission with Etanercept Monotherapy in Patients with Rheumatoid Arthritis: Results from the Corrona Registry [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). Poster

Pappas DA, St. John G, Etzel CJ, Fiore S, Blachley T, Kimura T, Punekar R, Emeanuru K, Boklage S, Kremer J. The Comparative Effectiveness of First-Line Tumor Necrosis Factor Inhibitor (TNFi) Compared with Non-TNFi Agents in Patients with Rheumatoid Arthritis: Results from the Corrona Registry [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10).

Pappas DA, Tundia N, Shan Y, Litman HJ, Kremer J. Unmet Treat-to-Target Goals with Available Targeted Immunomodulators in the Management of Rheumatoid Arthritis: Real World Evidence from the Corrona Registry [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). Poster

EADV 2018

Bagel J, Germino R, Guana A, Herrera V, Greenberg JD, Litman HJ, Guo N, Lebwohl M, Strober BE. Secukinumab Clinical and Patient-Reported Outcomes at 12-Month Follow-Up: Real-World Analyses From the US Corrona Psoriasis Registry. EADV 2018. 12-16 September, 2018. Paris, France. E-poster

Gottlieb AB, Litman HJ, Merola JF, Cirulli J, Williams CC, Linowski GJ, McLean RR, Malley W, Emeanuru K, Strober BE. Real-World Safety of Apremilast in Patients With Psoriasis: Results From the Corrona Psoriasis Registry. EADV 2018. 12-16 September, 2018. Paris, France. E-poster

Gottlieb AB, McLean RR, Merola JF, Cirulli J, Williams CC, Linowski GJ, Litman HJ, Gruschkus S, Emeanuru K, Strober BE. Real-World Efficacy of Apremilast in Patients With Psoriasis: Results From the Corrona Psoriasis Registry. EADV 2018. 12-16 September, 2018. Paris, France. E-poster

Merola JF, McLean RR, Gottlieb AB, Cirulli J, Williams CC, Linowski GJ, Litman HJ, Gruschkus S,  Emeanuru K, Strober BE. Demographics and Disease Characteristics of Patients With Psoriasis Treated With Apremilast: Results From the Corrona Psoriasis Registry. EADV 2018. 12-16 September, 2018. Paris, France. E-poster

Wu JJ, Singh R, Fleischer A, Litman HJ, McLean RR, Emeanuru K, Kang H, Valdecantos WC. Clinical Characteristics of Psoriasis (PsO) Patients across Disease Severity Groups. EADV 2018. 12-16 September, 2018. Paris, France. E-poster

Maui Derm NP – PA 2018

Voorhees AS, Karki C, Mason MA, Harrold LR, Guo N, Guana A, Tian H, Herrera V, Strober BE. Characterization of Non-Responders to TNFis in Patients With Moderate-to-Severe Psoriasis in Routine Clinical Practices in the United States. Maui Derm NP – PA 2018. 20-23 June, 2018. Colorado Springs, Colorado. Poster

Voorhees AS, Karki C, Mason MA, Harrold LR, Guo N, Guana A, Tian H, Herrera V, Strober BE. Patient Profile of Non-Responders to Ustekinumab in Patients With Moderate-to-Severe Psoriasis Enrolled in the Corrona Registry. Maui Derm NP – PA 2018. 20-23  June, 2018. Colorado Springs, Colorado. Poster

EULAR 2018

Curtis JR, Flake DD, Weinblatt M, Shadick NA,  Østergaard M, Hetland ML, Brahe CH, Hwang YG, Furst DE, Strand V, Etzel CJ, Pappas DA, Xingbin Wang X, Hwang CC, Sasso EH. Gutin A, Hitraya E, Lanchbury JS. Development of an Adjusted Multi-Biomarker Disease Activity (MBDA) Score for Rheumatoid Arthritis (RA) That Accounts for Age, Sex and Adiposity, with Subsequent Evaluation of Ability to Predict Risk for Radiographic Damage. Ann Rheum Dis2018;77(Suppl2):A1304. Publication

Danila MI, Chen L, O’Beirne R, Ruderman EM, Harrold LR, Melnick JA, Safford MM, Kremer JM, Curtis JR. Patient and Physician Reported Barriers to Achieving Rheumatoid Arthritis (RA) Disease Control. Ann Rheum Dis2018;77(Suppl):A281. Poster

Harrold LR, Litman HJ, Connolly SE, Alemao E, Kelly S, Rebello S, Blachley T, Kremer JM. Patient and Disease Characteristics That Predict Switching From a TNF Inhibitor or Another Biologic or Targeted Synthetic DMARD in Patients with RA in Clinical Practice. Ann Rheum Dis2018;77(Suppl): A911. Poster

Harold LR, GuoL, Connolly SE, Alemao E, Rebello S, Shan Y, Kremer JM.  Association between anti-citrullinated protein antibody status, erosive disease and healthcare resource utilisation in patients with ra. Ann Rheum Dis2018;77(Suppl): A1311 .Publication

Ljung L, Ueda P, Liao KP, Greenberg JD, , Etzel CJ, Solomon D, Askling J. Performance of the ERS-RA Cardiovascular Risk Prediction Tool: External Validation in a Large Swedish Cohort with RA. Ann Rheum Dis2018;77(Suppl): A292 .Poster

Mease PJ, Harrison RW, Accortt NA, Rebello S, Etzel CJ, Collier DH, Aras GA, Gharaibeh MMF, Greenberg JD. Persistence of Monotherapy or Combination Therapy With Disease-modifying Agents in Patients with Psoriatic Arthritis in a Real-world Setting. Ann Rheum Dis2018;77(Suppl):A612 .Poster

Mease PJ, Kremer JM, Cohen S, Curtis JR, Charles-Schoeman C, Loftus Jr EV, Greenberg JD, Palmetto N, Kanik KS, Graham D, Wang C, Biswas P, Chan G, DeMasi R, Valdez H, Hendrikx T, Jones TV. Incidence of Thromboemolic Events in the Tofacitinib Rheumatoid Arthritis, Psoriasis, and Ulcerative Colitis Development Programmes. Ann Rheum Dis2018;77(Suppl):A983.Poster

Mease PJ, Litman HJ, Accortt NA, Rebello S, Greenberg JD, Feng H, Gharaibeh MM, Aras GA, Collier DH. Disease Activity and Patient Characteristics by Comorbidity Among Psoriatic Arthritis Patients in the United States. Ann Rheum Dis2018;77(Suppl):A380.Poster

Mease PJ, Liu M, Gershenson B, Hur P, Greenberg JD. Discontinuation and Switching Patterns of Tumor Necrosis Factor Inhibitor (TNFi) Therapy in TNFi-Naive and TNFi-Experienced Patients with Psoriatic Arthritis in the US Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry. Ann Rheum Dis2018;77(Suppl): A382 .Poster

Mease PJ, Rosenstein E, Feng H, Liu M, Guerette B, Teng L, Rebello S, Ogdie-Beatty AR. Baseline Characteristics of Patients with Psoriatic Arthritis Initiated on Apremilast in the Corrona Psoriatic Arthritis/Spondyloarthritis (PSA/SPA) Registry. Ann Rheum Dis2018;77(Suppl): A1039.Poster

Pappas DA, Etzel CJ, Crabtree M, Best J, Zlotnick S, Kremer JM. Impact of Comorbidity Burden and Obesity on the Effectiveness of Tocilizumab in Patients with Rheumatoid Arthritis. Ann Rheum Dis2018;**(Suppl*): *** .Poster

Pappas DA, Litman HJ, Lesperance T, Rebello S, Karis E, Kricorian G, Hua D, Accortt NA. Persistence on Tumor Necrosis Factor Inhibitor (TNFi) Monotherapy Among Patients with Rheumatoid Arthritis (RA) in Remission or Low Disease Activity (LDA). Ann Rheum Dis2018;77(Suppl): A600 .Poster

Pappas DA, Saunders KC, Etzel CJ, Hua DW, Deering K, Zueger P, Garg V. Evaluation of the Use of Ultrasound to Manage Patients With Rheumatoid Arthritis Over Time: Results From the Corrona Registry. Ann Rheum Dis2018;77(Suppl): A906 .Poster

AAD 2018

Bonomo L, Abittan B, Hashim P, Karki C, Mason MA, Lebwohl M. Combination use of systemic therapies in psoriasis: baseline characteristics from the Corrona Registry. American Academy of Dermatology. 16-20, February 2018. San Diego, CA. e-poster

Callis-Duffin K, Herrera V, Mason MA, Gordon K, Harrison R, Guana A, Gilloteau I, Karki C, Lebwohl M. Impact of palmoplantar psoriasis on clinical and patient reported outcomes: Results from the Corrona Psoriasis Registry. American Academy of Dermatology. 16-20, February 2018. San Diego, CA. e-poster

Callis-Duffin K, Karki C, Mason MA, Gordon K, Harrison R, Guana A, Gilloteau I, Herrera V, Lebwohl M. Describing the clinical and patient reported outcomes of patients with scalp psoriasis enrolled in the Corrona Psoriasis Registry. American Academy of Dermatology. 16-20, February 2018. San Diego, CA. e-poster

Callis-Duffin K, Karki C, Mason MA, Gordon K, Harrison R, Guana A, Gilloteau I, Herrera V, Lebwohl M. The burden of nail psoriasis: a real world analysis from the Corrona Psoriasis Registry. American Academy of Dermatology. 16-20, February 2018. San Diego, CA. e-poster

Grace E, Karki C, Mason MA, Guo N, Hardin D. Prevalence of Inflammatory Bowel Disease Among Patients Enrolled in the Corrona Psoriasis Registry. American Academy of Dermatology. 16-20, February 2018. San Diego, CA. e-poster

Merola JF, Van Voorhees A, Bagel J, Evans CC, Lockshin B, Mason MA, Guo N, Karki C, Greenberg JD, Siegel M. Psoriasis Patients Achieving NPF Treat-To-Target Goals and Associated Quality of Life Improvement in the Corrona Psoriasis Registry Cohort. American Academy of Dermatology. 16-20, February 2018. San Diego, CA. e-poster

Van Voorhees A, Karki C, Mason MA, Harrold LR, Guo N, Guana A, Tian H, Herrera V, Strober BE. Characterization of non-responders to Anti-TNFs in moderate to severe psoriasis patients in routine clinical practices in the US. American Academy of Dermatology. 16-20, February 2018. San Diego, CA. e-poster

Van Voorhees A, Karki C, Mason MA, Harrold LR, Guo N, Guana A, Tian H, Herrera V, Strober BE. Patient profile of non-responders to ustekinumab in moderate to severe psoriasis patients enrolled in the Corrona registry. American Academy of Dermatology. 16-20, February 2018. San Diego, CA. e-poster

Wu J, Karki C, Mason MA, Guo N, Zhu B, Amato DA, Malatestinic WN, Burge RT, Greenberg JD, Al Sawah S . Demographics and disease burden of patients on IL-17A inhibitors as compared to other biologics: Data from the Corrona Psoriasis Registry. American Academy of Dermatology. 16-20, February 2018. San Diego, CA. e-poster

Wu J, Karki C, Mason MA, Guo N, Zhu B, Goldblum OM, Malatestinic WN, Burge RT, Greenberg JD, Al Sawah S. Ixekizumab patient demographics and self-reported burden in routine clinical practice: Findings from the Corrona Psoriasis Registry. American Academy of Dermatology. 16-20, February 2018. San Diego, CA. e-poster

Wu J, Karki C, Mason MA, Guo N, Zhu B, Goldblum OM, Malatestinic WN, Burge RT, Greenberg JD, Al Sawah S.  Ixekizumab patient clinical characteristics and treatment history in routine clinical practice: Findings from the Corrona Psoriasis Registry. American Academy of Dermatology. 16-20, February 2018. San Diego, CA. e-poster

Wu J, Singh R, Fleischer AB, Etzel CJ, Ganguli A, Schrader A, Colavita J, Valdecantos W. Correlation Between Improvements in Body Surface Area and Patient Reported Outcomes in Psoriasis. American Academy of Dermatology. 16-20, February 2018. San Diego, CA. e-poster

AMCP 2018

Mease PJ, Karki C, Liu M, Li Y, Hur P, Palmer JB, Greenberg JD. Discontinuation and Switching Patterns by Tumor Necrosis Factor Inhibitor Line of Therapy in Patients with Psoriatic Arthritis—Results From the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry. AMCP 2018. 23-26, April 2018. Boston, MA.

Mease PJ, van der Heijde D, Karki C, Liu M, Park Y, Greenberg JD. Discontinuation of Tumor Necrosis Factor Inhibitor Therapy in US Patients With Ankylosing Spondylitis: Data From the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry. AMCP 2018. 23-26, April 2018. Boston, MA.

ACR 2017

Bhatt BD, Palmer JL, Curtis JR, Velkuru S, Kremer JM. Changes in Blood Pressure with TNF Inhibitors for Psoriatic Arthritis. Arthritis Rheumatol. 2017; 69 (suppl 10). Poster

Curtis JR, Flake DD, Weinblatt M, Shadick NA, Ostergaard M, Lund Hetland M, Heegaard Brahe C, Hwang YG, Furst DE, Strand V, Etzel CJ, Pappas DA, Wang X, Hwang CC, Sasso EH, Gutin A, Hitraya E, Lanchbury JS. Development of an Adjusted Multi-Biomarker Disease Activity (MBDA) Score for Rheumatoid Arthritis (RA) That Accounts for Age, Sex and Adiposity, with Subsequent Evaluation of Ability to Predict Risk for Radiographic Damage. Arthritis Rheumatol. 2017; 69 (suppl 10). Poster

Curtis JR, Wallenstein G, Takiya L, Gruben D, Chen C, Shan Y, Blachley T, Dandreo KJ, Kremer JM. Patterns of Methotrexate Use and Discontinuation in a U.S. Rheumatoid Arthritis Registry. Arthritis Rheumatol. 2017; 69 (suppl 10). Podium

Curtis JR, Yun H, Etzel CJ, Yang S,  Chen L. Use of Machine Learning and Traditional Statistical Methods to Classify RA-Related Disability Using Administrative Claims Data. Arthritis Rheumatol. 2017; 69 (suppl 10). Poster

Danila MI, Ruderman E, Harrold LR, Melnick JA, O’Beirne R, Safford MM, Kremer JM, Curtis JR. Patient-Reported Barriers to Achieving Rheumatoid Arthritis  Disease Control. Arthritis Rheumatol. 2017; 69 (suppl 10). Poster

Farutin V, Prod’homme T, McConnell K, Halvey P, Washburn N, Cilfone N, Kyriakis S, Hillson J, Etzel CJ, Saunders KC, Pappas DA, Manning A, Ling L, Capila I. Molecular Profiling of RA Patients Suggests a Differential Involvement of Adaptive and Innate Cell Populations in Response to Anti-TNF Treatment. Arthritis Rheumatol. 2017; 69 (suppl 10). Poster

Ford K, Chernoff D, Wang X, Sasso EH, Etzel CJ, Pappas DA. Effect of Age and Body Mass Index (BMI) on Mulit-Biomarker Disease Activity MBDA Score in Patients with Rheumatoid Arthritis. Arthritis Rheumatol. 2017; 69 (suppl 10). Podium

Harrold LR, Litman HJ, Connolly SE, Alemao E, Price K, Kelly S, Rebello S, Hua D, Kremer JM. Comparative Effectiveness of Abatacept Versus TNFi in Patients with RA Who Are CCP+ in the United States Corrona Registry. Arthritis Rheumatol. 2017; 69 (suppl 10). Poster

Harrold LR, Litman HJ, Connolly SE, Alemao E, Rebello S, Hua W, Kremer JM. Association Between Anti-citrullinated Protein Antibody Status and the Incidence of Erosive Disease in Patients With RA. Arthritis Rheumatol. 2017; 69 (suppl 10). Poster

Harrold LR, Price K, Litman HJ, Connolly SE, Alemao E,  Rebello S, Hua D, Kremer JM. The Impact of Anti-Cyclic Citrullinated Peptide Seropositivity on Erosion Prevalence Among Patients with RA of Varying Disease Duration. Arthritis Rheumatol. 2017; 69 (suppl 10). Poster

Harrold LR, Reed GW, Best J, Zlotnick S, Persuitte G, Kremer JM. Comparative Effectiveness of Tocilizumab (TCZ) Monotherapy with Tumor Necrosis Factor Inhibitors (TNFi) in Combination with Varying Doses of Methotrexate (MTX) in Patients with Rheumatoid Arthritis. Arthritis Rheumatol. 2017; 69 (suppl 10). Poster

Lee YC, Kremer JM, Guan H, Greenberg JD, Solomon DH. Trends and Predictors of Chronic Opioid Use in Individuals with RA. Arthritis Rheumatol. 2017; 69 (suppl 10). Podium

Mease PJ, Accortt NA, Liu M, Rebello S, Gharaibeh M, Collier DH. Treatment Patterns in Rheumatoid Arthritis Patients Newly Initiated on Biologic and Non-Biologic Therapy Enrolled in a North American Clinical Registry. Arthritis Rheumatol. 2017; 69 (suppl 10). Poster

Mease PJ, Etzel CJ, Lisse J, Armstrong A, Huster W, Rebello S, Dodge R, Muram T, Al Sawah S, Murage M, Greenberg JD, Malatestinic W. The Relationship Between the Degree of Skin Involvement and Joint Activity in Patients with PsA: Experience from the Corrona Registry. Arthritis Rheumatol. 2017; 69 (suppl 10). Poster

Mease PJ, Etzel CJ, Lisse J, Armstrong A, Huster W, Rebello S, Dodge R, Muram T, Al Sawah S, Murage M, Greenberg JD, Malatestinic W. Treatment Changes by Joint Activity and Skin Severity in Patients with Comorbid PsA and PsO. Arthritis Rheumatol. 2017; 69 (suppl 10). Poster

Mease PJ, Etzel CJ, Lisse J, Armstrong A, Huster W, Rebello S, Dodge R, Muram T, Al Sawah S, Murage M, Greenberg JD, Malatestinic W. Current PsA Therapy Impacts the Relationship Between the Degree of Skin Involvement and Joint Activity. Arthritis Rheumatol. 2017; 69 (suppl 10). Poster

Mease PJ, Karki C, Liu M, Li Y, Hur P,  Greenberg JD. Discontinuation and Switching Patterns By TNFi Line of Therapy in Patients with Psoriatic Arthritis—Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry. Arthritis Rheumatol. 2017; 69 (suppl 10). Poster

Mease PJ, Kremer J, Cohen S, Curtis JR, Charles-Schoeman C, Loftus EV, Greenberg JD, Palmetto N, Kanik KS, Graham D, Wang C, Biswas P, Chan G, DeMasi R, Valdez H, Hendrikx T, Jones TV. Incidence of Thromboembolic Events in the Tofacitinib Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis and Ulcerative Colitis Development Programs. Arthritis Rheumatol. 2017; 69 (suppl 10). Poster

Mease PJ, Palmer JB, Lebwohl M, Karki C, Reed GW, Etzel CJ, Greenberg JD, Helliwell PS. Utilization of the Psoriasis Epidemiology Screening Tool to Identify Signs and Symptoms of Early Psoriatic Arthritis Among Those With Psoriasis: Analysis From the Corrona Psoriasis Registry. Arthritis Rheumatol. 2017; 69 (suppl 10). Poster

Mease PJ, van der Heijde, Karki C, Liu M, Park Y, Greenberg JD. Discontinuation of Tumor Necrosis Factor Inhibitor Therapy in US Patients With Ankylosing Spondylitis: Data From the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry. Arthritis Rheumatol. 2017; 69 (suppl 10). Poster

Mease PJ, van der Heijde, Karki C, Liu M, Park Y, Greenberg JD. Persistency of Tumor Necrosis Factor Inhibitor Therapy in US Patients With Ankylosing Spondylitis: Data From the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry. Arthritis Rheumatol. 2017; 69 (suppl 10). Poster

Pappas DA, Etzel CJ, Best J, Zlotnick S, Blachley T, Persuitte G, Kremer JM. Patterns of Prednisone Use in US Patients With Rheumatoid Arthritis Initiating Treatment With Tocilizumab in Routine Clinical Practice. Arthritis Rheumatol. 2017; 69 (suppl 10). Poster

Pappas DA, Karki C, Litman HJ, Blachley T, Suboticki JL, Griffith J, Kremer JM. Impact of Adalimumab on Prednisone Use in Patients with Rheumatoid Arthritis in a Real World Setting – Results from Corrona Registry. Arthritis Rheumatol. 2017; 69 (suppl 10). Poster

Pappas DA, Karki C, Shan Y, Suboticki JL, Griffith J, Kremer JM. Methotrexate Discontinuation from Combination Therapy with Adalimumab is not Associated with Inferior Outcomes at 6 Months. Arthritis Rheumatol. 2017; 69 (suppl 10). Poster

Pappas DA, Murray J, Etzel CJ, Nelson D, Gershenson B, Saunders KC, Rebello S, Kremer JM. Rheumatoid Arthritis Patient Characteristics Also Predict Response to Therapy with Biologic Agents: Results from the Corrona CERTAIN Study. Arthritis Rheumatol. 2017; 69 (suppl 10). Poster

Pappas DA, Reed GW, Karki C, Griffith J, Skup M, Garg V, Kremer J. Real-world Consistency of Response to Adalimumab Over Time in Patients With Rheumatoid Arthritis: Results From the Corrona Registry. Arthritis Rheumatol. 2017; 69 (suppl 10). Poster

Pappas DA, Reed GW, Zlotnick S, Best J, Magner R, Persuitte G, Greenberg JD. Repeated Rituximab Infusions for the Therapy of Rheumatoid Arthritis Is Not Associated With Increased Rates of Serious Infections. Arthritis Rheumatol. 2017; 69 (suppl 10). Poster

Xie F, Chen L, Yun H, Greenberg JD, Curtis JR. An Approach to Linkage of Registry Data to Medicare Claims Using Multiple Non-Unique Identifiers. Arthritis Rheumatol. 2017;69(suppl 10). Poster

Las Vegas Dermatology Seminar 2017

Callis Duffin K, Herrera V, Mason MA, Gordon K, Harrison RW, Guana A, Gilloteau I, Karki C, Mark Lebwohl M. Impact of Palmoplantar Psoriasis on Clinical and Patient Reported Outcomes: Results from the Corrona Psoriasis Registry. Las Vegas Dermatology Seminar 2017. 2-4 November, 2017. Las Vegas, NV. Poster

Callis Duffin K, Karki C, Mason MA, Gordon K, Harrison RW, Guana A, Gilloteau I, Herrera V, Lebwohl M. The Burden of Nail Psoriasis: A Real World Analysis from the Corrona Psoriasis Registry. Las Vegas Dermatology Seminar 2017. 2-4 November, 2017. Las Vegas, NV. Poster

Callis Duffin K, Karki C, Mason MA, Gordon K, Harrison RW, Guana A, Gilloteau I, Herrera V, Lebwohl M. Describing the Clinical and Patient Reported Outcomes of Patients with Scalp Psoriasis Enrolled in the Corrona Psoriasis Registry. Las Vegas Dermatology Seminar 2017. 2-4 November, 2017. Las Vegas, NV. Poster

AMCP Nexus 2017

Mease PJ, Karki C, Liu M, Kavanaugh A, Ritchlin CT, Huynh DH, Pandurengan R, Palmer JB, Greenberg JD. Trends in Clinical Characteristics Associated With Achievement of Minimal Disease Activity In Response to Biologic Therapy in Psoriatic Arthritis—Analyses From the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry. AMCP Nexus 2017. 16-19 October, 2017. Dallas, TX. Poster

Muram T, Novak A, Etzel CJ,  Armstrong AW, Malatestinic W, Huster WJ, Rebello S, Dodge R, Al Sawah S, Mease PJ.  Treating Both Skin and Joint Disease Activity in Patients with Psoriatic Arthritis and Psoriasis: Experience from the Corrona Registry. AMCP Nexus 2017. 16-19 October, 2017. Dallas, TX. Poster

EADV 2017

Strober B, Herrera V, Guana Adriana, Karki C, Mason M, Hur Peter, Greenberg JD, Lebwohl M. Secukinumab improves clinical and patient reported outcomes in psoriasis patients in a real world setting: Results from the Corrona Psoriasis Registry. 27th EADV Congress.  13-17 September 2017. Geneva, Switzerland. E-poster

EULAR 2017

Gottlieb AB, Strand V, Karki C, Mason M, Greenberg JD, Jugl S, Gandhi KK, Mease PJ. Secukinumab in Psoriatic Arthritis: High Disease Burden Observed in the Corrona Psoriasis Registry. Ann Rheum Dis2017;76(Suppl2): 1313. Publication

Harrold LR, Litman HJ, Connolly S, Alemao E, Price K, Kelly S, Rebello S, Hua D, Kremer JM. Comparative Effectiveness of Abatacept versus TNFi in Patients with Rheumatoid Arthritis Who are CCP+ in the United States Corrona Registry. Ann Rheum Dis2017;76(Suppl2): 1192. Publication

Harrold LR, Price K, Litman HJ, Connolly S, Alemao E,  Rebello S, Hua D, Kremer JM. The Impact of AntiI-cyclic Citrullinated Peptide Seropositivity on Erosion Prevalence Among Rheumatoid Arthritis Patients with Varying Disease Duration. Ann Rheum Dis2017;76(Suppl2): 1455. Publication

Harrold LR, Reed GW, Best J, Zlotnick S, Persuitte G, Kremer JM. Comparative Effectiveness of Tocilizumab (TCZ) Monotherapy with Tumor Necrosis Factor Inhibitors (TNFi) in Combination with Varying Doses of Methotrexate (MTX) in Patients With Rheumatoid Arthritis. Ann Rheum Dis2017;76(Suppl2): 1191.Publication

Mease PJ, Etzel CJ, Lisse JR, Armstrong AW, Huster WJ, Rebello S, Dodge R, Muram T,   Al Sawah-Folian S, Murage MJ, Greenberg, JD, Malatestinic W. The Relationship Between the Degree of Skin Involvement and Joint Activity in Patients with PsA:  Experience from the Corrona Registry. Ann Rheum Dis2017;76(Suppl2): 1330. Publication

Mease PJ, Karki C, Liu M, Ritchlin CT, Hunyh DH, Pandurengan R, Palmer JB, Greenberg JD. Trends in Clinical Characteristics Associated With Achievement of Minimal Disease Activity In Response to Biologic Therapy in Psoriatic Arthritis—Analyses From the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry. Ann Rheum Dis2017;76(Suppl2): 953 .Poster

Mease PJ, Palmer JB, Lebwohl M, Karki C, Reed GW, Etzel CJ, Greenberg JD, Helliwell PS. Utilization of the Psoriasis Epidemiology Screening Tool to Identify Signs and Symptoms of Early Psoriatic Arthritis Among Those With Psoriasis: Analysis From the Corrona Psoriasis Registry. Ann Rheum Dis2017;76(Suppl2): 953. Poster

Mease PJ, Singh R, Douglas K, Hua D, Litman HJ, Karki C, Griffith J. Effectiveness of Anti TNFs on Dactylitis and Enthesitis in Patients with Psoriatic Arthritis: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. Ann Rheum Dis2017;76(Suppl2): 1331. Publication

Mease PJ, van der Heijde D, Karki C, Liu M, Pandurengan R, Park Y,  Greenberg JD. Use of Biologics and NSAIDs in Treating Patients With Axial Spondyloarthritis in the US-Based Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry. Ann Rheum Dis2017;76(Suppl2): 352. Poster

Ogdie A, Palmer JL, Solomon DH, Kavanaugh A, Greenberg JD, Curtis JR, Harrold LR,  Kremer JM,  Mease PJ. MHAQ Response Among Patients with Psoriatic Arthritis Initiating a TNFi. Ann Rheum Dis2017;76(Suppl2): 1313. Publication

Pappas DA, Griffith J, Schlacher C, Shan Y, Karki C, Kremer JM. Effectiveness of Low and High Dose Methotrexate in Combination with Adalimumab in a Real World Setting: Results from the Corrona Rheumatoid Arthritis Registry. Ann Rheum Dis2017;76(Suppl2): 827. Poster

Pappas DA, Griffith J, Schlacher C, Suboticki JL, Harrison R, Shan Y, Karki C, Kremer JM. Effectiveness of Adalimumab Combination Therapy with Methotrexate and Non-Methotrexate csDMARDs: Results from the Corrona Rheumatoid Arthritis Registry. Ann Rheum Dis2017;76(Suppl2): 552. Poster

Pappas DA, Reed GW, Zlotnick S, Best J, Magner R, Persuitte G, Greenberg JD. Repeated Rituximab Infusions for the Therapy of Rheumatoid Arthritis is not Associated with Increased Rates of Serious Infections. Ann Rheum Dis2017;76(Suppl2): 846 . Poster

Pappas DA, Sasso EH, Bolce RJ, Liu X, Etzel CJ. The Multi-Biomarker Disease Activity (MBDA) Score for Assessing Response to Treatment with Adalimumab. Ann Rheum Dis2017;76(Suppl2): 1121. Publication

Reed GW, Gerber RA, Shan Y, Takiya L, Dandreo KJ, Gruben D, Kremer JM, Wallenstein G. TNFi and tofacitinib monotherapy and comparative effectiveness in clinical practice:  Results from Corrona Registry. Ann Rheum Dis2017;76(Suppl2): 60. Podium

Reed GW, Harrold LR, Pala O, Kremer JM. The Impact of Disease Activity on Patient Reported Cognitive Dysfunction (“Brain Fog”) in Rheumatoid Arthritis. Ann Rheum Dis2017;76(Suppl2): 808. Poster

ISPOR 2017

Priest J, Strand V, Litman HJ, Saunders KC, Persuitte GM, Kremer JM, Greenberg JD. Rheumatoid Arthritis and Patient Burden of Disease. International Society for Pharmacoeconomics and Outcomes Research. 20-24 May 2017. Boston, MA.

IDEOM 2017

Mease PJ, Palmer JB, Strober BE, Lebwohl M, Karki C, Reed GW, Etzel CJ, Greenberg JD, Helliwell PS.  Patients at Risk for Psoriatic Arthritis Among Those With Psoriasis: Analysis From the Corrona Psoriasis Registry. International Dermatology Outcome Measures 2017 Annual Meeting; May 5-6, 2017; Washington, DC.

JCR 2017

Yamanaka H, Kishimoto M, Joel Kremer JM, Natsumeda M, lto S, Koido N, Fukuda W, Sugimoto N, Higami K, Masato Okada M, lzumiyama T, Nakano K, Tamura N, Sagawa A, Ohta S, Tsuru T, Yamamura M, Yamanishi Y, Murakami K, Greenberg JD, Tanaka Y. Design Characteristics of the Corrona Japan-Rheumatoid Arthritis Registry. Mod Rheumatol2017;27(Suppl2017): 330.

AMCP 2017

Mease PJ, Palmer JB, Strober BE, Lebwohl M, Karki C, Reed GW, Etzel CJ, Greenberg JD, Helliwell PS. Patients at Risk for Psoriatic Arthritis Among Those With Psoriasis: Analysis From the Corrona Psoriasis Registry. AMCP 2017. 27-30 March, 2017. Denver, CO.

AAD 2017

Gottlieb A, Strober B, Armstrong AW, Greenberg JD,  Karki C , Mason M, Guo N,  Gilloteau I, Guana A, Lebwohl M. Secukinumab in Psoriasis Patients with Concurrent Psoriatic Arthritis: Patient-Reported Outcomes in the Corona Psoriasis Registry. JAAD. 2017;76;6;AB228.

Gottlieb A, Strober B, Armstrong AW, Greenberg JD,  Karki C , Mason M, Guo N, Gilloteau I, Guana A, Lebwohl M. Secukinumab in Psoriasis Patients with Concurrent Psoriatic Arthritis: Demographics and Disease Characteristics in the Corrona Psoriasis Registry. JAAD. 2017;76;6; AB227.

Harrold LR, Stolshek BS, Rebello S, Collier DH, Mutebi A, Wade SW, Malley W, Greenberg JD, Etzel CE. Time to Rebound in Joint Symptoms Following Discontinuation of TNFi Therapy After Achieving Low Disease Activity in Psoriatic Arthritis Patients Enrolled in the US Corrona Registry. JAAD. 2017;76;6; AB260.

Mease PJ,  Palmer JB,  Strober BE, Lebwohl M, Karki C, Reed GW,  Etzel CJ, Greenberg JD, Helliwell PS. Patients at Risk for Psoriatic Arthritis Among Those With Psoriasis: Analysis From the Corrona Psoriasis Registry. JAAD. 2017;76;6;AB191.

Mease PJ,  Palmer JB, Litman HJ, Karki C,  Greenberg JD. Impact of Nail Psoriasis on Clinical Presentation of Psoriatic Arthritis—Descriptive Analysis From the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry. JAAD. 2017;76;6;AB405.

Strober B, Armstrong AW,  Greenberg JD, Karki C, Mason M, Guo N, Herrera V, Gilloteau I, Guana A, Lebwohl M. Secukinumab Patient Demographics and Disease Characteristics in the Corrona Psoriasis Registry. JAAD. 2017;76;6;AB228.

Strober B, Armstrong AW,  Greenberg JD, Karki C, Mason M, Guo N, Herrera V, Gilloteau I, Guana A, Lebwohl M. Secukinumab Patient-Reported Outcomes in the Corrona Psoriasis Registry. JAAD. 2017;76;6; AB229.

Strober B, Greenberg JD, Karki C, Mason M, Guo N, Hur P, Zhao Y, Herrera V, Lin F, Lebwohl M. Impact of Psoriasis Severity on Patient-Reported Clinical Symptoms, Health-Related Quality of Life, and Work Productivity among US Patients: Real-World Data from the Corrona Psoriasis Registry. JAAD. 2017;76;6;AB406.

Strober B, Herrera V,  Hur P,  Karki C, Mason MA,  Siu K, Greenberg JD, Lebwohl M. Disease characteristics and patient reported outcomes in psoriasis patients treated with secukinumab in a real world setting: Results from the Corrona Psoriasis Registry. JAAD. 2017;76;6;AB102.

Strober B, Karki C, Mason M, Greenberg JD, Lebwohl M. Association between disease severity and body mass index in psoriasis patients enrolled in the Corrona Psoriasis Registry. JAAD. 2017;76;6;AB51.

Strober B, Karki C, Mason M, Greenberg JD, Lebwohl M. Impact of Psoriasis Area Severity Index (PASI) on patient reported outcomes in patients with psoriasis: Results from the Corrona Psoriasis Registry. JAAD. 2017;76;6;AB406.

Strober B, Karki C, Mason M, Guo N, Greenberg JD, Lebwohl M. Comorbidity burden and characterization of psoriasis patients with concurrent psoriatic arthritis in the Corrona Psoriasis Registry. JAAD. 2017;76;6;AB77.

Strober B, Karki C, Mason M, Guo N, Greenberg JD, Lebwohl M. Characterization of disease burden, comorbidities and therapy use of patients with psoriasis at enrollment: Results from the Corrona Psoriasis Registry. JAAD. 2017;76;6;AB67.

RWCS 2017 

Mease PJ, Karki C, Liu M, Kavanaugh A, Pandurengan R,  Ritchlin CT,  Palmer JB, Greenberg JD. Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis—Descriptive Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry. Rheumatology Winter Clinical Symposium. 15-18 February, 2017. Maui, HI.

Mease PJ, Karki C, Liu M, Kavanaugh A, Ritchlin CT, Huynh DH, Pandurengan R, Palmer JB, Greenberg JD. Baseline Patient Characteristics Associated With Response to Biologic Therapy in Patients With Psoriatic Arthritis Enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry. Rheumatology Winter Clinical Symposium. 15-18 February, 2017. Maui, HI.

Mease PJ, Palmer JB, Litman HJ, Karki C, Greenberg JD.  Impact of Nail Psoriasis on Clinical Presentation of Psoriatic Arthritis—Descriptive Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry. Rheumatology Winter Clinical Symposium. 15-18 February, 2017. Maui, HI.

Mease PJ, van der Heijde D, Karki C, Liu M, Pandurengan R, Park Y, Greenberg JD . Discontinuation of Biologic Therapy in Patients With Ankylosing Spondylitis—Data From the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry. Rheumatology Winter Clinical Symposium. 15-18 February, 2017. Maui, HI.

ACR 2016

Alemao E, Harrold L, Litman H, Connolly S, Kelly S, Hua W, Rosenblatt L, Rebello S, Kremer J. Work Status in Patients with Rheumatoid Arthritis Who Have Poor Prognostic Factors: Findings from a US Observational Cohort [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10).

Boytsov N, Reed GW, Harrold LR, Zhang X, Gaich CL, Larmore CJ, Shan Y, Rebello S, Araujo AB. Biologic Initiation Patterns Among Rheumatoid Arthritis Patients in Moderate or High Disease Activity While Using Conventional Disease Modifying Anti-Rheumatic Drugs. Arthritis Rheumatol. 2016; 68 (suppl 10).

Cappelli L, Palmer JL, Bingham C III. Clinical Responses to Tocilizumab Analyzed By Serologic Status in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10).

Curtis J, Harrold L, Kremer J, Palmer JL. Higher Multi Biomarker Disease Activity Scores Foreshadow Greater Longitudinal Improvement in RA Disease Activity [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10).

Etzel C, Stolshek BS, Rebello S, Collier D, Mutebi A, Wade SW, Malley W, Greenberg J, Harrold LR. Predictors of Persistency with TNFi in Biologic-Experienced Versus Biologic-Naive Psa Patients Enrolled in the Corrona Registry [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10).

Harrold L, Alemao E, Litman H, Connolly S, Kelly S, Hua W, Rosenblatt L, Rebello S, Kremer J. Impact of Poor Prognostic Factors on Treatment Decisions in Clinical Practice in Patients with Rheumatoid Arthritis: Findings from a US Observational Cohort [abstract]. Arthritis Rheumatol.2016; 68 (suppl 10).

Harrold LR, John A, Best J, Zlotnick S, Karki C, Li Y, Greenberg JD, Kremer J. Impact of Rituximab on Patient-Reported Outcomes in Patients with Rheumatoid Arthritis from the US Corrona Registry [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10).

Harrold LR, Litman HJ, Saunders KC, Dandreo KJ, Gershenson B, Greenberg JD, Low R, Stark J, Suruki R, Jaganathan S, Yassine M. The Real World Comparative Safety of Certolizumab Pegol (CZP) As Compared to Other TNFi in a National US Cohort [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10).

Harrold LR, Reed GW, Best J, Zlotnick S, Persuitte G, Kremer JM. Comparative Effectiveness of Tocilizumab Monotherapy with Tumor Necrosis Factor Inhibitors in Combination with Methotrexate in Patients with Rheumatoid Arthritis and Prior Exposure to Tumor Necrosis Factor Inhibitors [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10).

John A, Prehn AW, Tawfik H, Reed GW, Kremer J. Incidence and Factors Associated with the Development of Non Alcoholic Fatty Liver Disease(NAFLD) Among Patients with Rheumatoid Arthritis [abstract].Arthritis Rheumatol. 2016; 68 (suppl 10).

John A, Prehn AW, Tawfik H, Reed GW, Kremer J. Incidence of Non Alcoholic Fatty Liver Disease By Key Risk Factors Among Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10).

Kavanaugh AF, Geier J, Bingham C III, Chen C, Reed GW, Saunders KC, Chen Y, Koenig A, Cappelli L, Greenberg JD, Kremer JM. Real World Results from a Post-Approval Safety Surveillance of Tofacitinib (Xeljanz): Over 3 Year Results from an Ongoing US-Based Rheumatoid Arthritis Registry [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10).

Liao K, Etzel CJ, Greenberg JD, Guan H, Kremer J, Solomon DH. Modifiable Rheumatoid Arthritis Factors and Impact on Cardiovascular Risk [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10).

Mease PJ, Karki C, Liu M, Kavanaugh A, Pandurengan R, Ritchlin CT, Palmer JB, Greenberg JD. Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis—Descriptive Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10).

Mease PJ, Karki C, Liu M, Kavanaugh A, Ritchlin CT, Huynh DH, Pandurengan R, Palmer JB, Greenberg JD. Baseline Patient Characteristics Associated with Response to Biologic Therapy in Patients with Psoriatic Arthritis Enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry [abstract]. Arthritis Rheumatol. 2016; 68 (suppl

10).

Mease PJ, Palmer JB, Litman HJ, Karki C, Greenberg JD. Impact of Nail Psoriasis on Clinical Presentation of Psoriatic Arthritis—Descriptive Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10).

Mease PJ, van der Heijde D, Karki C, Liu M, Pandurengan R, Park Y, Greenberg JD. Discontinuation of Biologic Therapy in Patients with Ankylosing Spondylitis—Data from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10).

Ogdie A, Palmer JL, Greenberg JD, Harrold LR, Solomon DH, Kavanaugh A, Kremer J, Mease PJ, Curtis JR. Predictors of Achieving Remission Among Patients with Psoriatic Arthritis Prescribed TNF Inhibitors [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10).

Pappas DA, Griffith J, Litman HJ, Schlacher CA, Salim BA, Karki C, Kremer JM. Time to Initiation of Biologic Agents Is Associated with Glucocorticoid Use: Results from the Corrona Registry [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10).

Pappas DA, Rebello S, Liu M, Schenfeld J, Li Y, Collier DH, Accortt N. Therapy with Biologic Agents after Diagnosis of Solid Malignancies; Results from the Corrona Registry [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10).

Parenti D, Reed GW, Shan Y, Dandreo K, Kremer JM, DeHoratius RJ. Disease Activity Trends after Dose Escalation of Infliximab (Remicade) – Results from United States Consortium of Rheumatology Researchers of North America Registry [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10).

AMCP Nexus 2016

Ellis L, Reed GW, Shan Y, Parenti D, Kafka S. Patient Characteristics and Real World Utilization of Intravenous Golimumab in a Population of Rheumatoid Arthritis Patients Observed in the Corrona Registry. J Manag Care Spec Pharm. 2016;22; (suppl 10-a).

Mease PJ, Palmer JB, Litman HJ, Karki C, Greenberg JD. Impact of Nail Psoriasis on Patient-Reported Outcomes in Patients with Psoriatic Arthritis—Descriptive Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry. J Manag Care Spec Pharm. 2016;22; (suppl 10-a).

Mease PJ, Palmer JB, Liu M, Pandurengan R, Herrera V, Karki C, Greenberg JD. Are Patients With Ankylosing Spondylitis Really Different With Non-Radiographic Axial SpA? Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry. J Manag Care Spec Pharm. 2016;22; (suppl 10-a).

Mease PJ, Palmer JB, Liu M, Kavanaugh A, Pandurengan R, Ritchlin CT, Karki C, Greenberg JD. Patient-Reported Outcomes in Psoriatic Arthritis with Axial Involvement. J Manag Care Spec Pharm. 2016;22; (suppl 10-a).

Mease PJ, van der Heijde D, Karki C, Liu M, Pandurengan R, Park Y, Greenberg JD. Reasons for Biologic Therapy Discontinuation in Patients With Ankylosing Spondylitis: Analysis of the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry. J Manag Care Spec Pharm. 2016;22; (suppl 10-a).

Mease PJ, van der Heijde D, Karki C, Liu M, Pandurengan R, Park Y, Greenberg JD. Response to Biologic Therapy in Patients With Ankylosing Spondylitis: Analysis of Patient-Reported Outcomes From the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry.  J Manag Care Spec Pharm. 2016;22; (suppl 10-a).

EADV 2016

Strober B, Karki C, Mason M, Guo N, Greenberg JD, Lebwohl M.  Disease burden, comorbidities and treatment history of patients with psoriasis enrolled in a large prospective national registry (Corrona).  25th EADV Congress.  28 September – 2 October, 2016.  Vienna, Austria.

Strober B, Karki C, Mason M, Guo N, Greenberg JD, Lebwohl M.  Psoriasis patients with concurrent psoriatic arthritis: Characterization and Comorbidities at enrollment in Corrona Psoriasis Registry.  25th EADV Congress.  28 September – 2 October, 2016.  Vienna, Austria.

Strober B, Armstrong AW,  Greenberg JD, Karki C, Mason M, Guo N, Herrera V, Gilloteau I, Guana A, Lebwohl M.  Secukinumab Patient-Reported Outcomes in the Corrona Psoriasis Registry.  25th EADV Congress.  28 September – 2 October, 2016.  Vienna, Austria.

Strober B, Armstrong AW,  Greenberg JD, Karki C, Mason M, Guo N, Herrera V, Gilloteau I, Guana A, Lebwohl M.  Secukinumab Patient Demographics and Disease Characteristics in the Corrona Psoriasis Registry.  25th EADV Congress.  28 September – 2 October, 2016.  Vienna, Austria.

ISPE: ICPE 2016

Philips S, Araujo A, Proctor C, Malatestinic W, Larmore C, Harrold LR, Reed GW, Casso D, Johnson K, Stamer J, Oliveria SA. Dynamic Real World Data Platform Integrating Automatred Claims and Registry Data for Pharmacoepidemiologic Studies. (2016), Abstract. Pharmacoepidemiol Drug Saf, 25: 3–679. doi:10.1002/pds.4070.

EULAR 2016

Cohen S, Reed GW, Magner R, Parenti D, Kafka S, Ellis L, DeHoratius RJ, Greenberg JD. Achievement of Low Disease Activity in Patients Initiating Infliximab With and Without Dose Escalation. Ann Rheum Dis2016;75(Suppl2): 238.

Curtis JR, Liu M, Rebello S, Trivedi M, Lesperance T, Li Y, Accortt N.  Impact of Sustained Remission on Risk for Infection in Patients with Rheumatoid Arthritis Enrolled in a US Registry.  Ann Rheum Dis2016;75(Suppl2): 156.

Curtis JR, Shan Y, Saunders KC, Parenti D, Kafka S, Kremer JM.  An Examination of Dose Escalation Among Infliximab Users in the US Corrona RA Registry.  Ann Rheum Dis2016;75(Suppl2): 1009.

Etzel CJ, Stolshek B, Rebello S, Collier D, Mutebi A, Wade SW, Malley W, Greenberg JD, Harrold LR. Persistency with TNFi in biologic experienced versus biologic native PsA patients enrolled in Corrona Registry.  Ann Rheum Dis2016;75(Suppl2): 346.

Harrold LR, Stolshek B, Rebello S, Collier D, Mutebi A, Wade SW, Malley W, Greenberg JD, Etzel CJ.  Time to Rebound in Joint Symptoms Following Discontinuation of TNFi Therapy After Achieving Low Disease Activity or Remission in Psoriatic Arthritis Patients Enrolled in the US Corrona Registry.  Ann Rheum Dis2016;75(Suppl2): 342.

Harrold LR, Litman HJ, Connolly SE, Kelly S, Hua DW, Alemao E, Rosenblatt L, Rebello S, Kremer JM.  Impact of anti-cyclic citrullinated peptide and rheumatoid factor status on response to abatacept therapy: findings from a US observational cohort.  Ann Rheum Dis2016;75(Suppl2): 123.

Harrold LR, Litman HJ, Connolly SE, Kelly S, Hua DW, Alemao E, Rosenblatt L, Rebello S, Kremer JM. Is disease duration an independent predictor of low disease activity/remission among biologic-naive patients with rheumatoid arthritis treated with abatacept? Ann Rheum Dis2016;75(Suppl2): 970.

Harrold LR, John A, Karki C, Li Y, Greenberg JD, Kremer JM.  Impact of Rituximab on Patient-Reported Outcomes in Patients With RA From the US Corrona Registry.  Ann Rheum Dis2016;75(Suppl2): 1025.

Harrold LR, Litman HJ, Connolly SE, Kelly S, Hua DW, Alemao E, Rosenblatt L, Rebello S, Kremer JM. Relationship between anti-citrullinated protein antibody status and response to abatacept or anti-tumour necrosis factor therapy in patients with rheumatoid arthritis: a US national observational study. Ann Rheum Dis2016;75(Suppl2): 505.

Harrold LR, Palmer JL, Pappas DA, Kremer JM, Greenberg JD. Trends in the achievement of low disease activity among a US National sample of RA pts initiating biologics. Ann Rheum Dis2016;75(Suppl2): 199.

Harrold LR, Reed GW, John A, Barr CJ, Saunders KC, Soe K, Magner R, Greenberg JD, Kremer JM.  The Relationship Between Adherence to a Treat-to-Target Approach for Clinical Care of US Patients with Rheumatoid Arthritis and Achievement of Low Disease Activity.  Ann Rheum Dis2016;75(Suppl2): 199.

Kavanaugh A, Karki C, Griffith J, Etzel CJ, Kremer JM, Greenberg JD, Ganguli A.  Disease activity and biologic use in patients with rheumatoid arthritis and psoriatic arthritis in the past 10 years: Results from the Corrona registry. Ann Rheum Dis2016;75(Suppl2): 410.

Mease PJ, Skup M, Karki C, Etzel CJ, Malley W, Greenberg JD, Joshi A. Characterization of psoriatic arthritis patients by skin and joint severity: Results from the Corrona Spondyloarthritis Registry.  Ann Rheum Dis2016;75(Suppl2): 1158.

Mease PJ, Karki C, Liu M, Kavanaugh A, Ritchlin C, Huynh Q, Pandurengan R, Herrera V, Palmer J, Greenberg JD. Biologic discontinuations among patients with Psoriatic Arthritis: Results from Corrona Psoriatic Arthritis/Spondyloarthritis Registry. Ann Rheum Dis2016;75(Suppl2): 818.

Mease P, Karki C, Palmer J, Liu M, Pandurengan R, Herrera V, Greenberg JD.  Are patients with ankylosing spondylitis really different from non-radiographic axial SpA: results from Corrona Psoriatic Arthritis/Spondyloarthritis Registry.  Ann Rheum Dis2016;75(Suppl2): 323.

Pappas DA, Karki C, Liu M, Kremer JM, Greenberg JD, Garg V. Delay in initiation of biologics among bio-eligible patients with rheumatoid arthritis in US: Evidence from the Corrona registry.  Ann Rheum Dis2016;75(Suppl2): 248.

Pappas DA, John A, Kremer JM, Reed GW, Sommers T, Greenberg JD, Curtis JR.  Comparative Effectiveness of Biologic Agents for Patients with Rheumatoid Arthritis—Primary Analysis from the US Corrona CERTAIN Study.  Ann Rheum Dis2016;75(Suppl2): 1020.

Pappas DA, Karki C, Litman HJ, Greenberg JD, Garg V,  Kremer JM.  Need to advance therapy in rheumatoid arthritis patients treated with triple nbDMARD vs biologic combination therapy: Results from the Corrona registry.  Ann Rheum Dis2016;75(Suppl2): 249

Parenti D, Reed GW, Kafka S, Ellis L, Greenberg JD, DeHoratius RJ. Comorbidities and efficacy of anti-TNF therapies: History of Depression as an indicator of lack of response.  Ann Rheum Dis2016;75(Suppl2): 227.

Reed GW, Gerber RA, Shan Y, Takiya L, Dandreo KJ, Gruben D, Kremer JM, Wallenstein G.  Comparative effectiveness of TNFi and tofacitinib monotherapy in clinical practice: Results from CORRONA Registry.  Ann Rheum Dis2016;75(Suppl2): 228.

ISPOR 2016

Harrold L, Larmore C, Boytsov N, Reed G, Mason M, Gaich CL, Zhang X, Rebello S, Araujo AB. Disease activity in biologic naïve rheumatoid arthritis patients initiating tnf inhibitors. International Society for Pharmacoeconomics and Outcomes Research. May 21-25, 2016. Washington, DC.

AMCP 2016

Mease P, Karki C, Etzel C, Kavanaugh A, Ritchlin C, Malley W, Herrera V, Palmer J, Greenberg J. Real-World Clinical Characteristics and Disease Outcomes in Psoriatic Arthritis Patients by Extent of Body Surface Area Affected by Psoriasis: Results from Corrona Registry. J Manag Care Spec Pharm. 2016;22; (suppl 4-1).

Mease P, Karki C, Etzel C, Kavanaugh A, Ritchlin C, Malley W, Herrera V, Palmer J, Greenberg J. Clinical Characteristics and Disease Activity in Psoriatic Arthritis Patients with Dactylitis or Enthesitis in a Real-World Setting: Results from Corrona Registry. J Manag Care Spec Pharm. 2016;22; (suppl 4-1).

AAD 2016

Strober B, Van Voorhees A, Gottlieb A, Armstrong A,  Koo J, Gordon K, Guana A, Oliver J, Herrera V, Hirata Holmgren S, Karki C, Greenberg JD, Lebwohl M. Research objectives and design of the Corrona Psoriasis Registry: a large prospective cohort of psoriasis patients in the United States. JAAD. 2016;74;5;AB268.

Winter Rheumatology Symposium 2016

Mease PJ,  Karki CK, Etzel CJ, Kavanaugh A, Ritchlin CT, Malley W, Herrera V, Palmer JB, Greenberg JD. Real-World Clinical Characteristics and Disease Outcomes in Psoriatic Arthritis Patients by Extent of Body Surface Area Affected by Psoriasis: Results from Corrona Registry. ACR Winter Rheumatology Symposium.  January 23-29, 2016.  Snowmass, CO.

Mease PJ,  Karki CK, Etzel CJ, Kavanaugh A, Ritchlin CT, Malley W, Herrera V, Palmer JB, Greenberg JD. Clinical Characteristics and Disease Activity in Psoriatic Arthritis Patients with Dactylitis or Enthesitis in A Real-World Setting: Results from Corrona Registry.  ACR Winter Rheumatology Symposium.  January 23-29, 2016.  Snowmass, CO.

Winter Clinical Dermatology Conference 2016

Mease PJ,  Palmer JB, Etzel CJ, Kavanaugh A, Ritchlin CT, Malley W, Herrera V, Karki C,  Greenberg JD. Patient Reported Outcomes in Psoriatic Arthritis Patients by Extent of Body Surface Area Affected by Psoriasis: Results From the Corrona Registry.  Winter Clinical Dermatology Conference.  January 15-20, 2016.  Kauai, HI.

Mease PJ,  Palmer JB, Etzel CJ, Kavanaugh A, Ritchlin CT, Malley W, Herrera V, Karki C,  Greenberg JD. Patient Reported Outcomes in Psoriatic Arthritis Patients with Dactylitis or Enthesitis: Results From the Corrona Registry.  Winter Clinical Dermatology Conference.  January 15-20, 2016.  Kauai, HI.

ACR 2015

Curtis JR, Chen L, Kilgore M, Yun H, Greenberg JD. Clinical and Economic Costs of Not Achieving Remission in Rheumatoid Arthritis. Arthritis Rheumatol. 2015; 67 (suppl 10).

Curtis JR, Greenberg JD, Harrold L, Palmer JL. Impact of Comorbidities on the Multi-Biomarker Disease Activity Test in Rheumatoid Arthritis Patients. Arthritis Rheumatol. 2015; 67 (suppl 10).

Curtis JR, Shan Y, Kremer JM, Saunders K, Parenti D, Kafka S. An Examination of Dose Escalation Among Remicade (infliximab) Users in a US RA Registry. Arthritis Rheumatol. 2015; 67 (suppl 10).

Harrold L, Gandhi K, Litman H, Kelly S, Li Y, Alemao E, Deveikis S, Greenberg J. Impact of Anti-Citrullinated Protein Antibody Status and Response to Abatacept. Arthritis Rheumatol. 2015; 67 (suppl 10).

Harrold L, Gandhi K, Litman H, Kelly S, Li Y, Alemao E, Deveikis S, Kremer J. Is Disease Duration an Independent Predictor of Treatment Response Among Patients with Rheumatoid Arthritis Initiating Abatacept?  Arthritis Rheumatol. 2015; 67 (suppl 10).

Harrold L, John A, Reed GW, Karki C, Li Y, Kremer J, Haselkorn T, Greenberg JD. Impact of Tocilizumab Monotherapy in Patients with Moderate to High Disease Activity: Real-World Analyses from the US Corrona Registry. Arthritis Rheumatol. 2015; 67 (suppl 10).

Harrold L, John A, Reed GW, Karki C, Li Y, Kremer JM, Haselkorn T, Greenberg JD. Impact of Tocilizumab Monotherapy on Patient-Reported Quality of Life Outcomes in the US Corrona Registry. Arthritis Rheumatol. 2015; 67 (suppl 10).

Harrold L, John A, Reed GW, Karki C, Magner R, Kremer JM, Shewede A, Greenberg J. FactorsAssociated with Sustained Response in Patients with Rheumatoid Arthritis Who Received Rituximab within the US Corrona Registry. Arthritis Rheumatol. 2015; 67 (suppl 10).

Harrold L, Palmer JL, Curtis JR, Greenberg JD, Kremer JM. Trends over Time in Achievement of Low Disease Activity Among Biologic Initiators with Rheumatoid Arthritis. Arthritis Rheumatol. 2015; 67 (suppl 10).

Harrold L, Reed GW, Boytsov N, Gaich CL, Mason M, Zhang X, Larmore CJ, Deveikis S, Araujo AB. TNFi Combination Therapy, Switching and Persistence Patterns By Longitudinal Disease Activity Strata in Patients with Rheumatoid Arthritis. Arthritis Rheumatol. 2015; 67 (suppl 10).

Harrold L, Reed GW, Harrington JT, Barr CJ, Saunders KC, Gibofsky A, Ruderman EM, Haselkorn T, Greenberg JD, John A, Kremer JM. A Cluster-Randomized Trial of a Behavioral Intervention to Incorporate a Treat-to-Target Approach in the Clinical Care of Rheumatoid Arthritis Patients in the United States. Arthritis Rheumatol. 2015; 67 (suppl 10).

Kavanaugh A, Etzel CJ, Malley W, Karki C, Greenberg JD, Bao Y, Chen N, Garg V. Benefits of Achieving Comprehensive Disease Control (CDC) in Patients with Rheumatoid Arthritis: Evidence from the Corrona Registry. Arthritis Rheumatol. 2015; 67 (suppl 10).

Mease PJ, Karki C, Etzel CJ, Kavanaugh A, Ritchlin CT, Malley W, Herrera V, Palmer JB, Greenberg JD. Clinical Characteristics and Disease Activity in Psoriatic Arthritis Patients with Dactylitis or Enthesitis: Results from Corrona Registry. Arthritis Rheumatol. 2015; 67 (suppl 10).

Mease PJ, Karki C, Etzel CJ, Kavanaugh A, Ritchlin CT, Malley W, Herrera V, Palmer JB, Greenberg JD. Clinical Characteristics and Disease Outcomes in Psoriatic Arthritis Patients By Extent of Body Surface Area Affected By Psoriasis: Results from Corrona Registry. Arthritis Rheumatol. 2015; 67 (suppl 10).

Mease PJ, Lesperance T, Accortt N, Collier D, Liu M, Mason M, Deveikis S. Changes in Treatment Patterns in Psoriatic Arthritis Patients Newly Initiated on Biologic and Non-Biologic Therapy Enrolled in a North American Clinical Registry. Arthritis Rheumatol. 2015; 67 (suppl 10).

Pappas DA, Griffith J, Karki C, Liu M, Kremer JM, Ganguli A, Greenberg JD. The Impact of Biologic Agent Initiation after 1 Versus 2 Prior Csdmards in Patients with Rheumatoid Arthritis. Arthritis Rheumatol. 2015; 67 (suppl 10).

Pappas DA, Holt RJ, Shan Y, Kent JD, Nguyen JT, Kremer JM, Greenberg JD. The Influence of Patient Reported Morning Stiffness on Patient Global Assessment in Rheumatoid Arthritis Patients Not Achieving ACR/EULAR Boolean Remission in a Large US Registry. Arthritis Rheumatol. 2015; 67 (suppl 10).

Pappas DA, John A, Etzel CJ, Karki C, Li Y, Kremer JM, Haselkorn T, Greenberg JD. Persistency of Tocilizumab As Monotherapy or Combination Therapy in Patients with Rheumatoid Arthritis–Real-World Analyses from the US Corrona Registry. Arthritis Rheumatol. 2015; 67 (suppl 10).

Parenti D, Kafka S, Reed GW, Greenberg JD, DeHoratius R. Persistence Among Rheumatoid Arthritis Patients Initiating Intravenous or Subcutaneous Anti-Tumor Necrosis Factor Therapy in a Large US Registry Cohort. Arthritis Rheumatol.2015; 67 (suppl 10).

Strand V, Holt RJ, Litman HJ, Kent JD, Pashova H, Nguyen JT, Etzel CJ. Persistency of Patient Reported Morning (AM) Stiffness in a Large US Registry Cohort of Rheumatoid Arthritis (RA) Patients Initiating New DMARD Therapy. Arthritis Rheumatol. 2015; 67 (suppl 10).

AMCP 2015

Mease PJ, Palmer JB, Etzel CJ, Kavanaugh A, Ritchlin C, Malley W, Herrera V, Karki C, Greenberg JD. Patient Reported Outcomes in Psoriatic Arthritis Patients with Dactylitis or Enthesitis: Results from Corrona registry. J Manag Care Spec Pharm. 2015; 21 (suppl 10-a).

Mease PJ, Palmer JB, Etzel CJ, Kavanaugh A, Ritchlin C, Malley W, Herrera V, Karki C, Greenberg JD. Patient Reported Outcomes in Psoriatic Arthritis Patients by Extent of Body Surface Area Affected by Psoriasis: Results from Corrona registry. J Manag Care Spec Pharm. 2015; 21 (suppl 10-a).

EULAR 2015

Harrold LR, Gandhi K, Etzel CJ, Nadkarni A, Saunders KC,  Kelly S, Kremer JM. Channeling of biologic agents: comparing baseline characteristics of biologic naïve rheumatoid arthritis patients initiating abatacept, as compared to other biologic agents and small molecule agents. Ann Rheum Dis2015;74(Suppl2):1052.

Harrold LR, Gandhi K, Etzel CJ, Nadkarni A, Saunders KC,  Kelly S, Greenberg JD. The impact of rheumatoid arthritis on patient reported outcomes and quality of life prior to biologic initiation. Ann Rheum Dis2015;74(Suppl2):129.

Harrold LR, John A, Reed GW, Karki C, Magner R, JM Kremer, Shewade A, Greenberg JD. Influence of Rituximab retreatment on sustained response in patients with rheumatoid arthritis enrolled in the US Corrona registry. Ann Rheum Dis2015;74(Suppl2):1052.

Harrold LR, Reed GW, Harrington JT, Barr CJ, Saunders KC, Gibofsky A, Greenberg JD, John A, Devenport J, Kremer JM. A cluster randomized trial of a behavioral intervention to incorporate a Treat to Target approach in the clinical care of rheumatoid arthritis patients. Ann Rheum Dis2015;74(Suppl2):988.

Harrold LR, Reed GW, Solomon DH, Curtis JR, Liu M, Greenberg JD, Kremer JM. The comparative effectiveness of tocilizumab as compared to abatacept in those with prior exposure to anti-TNF agents. Ann Rheum Dis2015;74(Suppl2):138.

Kavanaugh A, Greenberg JD, Reed GW, Griffith J, Friedman A, Saunders KC, Ganguli A. Benefit of biologic initiation in moderate versus severe rheumatoid arthritis: evidence from a real-world registry. Ann Rheum Dis2015;74(Suppl2):457.

Kavanaugh A, Reed GW, Saunders KC, Koenig AS, Geier J, Kremer JM, Greenberg JD, Bingham CO. Clinical characteristics of RA patients newly prescribed tofacitinib Citrate (tofacitinib) in the United States after Food and Drug Administration approval: results from the Corrona US rheumatoid arthritis registry. Ann Rheum Dis2015;74(Suppl2):1041.

Mease PJ, Deveikis S, Etzel CJ, O’Connor J, Kremer JM, Kavanaugh A, Ruderman E, Curtis JR, Ritchlin C, van der Heijde D, Solomon DH, Greenberg JD. Characteristics of a US spondyloarthritis cohort: baseline data from the Corrona SpA registry. Ann Rheum Dis2015;74(Suppl2):1289.

Pappas DA, John A, Curtis JR, Etzel CE, Karki C, Ssemakula J, Kremer JM, Shewade A, Greenberg JD. Patterns of biologic discontinuations within the Corrona registry: CERTAIN study. Ann Rheum Dis2015;74(Suppl2):1044.

Pappas D, Reed GW, Bao Y, Grant SP, Garg V. Impact of biologic discontinuation in patients with rheumatoid arthritis: observation from the Corrona registry. Ann Rheum Dis2015;74(Suppl2):226.

ACR 2014

Curtis JR, Bharat A, Chen L, Greenberg JD, Kremer J, Pappas D. Physician awareness of suboptimal patient adherence to MTX: results from a large U.S. rheumatoid arthritis registry. Arthritis Rheum 2014;66(Suppl11):2367.

Harrold LR, Reed GR, Karki C, Magner R, Shewade A, John A, Kremer JM, Greenberg JD. Risk of infection associated with subsequent biologic use following rituximab—results from a national RA patient registry. Arthritis Rheum 2014;66(Suppl11):518.

Huyn Q, Etzel CJ, Cox V, Mease P, Kavanaugh A. Persistence of low disease activity after tumor necrosis factor inhibitor (TNFi) withdrawal in patients with psoriatic arthritis (PsA). Arthritis Rheum 2014;66(Suppl11):1594.

Kavanaugh A, Reed GW, Saunders KC, Koenig AS, Geier J, Kremer JM, Greenberg JD, Bingham C. Clinical characteristics of RA patients newly prescribed tofacitinib citrate (tofacitinib) in the United States after Food and Drug Administration approval: results from the Corrona US rheumatoid arthritis registry. Arthritis Rheum 2014;66(Suppl11):1537.

Mease P, Collier D, Karki C, Li G, Bitman B, Greenberg JD. Persistence and predictors of biologic TNFi therapy among biologic naïve psoriatic arthritis patients in a US registry. Arthritis Rheum 2014;66(Suppl11):1853.

Pappas DA, John A, Curtis JR, Reed GW, Karki C, Magner R, Kremer JM, Shewade A, Greenberg JD. Dosing of intravenous tocilizumab in a real-world setting—analyses from a US RA registry. Arthritis Rheum 2014;66(Suppl11):515.

Pappas DA, Kent JD, Kremer JM, Mason M,  Grahn AY, Greenberg JD, Holt RJ. Characteristics of rheumatoid arthritis patients not receiving early initiation of disease modifying therapy. Arthritis Rheum 2014;66(Suppl11):2415.

Strand V, Holt RJ, Saunders KC, Kent JD, Xu P, Grahn AY, Mason M, Etzel CJ. Correlation of Morning stiffness with measures of higher disease activity in a large US registry population of rheumatoid arthritis patients. Arthritis Rheum 2014;66(Suppl11):2813.

Strand V, Holt RJ, Saunders KC, Kent JD, Xu P, Grahn AY, Mason M, Etzel CJ. Prevalence of morning stiffness in a US registry population of rheumatoid arthritis patients. Arthritis Rheum 2014;66(Suppl11):418.

Yun H, Chen L, Reed GW, Kremer JM, Greenberg JD, Curtis JR. Should physician reduce patients’ glucocorticoids to offset the risk of serious infection event among RA patients who switched from non-biologic DMARDs and glucocorticoid to biologics? Arthritis Rheum 2014;66(Suppl11):2375.

Zhang J, Fenglong X, Chen L, Greenberg JD, Curtis JR. Evaluation of a methodological approach to determine timing of rheumatoid arthritis disease onset using administrative claims data. Arthritis Rheum 2014.66(Suppl11):1148.

DIA 2014

Lampl K. Nesting Studies in Registries to Support Comparative Effectiveness Research: An Industry Perspective. DIA 15-19 June 2014. San Diego, CA

EULAR 2014

Furst D, Cox V, Etzel CJ, Greenberg JD, Collier D. Neither RA disease nor TNFi increase the incidence of lymphoma in a large US RA registry. Ann Rheum Dis 2014;73(Suppl2):930.

Geier J, Saunders KC, Reed GW. Contextualization of safety endpoints in the tofacitinib rheumatoid arthritis (RA) development programme: collaboration with the Consortium of Rheumatology Researchers of North America (CORRONA) registry. Ann Rheum Dis 2014;73(Suppl2):1149-1150.

Greenberg JD, Shan Y, Reed GW, Bitman B, Collier D. Comparison of switching to reduced dose vs. continuation of standard dose etanercept for rheumatoid arthritis patients in the CORRONA registry. Ann Rheum Dis 2014;73(Suppl2):241.

Harrold LR, Etzel CJ,  Gibofsky A, Kremer JM, Pillinger M, Saag K, Schlesinger N, Terkeltaub R, Cox V, Greenberg JD. Sex differences in gout characteristics: tailoring care for women and men. Ann Rheum Dis 2014;73(Suppl2):112.

Harrold LR, Greenberg JD, Bao Y, Grant S, Kremer JM, Reed GW, Florentinus S, Karki C, Lacerda A, Ganguli A. Time to biologic therapy driven by rheumatoid arthritis disease activity and severity.Ann Rheum Dis 2014;73(Suppl2):243-244.

Harrold LR, Reed GW, Magner R, Shewade A, John A, Greenberg JD, Kremer JM.  Comparative effectiveness of rituximab versus subsequent anti-tumor necrosis factor in cumulative prednisone exposure in patients with rheumatoid arthritis with prior exposure to TNFi. Ann Rheum Dis 2014;73(Suppl2):508.

Pappas DA, John A, Reed GW, Karki C, Greenberg JD, Shewade A, Kremer JM. Persistency and its predictors of biologic monotherapy in patients with RA: analyses from the CORRONA RA registry. Ann Rheum Dis 2014;73(Suppl2):496-497.

Pappas DA , Lampl K, Kremer JM, Radominski SC, Gal J, Nyberg F, Malaviya A, Whitworth A, Rillo O, Gibofsky A, Popkova T, Ho M, Laurindo I, Reed GW, Kerzberg E, Horne L, Zahora R,  Saunders K , Pons-Estel B, Onofrei AU , Greenberg JD. Prevalence of cardiovascular risk factors and cardiovascular disease in rheumatoid arthritis patients across international regions: a comparison of the CORRONA International and CORRRONA US registries. Ann Rheum Dis 2014;73(Suppl2):639.

Pappas DA , Lampl K, Kremer JM, Radominski SC, Gal J, Nyberg F, Malaviya A, Whitworth A, Rillo O, Gibofsky A, Popkova T, Ho M, Laurindo I, Reed GW, Kerzberg E, Horne L, Zahora R,  Saunders K , Pons-Estel B, Onofrei AU , Greenberg JD. Variations in disease activity and therapeutic management of rheumatoid arthritis in different international regions: a comparison of data from the CORRONA International and CORRONA RA registries. Ann Rheum Dis 2014;73(Suppl2):400.

Pappas DA, Shaw J, Chang H, Cifaldi M, Reed GW, Garg V, Lacerda A, Mozaffarian N. Laboratory safety of adalimumab and other tumor necrosis factor inhibitors in the treatment of rheumatoid arthritis. Ann Rheum Dis 2014;73(Suppl2):931.

Rathbun A, Harrold L., Reed G. The moderating effects of depression on biologic disease modifying anti-rheumatic drugs in rheumatoid arthritis. Ann Rheum Dis 2014;73(Suppl2):631.

Reed G, Ganguli A, Saunders KC, Magner R, Greenberg JD. Biologic drug initiators: real world patterns of monotherapy and combination therapy after one year.  Ann Rheum Dis 2014;73(Suppl2):446.

Schlesinger N, Etzel CJ, Greenberg JD, Kremer JM, Harrold LR. Gout flare prophylaxis evaluated according to the 2012 American College of Rheumatology (ACR) guidelines: analysis from the CORRONA gout registry. Ann Rheum Dis 2014;73(Suppl2):782.

Solomon D, Reed GW, Kremer JM, Curtis J, Farkouh M, Harrold LR, Hochberg M, Tsao P, Greenberg JD. Cumulative disease activity in rheumatoid arthritis and the risk of cardiovascular events. Ann Rheum Dis 2014;73(Suppl2):637-638.

Strand V, Greenberg JD, Bao Y, Saunders K, Garg V,  Li G, Ganguli A. Assessing the impact of biologics treatment on use of mechanical devices/aids by rheumatoid arthritis (RA) patients using a large US patient registry. Ann Rheum Dis 2014;73(Suppl2):417-418.

Yoshida K, Radner H, Mjaavatten MD, Greenberg JD, Kavanaugh A, Kishimoto M, Matsui K, Okada M, Reed GW, Saeki Y, Tohma S, Kremer JM, Solomon DH. Cross-national comparison of biological disease-modifying antirheumatic drug discontinuation practice among rheumatoid arthritis patients in remission: CORRONA and Ninja collaboration. Ann Rheum Dis 2014;73(Suppl2):243.

ISPOR 2014

Dimitrios Pappas, Carol Etzel, Angela Bedenbaugh, Jeymi Tambiah, Jeff Greenberg

Baseline characteristics of elderly RA patients treated with Certolizumab Pegol and other TNF-a inhibitors. Results from the CORRONA registry.  International Society For Pharmacoeconomics and Outcomes Research. Montreal, Canada. 31, May – 4 June 2014.

ACR 2013

Askling J, Berglind N, Franzen S, Frisell T, Garwood C, Greenberg JD, Ho M. Rates of malignancies In patients from 5 rheumatoid arthritis registries across the world. Arthritis Rheum 2013;65(Suppl10):782.

Bray V, Bagley A, West Sterling Etzel C, Kremer J, Kolfenbach J. Infection Risk Among Patients Receiving Concurrent Denosumab and Biologic or Non-Biologic DMARD Therapy: An Analysis of the CORRONA Registry.  Arthritis Rheum 2013. 65 Suppl 10: 491.

Curtis JR, Chen L, Yun H, Harrold LH, Greenberg JD, Kremer JM. Generalizability of a U.S. rheumatoid arthritis registry: a comparison of participants’ vs. non-participants’ characteristics.  Arthritis Rheum 2013;65(Suppl10):1048.

Furst D, Lui M, Greenberg J, Kremer J. Higher TNFi dosing is not associated with more serious infectious events (SIE), elevated AST/ALT or WBC<1.5 in the US CORRONA database. Arthritis Rheum 2013;65(Suppl10):461.

Greenberg JD, Michaud K, Askling J, Yamanaka H, Symmons D, Holmqvist M, Frisell T, Reed G, Pappas DA, Tanaka E, Inoue E, Verstappen S, Garwood C,  Lampl K, Horne L, Berglind N, Franzen S, Tran T, Ho M, Nyberg F. Can RA registries provide contextual safety data for modern RCTs?  Arthritis Rheum 2013;65(Suppl10):2759.

Harrold LR, Etzel C, Pillinger M,  Saag K, Schlesinger N, Terkeltaub R, Cox V, Kremer JM. Sex differences in gout evaluation and management.  Arthritis Rheum 2013;65(Suppl10):1195.

Harrold LR, Etzel C, Schechter B, Malamet R, Cox V, Greenberg JD. Assessing treat to target in patients with and without tophi. Arthritis Rheum 2013;65(Suppl10):2008.

Harrold LR, Reed G, Magner R, Shewade A, John A, Greenberg JD, Kremer JM. Comparative effectiveness of rituximab vs. subsequent anti-tumor necrosis factor in patients with rheumatoid arthritis with prior exposure to TNFi.  Arthritis Rheum 2013;65(Suppl 10):1438.

Hopkins A, Martinez-Marti A, Reed G, He P, Greenberg JD, Lozada C, Pala O, Kremer JM, Pappas DA.  Effectiveness of TNF-á inhibitor therapy does not differ between elderly and younger patients with rheumatoid arthritis: results from the CORRONA registry.  Arthritis Rheum 2013;65(Suppl 10):1435.

Huynh D, Kavanaugh A, Etzel C, Cox V, Greenberg JD, Kremer JM. Anti-citrullinated protein antibodies in patients with psoriatic arthritis: clinical relevance.  Arthritis Rheum 2013;65(Suppl 10):304.

Kavanaugh A, Lee Susan, Solomon D, Greenberg JD, Kremer JM, Soto L, Etzel C, Reed GW. Discontinuation of TNF antagonists in patients in low disease activity: persistent benefits.  Arthritis Rheum 2013;65(Suppl 10):1425.

Labitigan M, Shrestha A, Reed GW, Magner R, Jordan N, Kremer JM, Greenberg JD, Bahce-Altunas A, Broder A. Higher disease activity in psoriatic arthritis is associated with elevated total cholesterol and triglycerides.  Arthritis Rheum 2013;65(Suppl 10):300.

Lillegraven S, Greenberg JD, Reed GW,  Saunders K, Curtis JR, Harrold LR, Hochberg MC,  Pappas DA, Kremer JM,  Solomon DH. Use of TNF inhibitors is associated with a reduced risk of diabetes in RA patients.  Arthritis Rheum 2013;65(Suppl 10):1040.

Mease P, Heredia E, Saunders K, Shuler C, Zhu B, Chaudhari M, Greenberg JD. Clinical characteristics of patients who switch biologic therapy within the first two years: results from a large US registry population.  Arthritis Rheum 2013;65(Suppl 10):328.

Pappas DA, Chen L, Harrold LR, Reed G, Kremer J, Greenberg JD, Curtis JR. Physician variability in rheumatoid patients not receiving biologics or non-biologic DMARDs: implications for quality reporting.  Arthritis Rheum 2013;65(Suppl 10):193.

Pappas DA, John A, Curtis JR, Reed GW, Sommers T, Greenberg JD, Shewade A, Solomon DH, Kremer JM. Effect of biologic agents on lipids and cardiovascular risk in rheumatoid arthritis patients.Arthritis Rheum 2013;65(Suppl 10):2827.

Pappas DA, John A, Curtis JR, Reed GW, Sommers T, Greenberg JD, Shewade A, Kremer JM. Shift in cardiovascular risk and lipid levels in rheumatoid arthritis using ATP-3 guidelines: CORRONA CERTAIN study. Arthritis Rheum 2013;65(Suppl 10):370.

Pappas DA, John A, Kremer JM, Karki CK, Sommers T, Reed GW, Curtis JR, Shewade A, Greenberg JD. Effect of tocilizumab on treatment patterns, effectiveness and safety with laboratory values for patients with rheumatoid arthritis: analyses from the CORRONA – CERTAIN Study.Arthritis Rheum 2013;65(Suppl 10):2344.

Pappas DA, John A, Kremer JM, Reed GW, Sommers T, Greenberg JD, Shewade A, Curtis JR. Management of hyperlipidemia in patients with rheumatoid arthritis: results from the CORRONA CERTAIN study.  Arthritis Rheum 2013;65(Suppl 10):362.

Pappas DA, Karki CK, Lee C, Reed GW, He P, Al Sawah S. Patient reported pain: a predictor of outcomes in rheumatoid arthritis from the Consortium of Rheumatology Researchers of North America (CORRONA) registry.  Arthritis Rheum 2013;65(Suppl 10):2269.

Pappas DA , Lampl K,  Kremer JM, Radominski SC, Gal J, Nyberg F, Malaviya A, Whitworth A, Rillo O, Gibofsky A, Popkova T,  Ho M, Laurindo I, Reed GW, Kerzberg E, Horne L, Zahora R,  Saunders K , Pons-Estel B, Onofrei AU , Greenberg JD. Prevalence of cardiovascular risk factors and cardiovascular disease in different international regions. Data from the CORRONA International and CORRONA US registries. Arthritis Rheum 2013;65(Suppl 10):392.

Pappas DA , Lampl K,  Kremer JM, Radominski SC, Gal J, Nyberg F, Malaviya A, Whitworth A, Rillo O, Gibofsky A, Popkova T,  Ho M, Laurindo I, Reed GW, Kerzberg E, Horne L, Zahora R,  Saunders K , Pons-Estel B, Onofrei AU , Greenberg JD. Variations in disease activity and therapeutic management of RA in different international regions. Data from the CORRONA International and CORRONA US registries.  Arthritis Rheum 2013;65(Suppl 10):1303.

Rathbun A, Harrold LR, Reed GW. Temporal associations of prevalent depression with the different domains of rheumatoid arthritis disease activity.  Arthritis Rheum 2013;65(Suppl 10):1044.

Yamanaka H, Askling J,  Berglind N, Franzén S, Frisell T, Garwood C. Greenberg  JD, Ho M, Holmqvist M, Horne L, Inoue E, Lampl K, Michaud K, Pappas DA, Reed G, Symmons D, Tanaka E, Tran T, Verstappen S,  Nyberg F.  Rates of hospitalized infections in rheumatoid arthritis patients from 5 rheumatoid arthritis registries across the world. Arthritis Rheum 2013;65(Suppl 10):1047.

ICPE 2013

Nyberg F, Askling J, Greenberg JD, Michaud K, Yamanaka H, Symmons D, Ho M. Using epidemiological registry data to provide background rate context for adverse events in a rheumatoid arthritis (RA) drug development program – a coordinated approach. International Conference on Pharmacoepidemiology and Therapeutic Risk Management 25-28 August 2013. Montreal, Canada.

Pappas DA, Kremer J, Greenberg J, Shewade A., Solomon D, Curtis JR. Dyslipidemia, inflammation and cardiovascular risk in patients with rheumatoid arthritis. International Conference on Pharmacoepidemiology and Therapeutic Risk Management 25-28 August 2013. Montreal, Canada.

GRAPPA 2013

Huynh D, Kavanaugh A, Etzel C, Cox V, Greenberg JD, Kremer JM. Anti-citrullinated protein antibodies in patients with psoriatic arthritis: clinical relevance.

LabitiganM, ShresthaA, Reed GW, Magner RP, Jordan N, Kremer JM, Greenberg JD, Bahce-Altuntas A, Broder AR. Higher Disease Activity In Psoriatic Arthritis Is Associated With Elevated Total Cholesterol and Triglycerides.

DIA 2013

Saunders K, Barr C. Characteristics of a US Rheumatoid Arthritis Cohort: Baseline Data from the CORRONA RA Registry. Drug Information Association. 23-27 June 2013. Boston, MA.

EULAR 2013

Finckh A, Scherer A, Kremer JM, Greenberg JD, Lubbeke A, Schwarz H, Rathbun A, Gabay C, Reed GW. Obese patients with rheumatoid arthritis have reduced response rates to biologic anti-rheumatic agents. Ann Rheum Dis 2013;72(Suppl 3):403.

Harrold L, Greenberg  J, Saunders K, Karki C, Kifayeh N, Kremer J. Characteristics of gout patients cared for by rheumatologists – results from the CORRONA gout registry site survey. Ann Rheum Dis 2013;72(Suppl 3):561.

Harrold L, Reed G, Magner R, Shewade A, John A, Reiss W, Greenberg J, Kremer J. Comparative effectiveness of rituximab versus anti-tumor necrosis factor switching for rheumatoid arthritis patients. Ann Rheum Dis 2013;72(Suppl 3):460.

Huynh D, Etzel C, Cox V, Kremer J, Greenberg J, Kavanaugh A. Anti citrullinated peptide antibody (ACPA in patients with psoriatic arthritis (PSA): clinical relevance. Ann Rheum Dis 2013;72(Suppl 3):673.

Labitigan M, Shrestha A, Jordan N, Reed G, Magner R, Bahce-Altuntas A, Broder A. Moderate to high disease activity in psoriatic arthritis is associated with elevated total cholesterol and triglycerides. Ann Rheum Dis 2013;72(Suppl 3):15.

Lillegraven S, Greenberg JD, Reed GW, Saunders K, Curtis JR, Harrold L, Hochberg M, Pappas D, Kremer JM, Solomon DH. Use of TNF inhibitors is associated with a reduced risk of diabetes in RA patients. Ann Rheum Dis 2013;72(Suppl 3):106.

Mease P, Collier D, Saunders KC, Grant S, Bitman B, Chaudhari M, Greenberg J. Biologic therapy, time to low disease activity, and effect of mono vs. background oral DMARD therapy among psoriatic arthritis patients in a US registry. Ann Rheum Dis 2013;72(Suppl 3):671.

Nyberg, F, Askling J, Greenberg JD, Michaud K, Yamanaka H, Symmons D, Ho M. Using epidemiological registry data to provide background rate context for adverse events in a rheumatoid arthritis drug development program – A Coordinated Approach. Ann Rheum Dis 2013;72(Suppl3):413

Pappas DA, John A, Curtis JR, Kremer J, Reiss W, Shewade A, Silverman GJ, Greenberg JD. Prevalence of low immunoglobulin levels and associations with rheumatoid arthritis factors. Ann Rheum Dis 2013;72(Suppl 3):448.

Pappas DA, John A, Kremer J, Reed G, Greenberg JD, Shewade A, Solomon DH, Curtis JR. Effect of biologic agents on lipids and cardiovascular risk in rheumatoid arthritis patients. Ann Rheum Dis 2013;72(Suppl 3):49.

Pappas DA, Lampl K, Kremer JM, Nyberg F, Gibofsky A, Ho M, Horne L, Saunders K, Onofrei AU, Greenberg JD. The CORRONA international rheumatoid arthritis registry: variations in disease activity and management across participating regions. Ann Rheum Dis 2013;72(Suppl 3):209.

Strand V, Williams S, Miller PSJ, Saunders K, Grant S, Kremer JM. Discontinuation of biologic therapy in rheumatoid arthritis (RA): analysis from the Consortium of Rheumatology Researchers of North America (CORRONA) Database. Ann Rheum Dis 2013;72(Suppl 3):71.

Verstappen S, Askling  J, Yamanaka H, Greenberg JD, Ho M, Michaud K, Symmons D, Nyberg F. Methodological challenges when comparing demographic and clinical characteristics of international observational studies. Ann Rheum Dis 2013;72(Suppl 3):552.

ACR 2012

Anandarajah A, Saunders KC, Reed GW, Onofrei AU, Greenberg JD, Ritchlin CT. Major adverse cardiovascular events are more common in rheumatoid arthritis than in psoriatic arthritis and are associated with different risk factors. Arthritis Rheum 2012;64(Suppl 10):2221.

Curtis J, Lang C, Beukelman T, Bharat A, Fenglong X, Saag KG, Delzell ES. Methods to link a US arthritis cohort with Medicare administrative claims data. Arthritis Rheum 2012;64(Suppl 10):924.

Curtis J, Shan Y, Zhang J, Greenberg JD, Reed GW. How much can patient reported outcomes improve among rheumatoid arthritis patients who have a clinical response to biologic therapy but have not attained low disease activity? Arthritis Rheum 2012;64(Suppl 10):2101.

Cush JJ,  Reed G, Saunders KC, Kremer JM, Greenberg JD,  Kavanaugh A. DMARD and biologic Use during pregnancy in rheumatoid and psoriatic arthritis patients in the CORRONA Registry. Arthritis Rheum 2012;64(Suppl 10):166.

Furst FE, Mozzaffarian N, Grant S, Cifaldi M, Clewell J, Kremer JM, Shaw J. Adalimumab treatment is associated with decreased concomitant rheumatoid arthritis medication use over 24 months. Arthritis Rheum 2012;64(Suppl 10):203.

Gibofsky A, Saunders KC, Ganguli A, Cifaldi M, Grant S, Clewell J, Mozaffarian N, Shaw J, McCaskill R, Reed G, Greenberg JD. Persistency and predictors of persistency of adalimumab among rheumatoid arthritis (RA) patients in a US registry. Arthritis Rheum 2012;64(Suppl 10):379.

Greenberg JD, Spruill T, Ogedebe G, Kremer JM, Shan Y, Saunders KC, Yazici Y, Harold LR. Race and ethnic disparities in rheumatoid arthritis outcomes in community-based U.S. rheumatology practices: results from the Consortium or Rheumatology Researchers of North America registry. Arthritis Rheum 2012;64(Suppl 10):2138.

Harrington J.T, Reed G, Saunders K, Lemire L, Whitworth A, Greenberg JD, Kremer JM. Standardized data collection supports reliable reporting of rheumatoid arthritis (RA) measures to the Medicare physicians’ quality reporting system. Arthritis Rheum 2012;64(Suppl 10):2051.

Harrold LR, Reed GW, Magner RP, Saunders KC, Greenberg JD, Kremer JM. Rituximab for treatment of rheumatoid arthritis: treatment effectiveness in the CORRONA database. Arthritis Rheum 2012;64(Suppl 10):454.

Harrold LR, Reed GW, Saunders KC, Shan Y, Spruill T, Greenberg JD. Patient and provider factors associated with compliance with rheumatoid arthritis treatment recommendations. Arthritis Rheum 2012;64(Suppl 10):2510.

Kaushik P, Messing SP, Arora I, Reed GW, Saunders KC, Greenberg, JD, Kremer JM. Subcutaneous nodules are significantly associated with cardiovascular events in patients with rheumatoid arthritis: results from a very large US registry. Arthritis Rheum 2012;64(Suppl 10):829.

Kotak S, Koenig AS, Collier DH, Saunders KC, He P, Kremer JM, Reed GW. Disease activity and treatment strategies in moderate rheumatoid arthritis patient population: data from the Consortium of Rheumatology Researchers of North America. Arthritis Rheum 2012;64(Suppl 10):1842.

Manno RL, Pappas DA, Saunders KC, Reed GW, Grant S, Bingham CO.  Disease-modifying antirheumatic drug use among elderly with rheumatoid arthritis. Arthritis Rheum 2012;64(Suppl 10):2480.

Pappas DA, Reed GW, John A, Shewade A, Saunders KC, Devenport J, Greenberg JD, Kremer JM.  Predictors of initiating biologic monotherapy in biologic naïve patients with rheumatoid arthritis (RA) in a United States registry population. Arthritis Rheum 2012;64(Suppl 10):491.

Pappas DA, Reed GW, Saunders KC, John A, Shewade A, Devenport J, Greenberg JD, Kremer JM. Characteristics associated with biologic initiation as monotherapy versus combination Therapy in patients with rheumatoid arthritis (RA) in a United States registry population. Arthritis Rheum 2012;64(Suppl 10):557.

Pepmeuller P. Jandali R, Sharma A, Grant S, Saunders KS. Use and long term use of complementary and alternative medicine in rheumatoid arthritis patients. Arthritis Rheum 2012;64(Suppl 10):377.

Reed GW, Collier DH, Koenig AS, Saunders KC, Kremer JM, Kotak S. Transitions Among Disease Activity States: Estimates and Models of Covariate Associations. Arthritis Rheum 2012;64(Suppl 10):36

Reed GW, Koenig AS, Saunders KC, Collier DH, Kremer JM, Kotak S. A methodology for estimating disease state transitions: repeated measures Markov models with covariate dependence. Arthritis Rheum 2012;64(Suppl 10):865.

Wenkert D, Grant S, Collier DH, Koenig AS, Kremer JM. 2002-04 vs.2007-09: Initiation of combination, and tapering/discontinuation (DC) patterns of TNFi and MTX in a US (RA) patient registry: analysis with CDAI scores. Arthritis Rheum 2012;64(Suppl 10):383.

AMCP 2012

Ingham M, Reed G, Bolce R, Greenberg J, Shan Y, Bolge S, Decktor D.  Patterns of response to TNF inhibitors by mode of administration from the CORRONA registry: implications for treat-to-target strategies.  AMCP Mar 2012;18(2):191.

EULAR 2012

Furst DE, Mozaffarian N, Grant S, Cifaldi M, Clewell J, Kremer J, Shaw JW. Adalimumab treatment is associated with decreased concomitant RA medication us over 24 months.  Ann Rheum Dis 2012;71(Suppl 3):364.

Harrold L, Cifaldi M, Saunders K, Reed G, Ganguli A, Shan Y, Greenberg J. Factors associated with work status and missed work days in rheumatoid arthritis. Ann Rheum Dis 2012; 71(Suppl 3):631.

Harrold L, John A, Reed G, Reiss W, Magner R, Chung CY, Saunders K, Kremer J, Greenberg J.  The use and effectiveness of rituximab in patients with rheumatoid arthritis observational study: CORRONA registry. Ann Rheum Dis 2012;71(Suppl 3):669.

Harrold L, Reed G, Saunders K, Shan Y, Spruill T, Greenberg J. Patient and provider factors associated with compliance with rheumatoid arthritis treatment recommendations.  Ann Rheum Dis 2012;71(Suppl 3):461.

Kotak S, Koenig A, Collier D, Saunders K, He P, Kremer J, Reed G. Characteristics of a moderate rheumatoid arthritis patient population who lost remission or low disease activity: data from the consortium of rheumatology researchers of North America Inc. (CORRONA). Ann Rheum Dis 2012;71(Suppl 3):656.

Kremer J, Wenkert D, Grant S, Xu P, Koenig A, Collier D.  The frequency of methotrexate (MTX) or prednisone discontinuation/switching in rheumatoid arthritis (RA) patients results from 2002-2004 and 2007 – 2009 in a large US registry.  Ann Rheum Dis 2012;71(Suppl 3):664.

Mease P, Saunders K, Bolge S, Decktor R, Reed G, Greenberg J.  The effect of dactylitis and enthesitis on disease burden in patients with psoriatic arthritis in the CORRONA registry. Ann Rheum Dis 2012;71(Suppl 3):577.

Pala O, Messing S, Hopkins A, Reed G, Perez-Rivera M, Acosta M, Kremer JM,  Lozada C, Pappas DA.  Effect of alcohol on response to therapy with TNF-A inhibitors for rheumatoid arthritis: results from CORRONA registry. Ann Rheum Dis 2012;71(Suppl 3):369.

Pala O, Messing S, Hopkins A, Reed G, Perez-Rivera M, Acosta M, Kremer JM, Lozada C, Pappas DA. Effect of smoking on response to therapy with the TNF-A inhibitors for Rheumatoid arthritis: results from the CORRONA registry. Ann Rheum Dis 2012;71(Suppl 3):521.

Pappas DA, Hooper M, Reed G, Shan Y, Wenkert D, Zhang J, Greenberg J,  Curtis J. Risk for herpes zoster after treatment with biologic and synthetic disease modifying agents for rheumatoid arthritis.  Ann Rheum Dis 2012;71(Suppl 3):346.

Pappas DA, John A, Greenberg JD, Devenport J, Kremer JM, Ogale S, Reed GW, Saunders KC, Curtis JR. Design characteristics of the CORRONA CERTAIN study: a US comparative effectiveness and biomarkers study of rheumatoid arthritis biologic agents.  Ann Rheum Dis 2012;71(Suppl 3):668.

ACR 2011

Bahce-Altuntas A, Schwartzman-Morris JS, Jordan N, Greenberg JD, Putterman C, Reed G, Broder AR. Higher frequency of metabolic syndrome In psoriatic arthritis compared with rheumatoidarthritis may be explained by high triglycerides and increased rates of obesity and diabetes. Arthritis Rheum 2011;63(Suppl 10):2634.

Bahce-Altuntas A, Schwartzman-Morris JS, Jordan N, Greenberg JD, Putterman C, Reed G, Broder AR. Inflammation may be associated with an unfavorable lipid profile in psoriatic arthritis patientsin the CORRONA registry. Arthritis Rheum 2011;63(Suppl 10):1306.

Greenberg JD, Bolce R, Shan Y, Saunders KC, Reed G, Kremer JM, Decktor D. Effect of weight, body mass index and weight-based dosing on persistency of anti-TNFs in psoriatic arthritis. Arthritis Rheum 2011;63(Suppl 10):1310.

Gross RL, Schwartzman-Morris JS, Krathen M, Reed G, Chang H, Saunders KC, Fisher MC. The risk of malignancy in a large cohort of patients with psoriatic arthritis. Arthritis Rheum 2011;63(Suppl 10):509.

Harrold LR, Cifaldi MA, Shan Y, Reed G, Saunders KC, Kremer JM, Greenberg, JD. Factors associated with work status and missed work days in patients with rheumatoid arthritis.  Arthritis Rheum 2011;63(Suppl 10):108.

Harrold LR, Reed G, Collier DH, Park GS, Chang H, Koenig AS, Saunders KC. Factors associated with relapse of remission in rheumatoid arthritis. Arthritis Rheum 2011;63(Suppl 10):326.

Harrold LR., Reed G, Curtis JR, Solomon DH, Hochberg M, Onofrei A et al; Comparative effectiveness of abatacept versus subsequent anti-TNF agents among rheumatoid arthritis patients with previous anti-TNF exposure. Arthritis Rheum 2011;63(Suppl 10):2595.

Jetanalin P, Messing SP, Kaukeinen K, Kremer JM, Lee SJ. Trend of tumor necrosis factor inhibitors use among patients with rheumatoid arthritis: analysis from the Consortium of Rheumatology Researchers of North America registry. Arthritis Rheum 2011;63(Suppl 10):449.

Kay J, Messing SP, Kremer JM, Greenberg JD, Furst DE. Clinical disease activity and acute phase reactant (APR) levels are discordant among patients with active rheumatoid arthritis (RA) and contribute separately to predicting outcome at 1 year. Arthritis Rheum 2011;63(Suppl 10):2511.

Navarro-Milan I, Chen L, Greenberg JD, Curtis JR. Application of the new American College of Rheumatology/European League Against Rheumatism rheumatoid arthritis remission criteria in a United States cohort. Arthritis Rheum 2011;63(Suppl 10):335.

Pappas DA, Rathbun A, Reed G, Kremer JM, Villanueva I, Devenport J, Ogale S. A profile of rheumatoid arthritis patients treated with tocilizumab in a United States registry population. Arthritis Rheum 2011;63(Suppl 10):1262.

Woodworth TG, Thomas E, Greenberg JD, Furst DE. Successful tapering of glucocorticoids (GC) in rheumatoid arthritis patients-results from the Consortium of Rheumatology Researchers of North America registry. Arthritis Rheum 2011;63(Suppl 10):2464.

EULAR 2011

Bahce-Altuntas A, Schwartzman-Morris J, Jordan N, Greenberg JD, Putterman C, Reed G, Broder A. Higher frequency of metabolic syndrome in psoriatic arthritis compared with rheumatoid arthritis maybe explained by increased rates of obesity and high triglycerides. Ann Rheum Dis 2011;70(Suppl 3):155.

Bahce-Altuntas A, Schwartzman-Morris J, Jordan N, Greenberg JD, Putterman C, Reed G, Broder A. Inflammation may be associated with an unfavorable lipid profile in psoriatic arthritis patients in theCORRONA registry.  Ann Rheum Dis 2011;70(Suppl 3):239.

Ingham M, Reed G, Bolce R, Greenberg JD, Dehoratius R, Decktor D. Patterns of anti-TNF treatment in the CORRONA registry: observed responses to maintenance, switching and discontinuation. Ann Rheum Dis 2011;70(Suppl 3):415.

ACR 2010

Chakravarty EF, Reed G, Decktor D, Bolge S, Bolce R, Ingham M, DeHoratius R. TNF switching in PsA patient. Arthritis Rheum 2010;62(Suppl 10):1960.

Eberle E, Knight E, Raddatz D, Messing S, Reed G, Greenberg JD, Kremer JM. Association of BMI and psoriatic arthritis disease activity. Arthritis Rheum 2010;62(Suppl 10):515.

Furst DE, Ranganath V, Kremer JM, Louie J, Khanna D, Rasouliyan L, Greenberg JD. Women with RA achieve remission less frequently than men, using the CORRONA database among 6668 patients. Arthritis Rheum 2010;62(Suppl 10):347.

Harrington JT, Harrold LR, Reed G, Chang H, Kremer JM, Greenberg JD. Rheumatoid arthritis (RA) disease activity assessment and treatment decisions in rheumatology practice. Arthritis Rheum 2010;62(Suppl 10):1003.

Harrington JT, Pappas DA, Messing S, Tu X, Chen R, Kaukeinen K, Pietras T. Dosing of anti-tumor necrosis factor biologics (anti-TNFs) for rheumatoid arthritis (RA) and psoriatic arthritis (PsA) in Clinical Practice in the United States. Arthritis Rheum 2010;62(Suppl 10):1799.

Harrold LR, Greenberg JD, Curtis JR, Furst DE, Bentley MJ, Shan Y, Reed G. The impact of the ACR treatment recommendations on physician prescribing in a U.S. cohort of rheumatoid arthritis patients. Arthritis Rheum 2010;62(Suppl 10):1010.

Harrold, L, Reed G, Rosenblatt LC, Mody M, Moniz D, Greenberg JD.  Comparable persistency and effectiveness of abatacept versus anti-TNF agents in the treatment of biologic-naïve rheumatoid arthritis patients using the CORRONA registry. Arthritis Rheum 2010;62(Suppl 10):1794.

Sterling KL, Carter GC, Messing S, Reed G, Chen R, Kaukeinen K, Tu X. Baseline factors related to response to conventional DMARD treatments. Arthritis Rheum 2010;62(Suppl 10):52.

EULAR 2010

Cuyun Carter G, Sterling K, Messing S, Reed G, Chen R, Kaukeinen K.  Baseline Predictors of Response to Anti-TNF Treatments. Ann Rheum Dis 2010;69(Suppl 3):351.

Furst DE, Ranganath V, Kremer JM, Louie J, Khanna D, Rasoulyan L, Greenberg JD, CORRONA. Women with RA achieve remission less frequently than men, using the CORRONA database among 6668patients. Ann Rheum Dis 2010;69(Suppl 3):354.

Greenberg J, Reed G, Harrold L, Bolce R, Bolge S, DeHoratius RJ, Decktor D. Characteristics of the psoriatic arthritis patient cohort within the CORRONA registry. Ann Rheum Dis 2010;69(Suppl 3):579.

Harrold L, Reed G, Greenberg J, Bolce R, Bolge S, Dehoraiuts RJ, Decktor D.  Persistency of anti-TNFs in psoriatic arthritis based on route of administration. Ann Rheum Dis 2010;69(Suppl 3):579.

Harrold L, Reed G, Rosenblatt L, Moniz Reed D, Greenberg J.  Comparative effectiveness of abatacept versus anti-TNF agents in the treatment of biologic-naïve rheumatoid arthritis patients, using the CORRONA registry. Ann Rheum Dis 2010;69(Suppl 3):478.

Kavanaugh A, Greenberg J, Lee S, Reed G, Kremer J, Onofrei A, Baumgartner S. Incidence of elevated liver enzymes (LFTS) in psoriatic arthritis (PS) patients: effect of TNF-inhibitors (TNF-i). Ann Rheum Dis 2010;69(Suppl 3):579.

Nelson D, Sarsour K, Johnston J, Chen R, Messing S, Kaukeinen K, Tu X, Reed G, Greenberg JD. Biologic disease-modifying anti-rheumatic drug treatment patterns and associated clinical outcomes. Ann Rheum Dis 2010;69(Suppl 3):680.

Randall E, Harrold LR, Reed GW, Furst DE, Ruderman EM.  Response to adding a TNF inhibitor (TNFi) to methotrexate in clinical practice.  Ann Rheum Dis 2010;69(Suppl 3):674.

Solomon D, Hochberg M, Fisher M, Curtis J, Furer V, Harrold L, Reed G, Kremer J, Greenberg J.  Malignancy risk in a very large cohort of rheumatoid arthritis.  Ann Rheum Dis 2010;69(Suppl 3):519.

ACR 2009

Anandarajah AP, El-Taha M, Peng C, Greenberg JD, and Ritchlin C. The association between focal bone loss (erosions) and generalized bone loss (osteoporosis) in rheumatoid arthritis. Arthritis Rheum 2009;60(Suppl 10):373.

Curtis JR, Chen L, Cush JL, Dao KH, Delzell E, Furst DE, Greenberg JD, Hochberg MC, Jain A, Kremer JM, Patkar N, Solomon DH. The risk for hospitalized and outpatient infections related to anti-TNF therapy and newer biologics. Arthritis Rheum 2009;60(Suppl 10):2059.

Finckh A, Scherrer A, Reed G, Greenberg JD, Lubbeke A, Schwarz H, C. Gabay C, Kremer JM. Obesity and RA disease severity: a comparison between European and American RA Patients. Arthritis Rheum 2009;60(Suppl 10):970.

Harrold LR, Greenberg JD, Curtis JR, Bentley MJ, Reed G, Harrington JT. Rheumatologists’ prescribing patterns for rheumatoid arthritis patients with active disease. Arthritis Rheum 2009;60(Suppl 10):1009.

Lee SJ, Reed G, Kremer JM, Kavanaugh A. Characteristics of rheumatoid arthritis (RA) patients starting abatacept and rituximab. Arthritis Rheum 2009;60(Suppl 10):1610.

Ranganath VK, Maranian P, Hahn T, Elashoff D, Furst DE, Kremer JM, Paulus HE. Comorbidities correlates better than age with CDAI improvement in RA patients using the CORRONA Registry. Arthritis Rheum 2009;60(Suppl 10):972.

Setoguchi S, Greenberg JD, Curtis JR, Hochberg MC, Reed G Tsao P, Farkouh ME, Kremer JM, Solomon DH. Markers of disease severity predict new-onset heart failure in rheumatoid arthritis. Arthritis Rheum 2009;60(Suppl 10):1375.

EULAR 2009

Bentley MJ, Reed GW. Development and validation of a modified disease activity score (MDAS28) in rheumatoid arthritis for use in standard care. Ann Rheum Dis 2009;68(Suppl 3):530.

Curtis JR, Chen L, Harrold L, NarongroeknawinP, Reed G, Solomon DH.  Physician preference motivates anti-TNF therapy independent of clinical disease activity. Ann Rheum Dis 2009;68(Suppl 3):243

Curtis JR, Patkar N, Jain A, Greenberg JD, Solomon DH. The validity of physician-reported hospitalized infections in a US rheumatoid arthritis cohort. Ann Rheum Dis 2009;68(Suppl 3):558.

Decktor DL, Harrold LR, Bolce R, Reed G, DeHoratius R, Greenberg JD. Patterns of drug use after initiation of anti-TNF rheumatoid arthritis. Ann Rheum Dis 2009;68(Suppl 3):235.

Furst DE, Chang H, Khanna D, Reed G, Moniz Reed D, Rosenblatt LC, Mody M, Kremer JM, Greenberg JD. Rates of remission in RA depend on remission definition, duration of disease state, age and disease activity-associated factors. Ann Rheum Dis 2009;68(Suppl 3):224.

Furst DE, Greenberg JD, Reed G, Chang H, Pangan AL. Likelihood of clinical remission on anti-TNF therapy (TNFI). Ann Rheum Dis 2009;68(Suppl 3):234.

Gibofsky A, Kremer JM, Moniz Reed D, Reed G, Vratsanos G, Greenberg JD . Experience with abatacept in a US observational cohort: clinical and patient-reported outcomes from the CORRONA registry. Ann Rheum Dis 2009;68(Suppl 3):437.

Kremer J, Reed G, John AK, Onofrei A. Physician behavior in response to liver enzyme elevation in rheumatoid arthritis RA TNFI MTX – Analysis of the Corrona Registry Database. Ann Rheum Dis 2009;68(Suppl 3):354.

Tang B, GreenbergJ, ReedG, DecktorD, BolceR, PiechCT. Analysis of Infliximab dose and interval patterns in patients with rheumatoid arthritis in the Consortium of Rheumatology Researchers of North America (CORRONA) Registry. Ann Rheum Dis 2009;68(Suppl 3):231.

ACR 2008

Anandarajah AP, Greenberg JD, El-Taha M, Reed G, Peng C, Ritchlin CT. The relationship between erosions and osteoporosis in patients with psoriatic arthritis. Arthritis Rheum 2008;58(Suppl 9):366-67.

Fisher MC, El-Taha M, Kremer JM, Peng C, Greenberg JD. Smoking cessation and improvement of RA disease activity. Arthritis Rheum 2008;58(Suppl 9):610.

Furst DE, Chang H, Ranganath VK, Kremer JM, Reed G, Law A, et al. Increases in hemoglobin levels are associated with improved activities of daily living (mHAQ) in rheumatoid arthritis patients. Arthritis Rheum 2008;58(Suppl 9):761-62.

Gibofsky A, Kremer JM, Reed DM, Reed G, Klem C, Greenberg JD. Early experience with abatacept in a US observational cohort: clinical and patient report outcomes from the CORRONA registry. Arthritis Rheum 2008;58(Suppl 9):309.

Greenberg JD, Gibofsky A, Reed G, Decktor DL, Dehoratius R, Kremer JM. Effectiveness of TNF inhibitors (TNF-I) in biologic naive and switched RA patients in a US cohort. Arthritis Rheum 2008;58(Suppl 9):524-25.

Sokolove J, Strand V, Greenberg JD, Curtis JR, Kavanaugh A, Kremer JM, et al. Risk of elevated liver enzymes (LFTS) with TNF inhibitors (TNF-I) in rheumatoid arthritis: Analysis in 6,861 patients with 22,552 visits. Arthritis Rheum 2008;58(Suppl 9):779.

Solomon DH, Curtis JR, Kremer JM, Reed G, Hochberg MA, Setoguchi S, et al. TNF blocker use and cardiovascular outcomes. Arthritis Rheum 2008;58(Suppl 9):544.

EULAR 2008

Anandarajah AP, Greenberg JD, El-Taha M, Peng C, Reed G, Ritchlin CT. The relationship between erosions and osteoporosis in patients with psoriatic arthritis Ann Rheum Dis 2008;67(Suppl II):101.

Furst DE, Sokolove J, Greenberg JD, Curtis JR, Kavanaugh A, Kremer JM, Reed G, Calabrese L, Hooper M, Baumgartner S, Strand V. Risk of elevated liver enzymes (LFTS) with TNF inhibitors (TNF-I) in rheumatoid arthritis: Analysis in 6,861 patients with 22,552 visits. Ann Rheum Dis 2008;67(Suppl II):52.

Solomon D, Greenberg JD, Reed G, Kishimoto M, Hinkle K, Abramson S, Kremer JM. Cardiovascular risk among patients with RA in CORRONA: comparing the explanatory value of traditional cardiovascular risk factors with RA. Ann Rheum Dis 2008;67(Suppl II):482.

Gibofsky A, Greenberg JD, Reed GW, Decktor DL, DeHoratius R, Kremer JM. Persistancy, Response and Remission on the TNF Antagonnists in RA in a U.S. Cohort. Ann Rheum Dis 2008;67(Suppl II):182.

ACR 2007

Callegari P, Dabbous O, Kremer J, Reed G. A Review of Lymphoma Occurring in Rheumatoid Arthritis Patients in the Consortium of Rheumatology Researchers of North America (CORRONA) Database. Arthritis Rheum 2007;56(Suppl 12):989.

Curtis JR, Reed G, Greenberg J, Teng GG, Kremer J. Hepatotoxicity Associated with Non-Biologic DMARDs: Implications for Evaluation of New Rheumatic Disease Therapies. Arthritis Rheum 2007;56(Suppl 12):310.

Furst DE, Chang C, Ranganath V, Reed G, Khanna D, Kremer J, Greenberg J. Defining Change in Disease Activity Parameters Associated with Loss of Response Over Time in RA Patients. Arthritis Rheum 2007;56(Suppl 12):1817.

Furst DE, Chang H, Greenberg J, Ranganath V, Reed G, Ozturk Z, Kremer J. Increasing RA Severity and Disease Comorbidities Are Associated with Decreasing Hemoglobin in the CORRONA Database. Arthritis Rheum 2007;56(Suppl 12):987.

Furst DE, Kremer J, Strand V, Reed G, Greenberg J. The Rate of Infection Adverse Events (AE’s) is Increased as Disease Activity Increases in Rheumatoid Arthritis (RA). Arthritis Rheum 2007;56(Suppl 12):958.

Greenberg J, Strand V, Keystone E, Curtis J, Maury E, Reed G, Kremer J, Nasir A, Henderson J, Kavanaugh A, Hochberg M. TNF Inhibitors (TNF-I) and Risk of Malignancy in 8,072 RA Patients Followed Over 15,495 Patient Years. Arthritis Rheum 2007;56(Suppl 12):282.

Lee SJ, Reed G, Soto L, Kremer J, Kavanaugh A. Persistence of Clinical Benefit in Rheumatoid Arthritis After Discontinuation of TNF-Inhibitor Therapy: Analysis from the CORRONA Database. Arthritis Rheum 2007;56(Suppl 12):728.

Ridley D. Determinants of Return to Employment in Rheumatoid Arthitis (RA) in the United States from the CORRONA Registry. Arthritis Rheum 2007;56(Suppl 12):99.

Surnbul-Yuksel B, Kremer JM, Greenberg JD, Pala O, Reed G, Cavaliere LF, et al. Subcutaneous nodules (SCN) may predict increased risk for cardiovascular disease (CVD) in patients from the CORRONA database with rheumatoid arthritis (RA): An updated analysis. Arthritis Rheum 2007;56(Suppl 12):4273.

EULAR 2007

Callegari P, Dabbous O, Keenan G, Kremer JM, Rahman M, Reed G, et al. A review of reports of lymphoma occurring in patients with rheumatoid arthritis in the Consortium of Rheumatology Researchers of North America (CORRONA) database. Ann Rheum Dis 2007;66(Suppl II):165.

Dabbous O, Kremer JM, Dehoratius R, Keenan G, Peng C, Tang B, et al. Racial differences in baseline characteristics, disease activity, and management among rheumatoid arthritis patients: Findings from the Consortium of Rheumatology Researchers of North America (CORRONA) database. Ann Rheum Dis 2007;66(Suppl II):166.

Dabbous O, Kremer JM, Rambharose J, El Taha M, Reed G, Tang B, et al. Infliximab, etanercept, and adalimumab switchinu in patients with rheumatoid arthritis in the consortium of rheumatology researchers of North America (CORRONA) database. Ann Rheum Dis 2007;66(Suppl II):167.

Greenberg JD, Kavanaugh A, Hochberg M, Kremer JM, Reed G, Zheng C, et al. Association of methotrexate(MTX), TNF-inhibitors (TNF-1) and prednisone (PRED) with risk of infection among RA patients. Ann Rheum Dis 2007;66(Suppl II):171.

Greenberg JD, Kremer JM, Reed G, Strand V. Agreement of composite response measures without acute phase reactants (APR) with ACR and EULAR response criteria in RA. Ann Rheum Dis 2007;66(Suppl II):261.

ACR 2006

Coulson K, Pepmueller P, Hinkle K, Kremer JM, Reed G. Effects of anti-tumor necrosis factor (TNF) therapy and methotrexate on bone density in rheumatoid arthritis. Arthritis Rheum 2006;54(Suppl 9):45.

Dabbous O, Kremer JM, El Taha M, Reed G, Tang B, Arjunji R, et al. Infliximab, etanercept and adalimumab switching in patients with rheumatoid arthritis in the consortium of rheumatology researchers of North America (CORRONA) database. Arthritis Rheum 2006;54(Suppl 9):705.

Dabbous O, Kremer JM, El Taha M, Reed G, Tang B, Thompson H, et al. Socioeconomic status as a determinant of Anti-TNF alpha therapy for rheumatoid arthritis patients: CORRONA database. Arthritis Rheum 2006;54(Suppl 9):61-2.

Greenberg JD, Lin S, Decktor DL, Dabbous O, Baumgartner S, Montgomery M, et al. Association of duration of TNF antagonist treatment with reduction in cardiovascular outcomes in RA patients. Arthritis  Rheum 2006;54(Suppl 9):422-23.

Greenberg JD, Yazici Y, Kremer JM, Chang H, Kishimoto M, Abramson SB. Decline of NSAID gastroprotection in patients treated by rheumatologists in the post-rofecoxib era. Arthritis Rheum 2006;54(Suppl 9):110.

Lee SJ, Kavanaugh A, Chang H, Kremer JM. Recent trends in the use of tumor necrosis factor inhibitors (TNF-I) in patients with early onset rheumatoid arthritis (EORA): analysis from the CORRONA database. Arthritis Rheum 2006;54(Suppl 9):196.

Pala O, Sumbul-Yuksel B, Greenberg JD, Reed G, Cavaliere LF, Greenstein N, et al. Independent association of subcutaneous nodules (SCN) with cardiovascular disease (CVD) in patients from the CORRONA database with rheumatoid arthritis (RA). Arthritis Rheum 2006;54(Suppl 12):4066-67.

Reddy SM, Schwartzman JS, Abramson SB, Chang H, Kremer JM, Greenberg JD. Comparison of disease activity and functional status among psoriatic arthritis subtypes. Arthritis Rheum 2006;54(Suppl 9):712-13.

Yazici Y, Greenberg J, Reed G, Kishimoto M, Hinkle K, Abramson S, Kremer J. Decreasing disease activity thresholds for initiating TNF antagonists from 2003 to 2005 among 1790 RA patients from the CORRONA database. Arthritis Rheum 2006; 54: S246.

EULAR 2006

Kremer JM, Reed G. Obesity is an independent contributor to functional capacity and inflammation in rheumatoid arthritis and psoriatic arthritis. Ann Rheum Dis 2006;65(Suppl II):307.

Kremer JM, Reed G, White B, Baumgartner S.  An analysis of risk factors and effect of treatment on the development of cardiovascular disease in patients with rheumatoid arthritis. Ann Rheum Dis 2006;65(Suppl II):307.

Yazici Y, Greenberg JD, Reed G, Hinkle K, Abramson S, Kremer JM. Clinical disease activity index (CDAI) is strongly correlated with DAS28 and change in CDAI is a strong predictor of ACR 20 response. Ann Rheum Dis 2006;65(Suppl II):608.

Yazici Y, Greenberg JD , Reed GW , Kishimoto M , Hinkle K , Abramson S, Kremer JM. Reduced TNF utilization in early rheumatoid arthritis (RA) versus late RA iN A U.S. cohort. Ann Rheum Dis 2006;65(Suppl II):513.

ACR 2005

Cassell S, Tutuncu Z, Kremer J, Lee SJ, Reed G, Puglises D, et al. Psoriatic arthritis patients have different rates of adverse events than rheumatoid arthritis pts when treated with tumor necrosis factor inhibitors: analysis from the CORRONA database. Arthritis Rheum 2005;52: S211.

Cush JJ, Kremer JM, Reed GW. Hard outcomes in rheumatoid arthritis patients enrolled in the CORRONA database. Arthritis Rheum 2005; 52: S549.

Greenberg J; Schloss, S; Kurucz, O; Reddy, S; Abellana, V; McCullagh, E; Abramson, S; Bingham, C. Pilot study of tuberculosis screening strategies for rheumatoid arthritis patients. Arthritis Rheum 2005; 52: S545.

Greenberg JD; Abramson, SB; Lee, S; Rosenstein, E; Reed, G; Hinkle, K; Kavanaugh, A; Kremer, J. NSAID and COXIB prescribing by rheumatologist for patients with gastrointestinal (GI) and cardiovascular (CV) risk in 2004-2005. Arthritis Rheum 2005; 52: S664.

Greenberg, JD; Kishimoto, M; Cohen, SB; Olenginski, TP; Harrington, T; Kafka, SP; Reed, G; Hinkle, K; Kremer, J; Abramson, SB. Low baseline joint count attenuates response to anti-TNF agents: What are the goals of biologic therapy? Arthritis Rheum 2005; 52: S562.

Greenberg, Jeffrey D; Bingham, Clifton O 3rd; Abramson, Steven B; Reed, George; Sebaldt, Rolf J; Kremer, Joel. Effect of cardiovascular comorbidities and concomitant aspirin use on selection of cyclooxygenase inhibitor among rheumatologists.  Arthritis Rheum 2005; 53: S12.

Kishimoto, M; Greenberg, J; Abramson, SB; Harrington, T; Olenginski, TP; Kafka, SP; Reed, G; Hinkle, K; Kremer, J; Cohen, SB. Drug survival time on anti-TNF agents: Does prior anti-TNF use influence RA outcomes?  Arthritis Rheum. 2005; 52: S347.

Pappas, DA; Greenberg, JD; Stevens, C; Reed, G; Greenstein, N; Flaherty, L; Kremer, JM. Identification of a single nucleolide polymorphism in MIF gene associated with erosive radiographic damage in patients with rheumatoid arthritis. Arthritis Rheum 2005; 52: S146.

Pappas, DA; Greenberg, JD; Stevens, C; Reed, G; Greenstein, N; Flaherty, L; Kremer, JM. Polymorphisms of the uteroglobin gene as a marker of disease activity in rheumatoid arthritis. Arthritis Rheum. 2005; 52: S120.

Pappas, DA; Stevens, C; Greenberg, JD; Reed, G; Greenstein, N; Kremer, JM; Flaherty, L. Identification of single nucleotide polymorphisms in the Mmp3 and SCGB1A1 genes associated with RA susceptibility in a Caucasian population. Arthritis Rheum 2005; 52: S147

Reddy SM, Reed G, Anandarajah A, Greenberg JD, Abramson SB, Kremer J, Ritchlin CT.  Comparative analysis of disease activity, radiographic features, and bone density in psoriatic and rheumatoid arthritis. Arthritis Rheum 2005; 52: S640.

EULAR 2005

Greenberg JD, Abramson SB, Reed GW, Reddy SM, Hinkle K, Kremer JM. Coxib prescribing by rheumatologists in the immediate post-rofecoxib Era. Ann Rheum Dis 2005;64(Suppl III):405.

Kafka SP, Hinkle K, Reed GW, Kremer JM. Discontinuing or switching TNF antagonists in patients with rheumatoid arthritis: data collected from the CORRONA database. Ann Rheum Dis 2005;64 (Suppl III):467.

Lavelle L, Reed GW, Kremer JM. Effects of smoking on rheumatoid arthritis disease severity. Ann Rheum Dis 2005;64(Suppl III):90.

Reddy SM, Greenberg JD, Abramson SB, Reed GW, Hinkle K, Kremer JM. Comparison of disease activity measures and radiographic features of psoriatic arthritis and a matched rheumatoid arthritis cohort. Ann Rheum Dis 2005;64(Suppl III):337.

Ritchlin CT, Reed GW, Anandarajah A, Durham R, Kemshetti S, Hinkle K, Kremer JM. Comparative analysis of bone density in psoriatic and rheumatoid arthritis. Ann Rheum Dis 2005;64(Suppl III):219.

ACR 2004

Furst DE, Reed G, Kremer J. Do RA patients with longer disease duration and previous DMARD use respond less well to DMARDs than those with earlier disease or less previous DMARD use? Arthritis Rheum 2004;50:S556.

Greenberg JD, Bingham CO, Reed G, Hinkle K, Abramson SB, Kremer J. Utilization of gastrointestinal prophylaxis for aspirin and NSAID-related gastropathy. Arthritis Rheum 2004;50:S316.

Kremer JM, Lavelle L, Hinkle K, Reed G. Clinical Factors Associated With Infection, and Opportunistic Infection, in Patients With Rheumatoid Arthritis (RA) from the CORRONA Database. Arthritis Rheum 50:S688, 2004.

Kremer JM, Hinkle K, Reed G. Clinical and Demographic Features Associated with Change in Bone Density (DEXA) Scores in Patients with Rheumatoid Arthritis (RA) from the CORRONA Database. Arthritis Rheum 50: S499, 2004.

Kremer JM, Hinkle K, Reed G. Clinical and Demographic Factors Associated with Change of Non-Steroidal, Anti-inflammatory Drugs (NSAIDs) in Patients with Rheumatoid Arthritis (RA) from the CORRONA Database. Arthritis Rheum 50:S398, 2004.

Lee S, Kavanaugh A, Reed G, Abramson S, Kremer J. Race and Education Influence Treatment and Disease Activity in Patients with Rheumatoid Arthritis (RA): Analysis from the CORRONA Database. Arthritis Rheum 50:S390, 2004.

Tutuncu ZN, Kavanaugh A, Reed G, Abramson S, Kremer J. Older Onset Rheumatoid Arthritis Patients Receive Biologic Therapies Less Frequently Than Younger Patients Despite Similar Disease Activity and Severity: Analysis from the CORRONA Database. Arthritis Rheum 50:S402, 2004.

ACR 2003

Kremer JM, Cush J, Furst D, Kavanaugh A, Reed G, Sebaldt R, Strand V, for the CORRONA database. Predictors of Change of Disease Modifying Antirheumatic Drugs In patients With Rheumatoid Arthritis From the CORRONA database.  Arthritis Rheum 48; S338, 2003.

Greenberg, JD; Bingham, CO; Abramson, SB; Reed, G; Kremer, JPredictors of aspirin co-prescription among NSAID and COX-2 inhibitor users with cardiovascular risk factors.  Arthritis Rheum; 48(9):S218-S218, 2003.